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Summary 
 
Introduction  Endophenotypes as a link between heterogeneous phenotype and 
complex genetics of Attention-Deficit/Hyperactivity Disorder (ADHD) were the focus of the 
present work. Response inhibition, working memory, response time variability and sensory 
gating served as candidate endophenotypes, and the previously with ADHD associated genes 
coding for Catechol-O-Methyl-Transferase (COMT), the Dopamine Transporter (DAT, SLC6A3) 
and Latrophilin-3 (LPHN3) were examined for their moderating influence on 
endophenotypes. We investigated medicated (N=36) and unmedicated (N=42) ADHD 
patients and matched healthy control children and adolescents (N=41) on a range of 
neuropsychological tasks while simultaneously recording a 21-channel EEG and deriving 
event-related and topographical parameters corresponding to specific cognitive operations. 
NoGo-Anteriorization (NGA) based on P300 responses during Go and NoGo trials was the 
main electrophysiological correlate of response inhibition. Sensory gating described the 
suppression of the P50 wave to the second of two consecutive stimuli, serving to prevent 
overstimulation of higher cortical areas. Working memory event-related potential 
components of interest were indicative of early sensory processing (P100 for target and 
N100 for non-target stimuli), selection of material (P150), memory retrieval (N300), event 
categorization (P300 for target stimuli) and updating of working memory contents (P450 for 
non-target stimuli). Behavioural performance was quantified in terms of omission errors 
reflecting inattention and false reactions reflecting impulsivity as well as speed and 
variability of reaction times (RTV). 
 
Results Higher rates of omission errors in unmedicated ADHD patients point towards 
difficulties with both inattention and working memory. RTV was also more pronounced in 
patients without the support of medication. At the second measurement, they furthermore 
displayed longer reaction times and a higher number of commission errors. Early sensory 
processing was largely intact in ADHD, the only exceptions being in interaction with DAT and 
COMT. NGA as electrophysiological correlate of response inhibition overall did not prove to 
be an optimal endophenotype candidate, since it was not yet developed in approximately 
half of the examined children and adolescents. It was independent of diagnosis; ADHD risk 
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alleles for DAT conferred lower NGA as well as more variable reaction times across groups. 
DAT genotype interacted with diagnosis on the level of centroid location in the response 
inhibition task. While in the homozygous 10 repeat (10R) carriers diagnosis did not moderate 
centroid locations, having at least one protective Val allele in combination with 
psychostimulant medication moved centroids to more anterior areas. However, DAT 
genotype did not manifest in behavioural deficits in this task. In the case of sensory gating, 
homozygosity for the DAT allele associated with ADHD (10R) generally conferred impairment 
in sensory gating. ADHD itself only became relevant in participants without genetic risk, 
where patients without medication struggled most with suppression. In the working memory 
task, DAT modulated selection of material (P150). While under high load unmedicated 
patients had delayed responses compared to both other diagnostic groups without genetic 
risk playing a role, low load conditions showed that the combination of risk genotype and 
stimulant medication led to latencies even below healthy controls. While among 
unmedicated patients being in the DAT risk group led to enhanced P100 amplitudes, these 
patients showed dampened P100 responses compared to other diagnostic groups 
amplitudes if carrying at least one 9R allele. Carrying the risk genotype also meant 
tendentially higher target P300 amplitudes in unmedicated patients, whereas without 
genetic risk, they had the lowest P300 amplitudes reflecting aberrant event categorization 
and evaluation.  
 
An interesting trend emerged for LPHN3, where carrying all risk variants was associated with 
higher NGA scores in ADHD patients irrespective of medication. This warrants further study, 
as the haplotype also exerts a positive influence on sensory gating abilities specifically in 
patients. At the same time within the genetic risk group, patients without medication had 
the weakest NGA. However, on centroid level the LPHN3 risk haplotype effected more 
posterior Go centroids, putatively facilitating response execution, which is supported by a 
higher number of false alarms. When response inhibition was required (NoGo trials), the risk 
variants caused unmedicated patients to have more posterior NoGo centroids compared to 
both their medicated counterparts as well as controls, speaking to differences in inhibition-
related brain activation. The LPHN3 genotype produced very different effects on sensory 
gating in controls and patients. While as expected the ADHD risk SNPs in combination led to 
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compromised gating, this was reversed in healthy controls where the haplotype was acting 
in a protective manner with enhanced filtering. 
During working memory operations, the risk haplotype showed stronger N300 responses 
suggesting investment of more resources and thus better retrieval. 
 
While COMT did not exert an influence on NGA directly, carriers of the risk Met allele had 
more posteriorly located centroids both during response execution and inhibition, and 
displayed more variable responses in addition to being more prone to false alarms.  
On the level of P300 response as the basis of the NGA phenomenon, unmedicated patients 
produced smaller P300 during successful execution of responses than controls in absence of 
the risk allele, while with risk Met they had shorter latencies and presumably a greater 
tendency towards premature behavioural reactions. Carrying the COMT risk allele for ADHD 
(Met) was associated with higher RTV. Additionally, it brought out impairments in sensory 
gating, thus making patients without medication less able to filter out irrelevant and 
potentially interfering information, while they were able to compensate even without 
medication if they had the protective Val/Val genotype. The influence of COMT on sensory 
gating seems to be specific for ADHD, as this gene was of no consequence in healthy 
controls. In the working memory task, Met was beneficial for updating processes as reflected 
by the P450 amplitude. In ADHD irrespective of medication COMT did not change P450 
strength, but for controls this effect was observed.   
 
With regard to longitudinal development, the most striking finding was a universal 
quickening of responses (latency shortening) with simultaneous reduction in strength 
(amplitude decrease) that was largely independent of genotype and diagnosis. Reaction 
times, RTV and error counts were also lower at the second measurement, albeit not across 
tasks. No developmental effects emerged for NGA. Including COMT genotype in the analysis, 
higher P150 amplitudes for carriers of the Met allele were only observed at T1, and the time-
dependent reduction of amplitude and latency for target components (P100 and P300) were 
limited to ADHD patients and absent in controls, however P300 responses were weaker in 
controls than either patient group. This suggests already less resource investment at T1 for 
the same or better behavioural results. 
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Zusammenfassung 
 
Einleitung Endophänotypen als Bindeglied zwischen heterogenem Phänotyp und der 
komplexer genetischer Basis des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms (ADHS) 
besitzen großes Potential als diagnostische Marker. Im Fokus der vorliegenden Arbeit 
standen Antworthemmung, Arbeitsgedächtnis, Reaktionszeitvariabilität (RTV) und 
sensorisches Gating als Kandidaten-Endophänotypen, sowie die Untersuchung des Einflusses 
von genetischen Varianten in den ADHS-assoziierten Genen COMT, DAT und LPHN3. Die  
Stichprobe im Kindes- und Jugendlichenalter bestehend aus medizierten (N=36) und 
umedizierten (N=42) ADHS-Patienten sowie gesunden Kontrollen (N=41) wurde in einer Serie 
neuropsychologischer Tests unter simultaner Ableitung eines 21-Kanal-EEGs untersucht. 
Abhängige Variablen waren neben Verhaltensmaßen ereigniskorrelierte und topographische 
EEG-Parameter. Die NoGo-Anteriorisierung (NGA) als elektrophysiologisches Korrelat von 
Antworthemmung basiert auf der Lage der Feldschwerpunkte (Zentroide) der P300-Peaks in 
Antwortausführungs- (Go) und Inhibitionstrials (NoGo). Sensorisches Gating beschreibt die 
Fähigkeit, bei schneller Folge konkurrierender Reize die Weiterleitung des zweiten Reizes zur 
Prävention einer kortikalen Überstimulation zu unterbinden, was sich elektrophysiologisch in 
einer gedämpften P50-Amplitude zeigt. Um sowohl frühe als auch späte Auffälligkeiten im 
arbeitsgedächtnisbezogenen Informationsverarbeitungsprozess erfassen zu können, wurden 
ereigniskorrelierte Komponenten analysiert, welche frühe sensorische Verarbeitung (P100 
und N100), Materialselektion (P150), Abruf von Gedächtnisinhalten (N300), 
Ereigniskategorisierung (P300) und Aktualisierung der Arbeitsgedächtnisinhalte (P450) 
reflektieren. Auslassungsfehler dienten als Indikator für Aufmerksamkeitdefizite sowie 
Falschalarme als Indikator für Impulsivität. 
 
Ergebnisse  Unmedizierte ADHD-Patienten zeigten neben variableren Reaktionszeiten 
mehr Auslassungsfehler, was Hinweise auf Defizite in Bezug auf Aufmerksamkeit, 
Arbeitsgedächtnis und Zustandsregulation gibt. Zum zweiten Messzeitpunkt waren überdies 
längere Reaktionszeiten und mehr Falschalarme zu beobachten.  Unterschiede in der frühen 
sensorische Verarbeitung manifestieren nur in Interaktion mit dem genetischen Hintergrund 
(COMT, DAT). Die NGA erwies sich in unserer Untersuchung als beschränkt geeigneter 
Endophänotyp, da diagnostische Marker hingegen vor allem im in Frühstadium der Störung 
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von Bedeutung sind, jedoch bei viele Probanden im eingeschlossenen Altersspektrum keine 
NGA  nachzuweisen war. Im Längsschnittverlauf kristallisierte sich eine übergreifende 
Beschleunigung (Latenzverkürzung) und Abschwächung der Stärke (Amplitudenreduktion) 
der elektrophysiologischen Reaktionen im Zeitverlauf unabhängig von Genotyp und 
Diagnose heraus. Reaktionszeiten, RTV sowie Fehlerzahlen nahmen ebenfalls ab.  Es zeigten 
sich keine Entwicklungseffekte bei NGA.  Träger des COMT-Risikoalleles (Met) hatten nur zu 
T1 höhere P150-Amplituden, und die Abnahme von Latenzen und Amplituden der 
Targetkomponenten (P100 und P300) von T1 zu T2 blieb beschränkt auf die ADHS-Gruppen, 
wobei P300-Reaktionen in Kontrollen am schwächsten ausgeprägt waren. Dies deutet darauf 
hin, dass bereits beim ersten Messzeitpunkt die Investition von weniger Ressourcen in 
gleicher behavioraler Leistung resultiert. 
 
Diagnoseunabhängig war neben einer höheren RTV die NGA bei Trägern der ADHS-
Risikovariante (10R/10R) schwächer ausgeprägt. Die Interaktion von DAT und diagnostischer 
Gruppe bedeutete auf Zentroidebene, dass nur in Anwesenheit eines protektiven Val-Allels 
die Stimulanzienmedikation mit einer Anteriorisierung beider Feldschwerpunkte 
korrespondierte. Während homozygote 10R-Träger generell Beeinträchtigungen im 
sensorischen Gating zeigten, kam ohne genetisches Risiko die Diagnose zum Tragen, da hier 
die Gruppe mit unmedizierten ADHS die größten P50-Suppressionsdefizite aufwies. Während 
der Arbeitsgedächtnisaufgabe modulierte DAT die Materialauswahl (P150). Wiesen unter 
hohem kognitivem Load die ADHS-Patienten ohne Medikation unabhängig vom Genotyp 
verzögerte Reaktionen im Vergleich zu beiden anderen Gruppen auf, so zeigten medizierte 
Patienten mit Risikogenotyp unter niedrigem Load verkürzte Latenzen auch im Vergleich zu 
gesunden Kontrollen. Während bei unmediziertem ADHD der DAT-Risikogenotyp mit 
höheren P150-Amplituden und somit verstärkter Ressourcenallokation zur Materialselektion 
korrespondierte, zeigte diese Gruppe bei Vorhandensein eines 9R-Allels gedämpfte P100-
Amplituden im Vergleich zu medizierten Patienten und Kontrollen, was auf abnorme frühe 
sensorischen Verarbeitung hinweist. Zuletzt bedeutete der DAT-Risikogenotyp für 
unmediziertes ADHS höhere P300-Amplituden, während diese Gruppe mit dem protektiven 
Genotyp die schwächsten P300-Reaktionen zeigten. Dies gibt Hinweise auf 
Beeinträchtigungen bei der Ereigniskategorisierung. 
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Ein interessanter Trend zeigte sich bei der Analyse der Implikationen des LPHN3-
Risikohaplotyps, der bei ADHS medikationsunabhängig mit besserer NGA assoziiert war. Da 
die Kombination aus Risikovarianten ebenfalls einen ADHS-spezifischen positiven Einfluss auf 
sensorisches Gating ausübte, sind fortführende Studien zur Funktionalität dieses Haplotyp 
angeraten. Auf Zentroidebene wiesen  Träger des Risikohaplotyps generell mehr posterior 
gelegene Go-Feldschwerpunkte auf, was die Ausführung von Reaktionen begünstigt und sich 
entsprechend in einer höheren Anzahl an Falschalarmen niederschlägt. Bei erforderlicher 
Antworthemmung (NoGo) ging der Risikohaplotyp bei unmedizierten ADHS-Patienten mit 
mehr posterioren Zentroiden als in den Vergleichsgruppen einher, was für Unterschiede in 
inhibitionsspezifischer Gehirnaktivität spricht. In Bezug auf sensorisches Gating erzeugte der 
LPHN3-Haplotyp gegensätzliche Effekte bei Patienten und Kontrollen. Während der ADHS-
Risikohaplotyp in der unmedizierten ADHS-Gruppe erwartungsgemäß mit schwächerem 
Gating assoziiert war, manifestiert er in Kontrollen und medizierten Patienten protektive 
Eigenschaften in Form überlegener Filterfähigkeiten. Abschließend korrespondiert der 
Risikohaplotyp bei Arbeitsgedächtnisaufgaben mit höheren N300-Amplituden als Indiz für 
Ressourceninvestition beim Abruf von Gedächtnisinhalten. 
 
 Während sich die NGA als unabhängig vom COMT-Genotyp erwies, lagen die Zentroide bei 
Probanden mit Met-Allel weiter posterior, sie zeigten darüber hinaus eine variablere und 
fehleranfälligere Leistung (Falschalarme). Die der NGA zu Grunde liegende Go-P300 war 
ohne Risikoallel bei unmedizierten ADHS-Patienten schwächer ausgeprägt als bei Kontrollen, 
wohingegen die Präsenz eines Met-Allels mit verkürzten Latenzen und mehr vorschnellen 
Reaktionen einherging. Generell bedeutete die mit ADHS assoziierte COMT-Variante  eine 
erhöhte RTV sowie schlechtere Gatingleistung in unmediziertem ADHD, während sie durch 
das protektive Val-Allele in die Lage versetzte, dieses Defizit ohne Medikation zu 
kompensieren. Dieser Einfluss von COMT auf sensorisches Gating war spezifisch für ADHS. In 
Aufgaben, welche das Arbeitsgedächtnis beanspruchen, war die Met-Variante von Vorteil für 
Aktualisierungsvorgänge (P450), was im Gegensatz zu den Gating-Effekten nur in Kontrollen 
auftrat. 
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Preface 
Ever since Sir Alexander Crichton remarked upon “mental restlessness” as a pervasive 
problem throughout the lifespan in 1798 (Crichton, 2008), the idea of a childhood disorder 
being of relevance in an adult has periodically piqued the interest of the scientific world. 
Explanations ranged from lack of moral control over a defect in the ego apparatus to minimal 
brain damage. First reports of what would now be considered rather clear-cut cases of adult 
Attention-Deficit/Hyperactivity Disorder (ADHD) date back even further to the Elizabethan 
era (1558–1603), impressively embodied by Robert Devereux, the 2nd Earl of Essex. The long-
time favourite of Queen Elizabeth 1st infamously drew a sword on his sovereign in a fit of 
temper after being reprimanded for an insolent comment that slipped his tongue. Needless 
to say he ultimately – and literally – lost his head in reward of such unintentional but utterly 
unacceptable behaviour. His biography reads like a case study for adult ADHD: impetuous 
and rash, prone to inexplicable but fleeting mood swings, great ambitions thwarted by an 
inability to approach even simple matters in an organised manner and so on (Strachey, 1971). 
Charming during one's youth, but considerably debilitating with regard to one's own future 
and increasingly annoying to others, who are unwilling to tolerate that kind of behaviour in a 
person considered an adult and thus expected to act like one. While untreated ADHD in a 
child certainly hampers academic and personal development, it can become positively 
dangerous in adults as the spectrum of potentially harmful activities at one’s disposal 
widens, encompassing risky financial decisions, reck- or careless driving, facilitated access to 
illicit drugs misused for self-medication when not receiving ADHD-specific drugs or engaging 
in casual relationships (Barkley et al., 2004, Flory et al., 2006, Jerome et al., 2006, Manor et 
al., 2010). 
 
In light of the serious consequences of a persisting insufficiently treated ADHD 
alluded to in the first paragraph, it is paramount to accurately diagnose the condition as early 
as is reasonably possible with methods that are both sensitive and specific for ADHD. 
However, most of the impairments ADHD children present with unfortunately are rather 
unspecific, and diagnosis to this point ultimately relies on a clinician’s observation-and 
symptom based judgement. Diagnostic and treatment-related decisions are additionally 
complicated by the considerable heterogeneity of ADHD presentations. In the scope of the 
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present work, the author will venture to explore objectively determinable behavioural, 
neurophysiological and genetic parameters with regard to their suitability as diagnostic 
predictors.  
 
The array of neuropsychological tests was selected to tease out impairments in 
performance and underlying neurophysiological processes by tapping into prefrontally 
governed executive functions (EFs). Executive functions are a set of abilities at the root of 
and crucial for goal-directed behaviour, which is why they show great promise in terms of 
explanatory value for many of the maladaptive ADHD traits. However, deficits in EFs on a 
behavioural level are found not only in ADHD but also in a range of psychiatric conditions 
such as autism, oppositional defiant disorder, conduct disorder and Tourette syndrome 
(Sergeant et al., 2002). Furthermore, seeing that predictors should possess a certain degree 
of specificity for the state to be predicted, the fact that not every ADHD patient necessarily 
presents with deficits in any or all of those domains (Seidman, 2006) - possibly due to 
compensatory mechanisms or confounding environmental variables - raised doubts as to 
their suitability as diagnostic markers. However, endophenotypes as a link between genotype 
and phenotype have emerged as promising means to uncover underlying differences in 
fundamental processes despite overtly similar performance. Employing brain imaging 
techniques to measure functional correlates of potentially normal behavioural performance 
of ADHD children and healthy controls in neuropsychological tasks allows for the 
identification of more basic deficits in information processing and response control as 
endophenotypes. We recorded a 21-channel electroencephalogram (EEG), allowing us to 
relate neuronal activity to performance with high temporal resolution. Finally, we were 
interested in the influence of three genes found to be associated with the broad ADHD 
phenotype, namely Catechol-O-Methyl-Transferase (COMT), the Dopamine Transporter (DAT, 
SLC6A3) and Latrophilin-3 (LPHN3) in sample comprising children and adolescents with a 
clinically diagnosed ADHD (unmedicated or receiving psychostimulant medication) and 
matched healthy controls. 
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1 Introduction to Attention-Deficit/Hyperactivity Disorder 
1.1 Phenomenology 
ADHD affects about 5% of children and adolescents around the globe (Polanczyk et al., 
2007) and is thus one of the most prevalent psychiatric disorders of childhood and 
adolescence. Partly owing to a remarkable genetic component, ADHD has a strong 
tendency to persist into adulthood (40-65% according to WHO statistics), albeit with a 
changed phenotype indicative of on-going brain development. The clinical phenotype 
is extremely heterogeneous and comprises symptoms from the broad domains of age-
inappropriate hyperactivity, maladaptive impulsivity, inattention and emotional 
dysregulation. From childhood and adolescence to adulthood, motor hyperactivity 
declines while inattention persists (Wilens and Dodson, 2004). Emotional dysregulation 
emerges as a major issue for adult ADHD patients, manifesting in irritability and 
unpredictable mood swings. Patients show a compromised ability to deal with stress, 
partly due to a lack of organizational and emotion regulation skills (Sobanski et al., 
2010). The fact that the most readily recognizable feature of the disorder – 
hyperactivity – attenuates with age has contributed to the long-held notion that there 
is no such thing as adult ADHD, and that the disorder is solely an affliction of 
childhood. However, research monitoring the development of neuropsychological 
profiles of ADHD patients confirmed the persistence of impairments in basic processes 
underlying cognitive functioning. As the prefrontal cortex (PFC) – the major control 
instance of human behaviour - matures, inhibitory control increases. So as patients 
grow older, more sophisticated strategies to conceal the more disrupting impulsive 
tendencies enter the behavioural repertoire. Still, patients’ reports suggest that this 
formerly externally visible hyperactivity basically becomes internalized in the form of a 
feeling of restlessness and being driven without purpose.  
 
Currently, childhood ADHD (cADHD) is diagnosed according to criteria laid down 
in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV; American 
Psychiatric Association) or the International Classification of Diseases 10 (ICD10; World 
Health Organization). For adult ADHD, tools like Conners' Adult ADHD Rating Scales or 
the Utah criteria incorporated items pertaining to difficulties with planning, structuring 
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and organizing, while assessment of the hyperactive domain has been supplemented 
by a more or less constant feeling of restlessness in absence of the overt motor 
behaviour observed in children. The phenotypical heterogeneity of ADHD is roughly 
accounted for by the recognition of three subtypes - the primarily hyperactive subtype, 
the primarily inattentive subtype and the combined subtype. The relative frequency of 
those subtypes again differs between clinical and community samples (inattentive type 
most prevalent in general population, combined type most common in clinic samples), 
indicating that combined symptoms from multiple affected domains make children 
more likely to be referred to a mental health expert than primarily inattentive cases 
(Faraone et al., 1998, Carlson and Mann, 2000). The gender ratio in ADHD is skewed 
towards males (10:1 in clinically referred samples and 5:1 in non-referred children; 
(Arnold, 1996, Gaub and Carlson, 1997), but ADHD in girls predominantly manifests in 
the inattentive subtype, and owing to the nature of this subtype’s symptoms it is less 
likely to provoke disruptive behaviour and social difficulties. Furthermore, they develop 
less psychiatric comorbidities, and this might ultimately result in a referral bias 
(Biederman et al., 2002). The traditional view of ADHD as a clinical entity and the 
diagnostic process is currently under revision. The practical use of diagnosing ADHD as 
distinct categorical subtypes is currently under debate and the fifth edition of the DSM 
is going to discard with those subtypes and furthermore account for the symptomatic 
decline with age by adding symptoms typical of adult ADHD as well as by lowering the 
number of symptoms required for diagnosis. In contrast to many other clinical entities, 
ADHD is being viewed as a continuum rather than a category [16-17], hence those 
suffering from a clinically relevant ADHD are at the extreme end of the distribution of a 
trait that can to some degree be found in all humans.  
 
In addition to questions directly related to the disorder, an important issue in 
the study and treatment of ADHD are psychiatric comorbidities, since presentations 
with an isolated ADHD are rather the exception. Over their lifespan, ADHD patients 
have dramatically high prevalences of comorbid conduct, mood and anxiety disorders, 
substance abuse and Cluster B personality disorder, motor tics and learning disorders 
(Jacob et al., 2007, Halmoy et al., 2009, Wilens et al., 2009).This in combination with 
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the nature of ADHD prevents afflicted children from realizing their full potential at 
school in terms of academic achievement (Barkley et al., 2006a). One long-term study 
on school outcomes for 370 cADHD cases compared with normal controls confirmed 
that they had tripled grade retention rates and were 2.7-times more likely to drop out 
of school without a degree (Barbaresi et al., 2007, Biederman et al., 2010a, Biederman 
et al., 2010b). Naturally, this along with the persistence of the general symptoms is 
likely to have serious implications for their future paths, probably limiting career 
options very early on. This is supported by reports of considerably lower rates of 
employment for individuals diagnosed with ADHD (24 vs. 79% for controls; (Halmoy et 
al., 2009), and difficulties in the workplace when it comes to job performance (Barkley 
et al., 2007, Sobanski et al., 2010) or continuity of employment. Furthermore, impaired 
social cognition (for a review, see (Uekermann et al., 2010), emotion processing (Da 
Fonseca et al., 2009) and dysfunctional peer relationships (Hoza et al., 2005) put an 
additional strain on quality of life, which has been found to be lower in ADHD patients 
(Klassen et al., 2004, Adler et al., 2006). 
 
In the early stages of aetiological research, investigators were keen on 
identifying one deficit to explain the entirety of ADHD, not taking into account the fact 
that such an endeavour was very likely to prove futile in such a heterogeneous disorder 
where no two patients look alike. The following selection of models is merely an 
illustration of the variety of research inspired by the one-core-deficit idea, and is by no 
means intended to be comprehensive.  Barkley for example proposed that an inhibitory 
deficit is at the heart of other impairments pertaining to executive functions like 
working memory, self-regulation of affect, motivation and arousal, internalisation of 
speech and reconstitution (Barkley, 1997). The self-regulation aspect of Barkley’s 
theory was expanded by Sergeant in his cognitive energetic model, which identified the 
core problem in ADHD to be inadequate allocation of energetic resources and thereby 
introduced the concept of an increased variability in attention instead of a linear 
decline over time (Sergeant, 2000). In an attempt to bring order to the chaos of 
executive functioning, Zelazo & Mueller (2002) made a distinction between hot 
executive functions that involve the affective dimension and cool, more abstract EFs 
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(Zelazo and Müller, 2002). Today, research has embraced the concept of causal 
heterogeneity and multiple developmental pathways to ADHD (Sonuga-Barke, 2003, 
Nigg et al., 2005, Sonuga-Barke, 2005), and in accordance with the idea of equifinality 
in psychopathology aetiologically distinct pathways will ultimately manifest in the 
clinical picture summarised under the header of ADHD. 
 
1.2 Neuropsychology of ADHD and the concept of endophenotypes 
Neuropsychological impairments for both young and older ADHD patients have been 
reported in a wide variety of tasks assessing executive functions (response inhibition, 
verbal and spatial working memory and cognitive flexibility), delay aversion and so on 
(Martinussen et al., 2005, Wåhlstedt et al., 2009, Biederman et al., 2011). However, 
neuropsychological profiles are as heterogeneous as the phenotypical presentation of 
the disorder, supporting the notion of multiple pathways in the aetiopathogenesis of 
ADHD. Data collected from 3734 patients confirmed, on the whole, a performance 
impairment of medium ES for this population on planning, working memory, vigilance 
and response inhibition tasks (Willcutt et al., 2005, Bidwell et al., 2007). Bidwell and 
colleagues (2007) examined a large sample of twin pairs either con- or discordant for 
ADHD with a battery assessing executive functions (working memory, response 
inhibition, set shifting and interference control), processing speed and response time 
variability. They found ADHD children to fare significantly worse than matched control 
twins on all of the aforementioned variables, with the exception of motivational and 
delay aversion measures. Even though the co-twin in the discordant pairs showed no 
clinically relevant signs of ADHD, they had intermediate scores on most tests, meaning 
that they to some degree had also inherited the ADHD-related disadvantages. It has to 
be noted though that the outcomes from those kinds of tests do not constitute reliable 
markers for diagnosis, since they are neither consistently present in every ADHD 
patient nor do controls always outperform peers with ADHD, furthermore as 
mentioned before EF deficits are a common finding in many psychiatric disorders and 
thus lack specificity. 
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In a meta-analysis by Willcutt et al. (2005) on executive functioning in ADHD, 
the markers most reliably associated with the disorder were related to response 
inhibition (SSRT), vigilance (omission errors in CPT), verbal and spatial working 
memory. If not used singly but in combination, tests of executive functioning can well 
distinguish ADHD patients from healthy individuals. Combinations of working memory 
and response inhibition have proven to be particularly useful for the identification of 
ADHD children (Holmes et al., 2010). ADHD children made more errors of omission and 
commission in a CPT, had compromised verbal and visuo-spatial working memory as 
well as reduced cognitive flexibility as indicated by the Wisconsin Card Sorting Test and 
compromised planning abilities in the Tower of London (Holmes et al., 2010). 
However, correlations between behavioural output indicating EF deficits and ADHD 
symptom are typically weak (Willcutt et al., 2005), and problems arise when trying to 
disentangle neuropsychological profiles of similar psychiatric groups. Geurts et al. 
(2002) found autistic children to display more generalised EF deficits in direct 
comparison with an ADHD group, but for example on Stop Signal Reaction time as a 
measure of inhibitory control. The two clinical groups were equally impaired compared 
to healthy controls (Geurts et al., 2004).  
 
The endophenotype concept in psychiatric research.  Endophenotypes - also known as 
intermediate phenotype – are latent traits carrying genetic load and associated with 
behavioural symptoms. As markers of genetic liability they serve as a link between 
genotype and phenotype; they are thought to underlie behavioural symptoms but to 
be one level closer to the genetic basis of a disorder and thus more directly reflecting 
genetic vulnerability (Almasy and Blangero, 2001). One endophenotype can be 
responsible for multiple overt behavioural symptoms. For example, deficient response 
inhibition in the case of ADHD can result in blurting out comments, getting up in the 
middle of a meeting, carelessly crossing the street or interrupting on-going work due to 
an intruding impulse. Focusing on those intermediate phenotypes allows researchers 
to select more homogeneous groups of patients and also facilitate the identification of 
risk genes underlying these more basic deficits. In order for a marker to be considered 
useful as an intermediate phenotype, it has to fulfil certain criteria: a primary deficit in 
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the disorder in question, it should still be a dimensional attribute also found in the 
normal population. An endophenotype has to be a heritable and familial trait and 
crucially, it needs to be quantitatively measurable, so that ultimately those 
endophenotypes can predict ADHD the same way blood cholesterol can predict 
coronary heart disease (Castellanos and Tannock, 2002, Rommelse et al., 2008c). 
Additionally, mean values of unaffected siblings should lie somewhere between those 
of patients and those of healthy controls as they share some of their ADHD sibling's 
genetic background and thus very likely also inherited some of the genetic variants 
contributing to the disorder. Rommelse and colleagues (2008) confirmed the suitability 
of executive functions – particularly response inhibition (RI) and working memory - as 
endophenotypes of the disorder, as they could show that an EF component comprising 
response inhibition and working memory was compromised in cases and affected 
siblings to an equal extent and in unaffected siblings at an intermediate level as 
compared to healthy controls (Rommelse et al., 2008b). 
 
Figure 1:  Explanatory value of an endophenotype for multiple behavioural symptoms 
 
Response inhibition for example could just as well be considered an 
endophenotype if approximated by errors of commission or Stop Signal Reaction 
Times, without employing more time-consuming electrophysiological methods. 
However, be it due to the phenotypical diversity according to the 18 symptoms 
currently used to diagnose ADHD, or the heterogeneous patterns of deficits in 
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behavioural performance in neuropsychological tests: stable differences are hard to 
come by when comparing ADHD patients with normally developing individuals. The 
highly structured nature of a neuropsychological examination in a laboratory might 
further mask underlying deficits, which under natural circumstances would clearly 
impact on tasks of daily life. Draeger and associates observed that as soon as the 
experimenter left the room, a significant deterioration of performance occurred in the 
ADHD group (Draeger et al., 1986). So even in the face of normal performance in terms 
of errors rates, this effort to keep up appearances is likely to show in 
electrophysiological activity preceding or accompanying correct and incorrect 
responses. Indeed, even in the absence of overt behavioral impairments there are 
often distinct differences in underlying brain activity in ADHD patients. Despite normal 
behavioral performance in tests of spatial and verbal working memory and executive 
functioning, connectivity was enhanced in ADHD adults in one network (right PFC, left 
dorsal cingulate cortex and left cuneus) and decreased in another (ventrolateral PFC, 
anterior cingulate cortex (ACC), superior parietal lobule and cerebellum) during a basic 
activation task (Wolf et al., 2009). Valera et al. (2005) had previously observed lower 
cerebellar activation during an n-back working memory task, again in absence of 
behavioral effects (Valera et al., 2005). They furthermore found a gender effect in 
working memory-related brain activity on top of generally lower prefrontal activity in 
ADHD patients (Valera et al., 2010). Women did not differ from controls, whereas men 
had decreased activation in left cerebellar and occipital areas, and enhanced activity in 
right frontal, temporal and subcortical regions compared with healthy controls. This 
illustrates the benefits of using imaging techniques during the examination of 
neuropsychological functioning to gain a deeper insight into the integrity of basal 
processes and recommends functional parameters as endophenotypes for the study of 
psychiatric disorders such as ADHD 
 
1.3 Candidate genes 
Investigations into structural and functional ADHD neuroanatomy point mainly towards 
abnormalities in fronto-striatal circuitry (Seidman et al., 2005). As both the PFC and the 
basal ganglia rely heavily on catecholaminergic neurotransmission, it makes sense to 
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take a closer look at genes coding for the main modulators of catecholaminergic action 
in those regions. COMT is expressed mainly in the PFC and degrades catecholamines 
such as dopamine (DA), norepinephrine (NE) and epinephrine, thus limiting the 
duration of action in the synaptic cleft. Similarly, the DAT is more abundant in the 
striatum, where the reuptake of DA and to a lesser extent NE into the neuron via the 
DAT marks the end of the synapses’ active period. 
 
1.3.1 Catechol-O-Methyl Transferase (COMT) 
COMT is of critical importance for maintaining the balance of catecholamines and 
thus the functionality of prefrontal brain areas (Grossman et al., 1992). The gene 
coding for this enzyme located on Chromosome 22q11.21 has been studied 
extensively, with much of the published research focusing on the 
Valine158Methionine-coding single nucleotide polymorphism (SNP) in Exon 3 of the 
gene, where the change from C to G in the nucleotide sequence of the COMT gene 
leads to an exchange of amino acid 158 from valine (Val) to methionine (Met). This 
results in the production of a more thermo-labile and thus less active enzyme and 
ultimately higher catecholamine availability (Lachman et al., 1996).  
 
Findings regarding functional implications of COMT genotype are 
heterogeneous. For healthy children and adults, the Met allele seems to be largely 
beneficial for prefrontally mediated functioning (Malhotra et al., 2002, Gallinat et al., 
2003, Diamond et al., 2004, de Frias et al., 2005); others find no link [(Blanchard et 
al., 2011); meta-analysis by (Barnett et al., 2008)] or the exact opposite pattern, 
where Val helps performance [22q11 (Baker et al., 2005); ADHD (Bellgrove et al., 
2005)]. It has been proposed that the Val allele mainly confers an advantage in terms 
of cognitive flexibility (Bilder et al., 2004). A recent study by Dumontheil et al. (2011) 
suggests developmental changes in the impact of COMT on cognitive tasks, since they 
found the beneficial influence of the Met allele first manifesting around the age of 10 
(Dumontheil et al., 2011). Gender has also been implicated as a potential moderator, 
with the positive relationship between different cognitive functions and COMT 
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genotype (or rather number of Met alleles) only manifesting in males (Barnett et al., 
2007). 
 
In ADHD, having the normal Val allele with its quick degradation of 
catecholamines has been hypothesized to contribute to the often reported hypo-
dopaminergic state in ADHD. Impaired sustained attention in ADHD children with at 
least one Met alleles has been described (Bellgrove et al., 2005), while others find no 
behavioural difference on measures of working memory and different measures of 
response inhibition (Mills et al., 2004). Interestingly, the Val allele which has been 
found to be more frequent in childhood ADHD also confers a more favourable 
response to Methylphenidate (MPH) than Met/Met patients in terms of symptom 
severity (Kereszturi et al., 2008). The nature of the relationship between COMT and 
ADHD is also far from clear. While some studies find an association of the Val158Met 
polymorphism with ADHD (Eisenberg et al., 1999, Qian et al., 2003, Palmason et al., 
2010) and higher ADHD scores in Met carriers (Palmason et al., 2010), others cannot 
confirm those results (Hawi et al., 2000, Bellgrove et al., 2005, Turic et al., 2005). A 
recent meta-analysis by Cheuk and Wong (2006) found no association between COMT 
Val158Met polymorphism and ADHD, although the authors acknowledge there was 
considerable clinical heterogeneity between studies, which might have biased the 
pooled results (Cheuk and Wong, 2006). This casts serious doubt on a direct 
association between the polymorphism and the disorder, it seems far more likely that 
having a certain genotype in combination with ADHD related structural and functional 
alterations has an additive effect and might provoke more serious impairment in 
ADHD patients compared to healthy individuals.  
 
1.3.2 Dopamine Transporter 1 (DAT) 
The gene coding for the DAT is located on Chromosome 5p15.3 (Kawarai et al., 1997), 
and it is mainly expressed and influencing dopaminergic neurotransmission in the 
striatum and cerebellar vermis and to a much lesser degree in PFC (Ciliax et al., 1999, 
Durston et al., 2005, Scherk et al., 2009). The most commonly studied polymorphism 
is a variable number tandem repeat of 40bp in the 3’ untranslated region (3’UTR). In 
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human populations the reported number of repeats ranges from 3 to 13, with 9R and 
10R alleles emerging as the most common alleles (Mitchell et al., 2000). The 9R allele 
is associated with lower gene expression and thus reduced transporter activity and 
more DA in the synaptic cleft (Heinz et al., 2000, Mill et al., 2002). Especially motor 
inhibition requires basal ganglia and PFC to work in concert (Chambers et al., 2009). 
The PFC requests an increase of behavioural control by top down commands, and DA 
then acts as an executive messenger, translating the PFC commands into inhibitory 
signals to motor areas in the cortex (Mink, 1996). DAT is the main target of 
psychostimulant drugs used for the treatment of ADHD, which presumably exert their 
effect by increasing catecholaminergic stimulation of α2-adrenoreceptors and D1 
receptors (Arnsten and Dudley, 2005, Gamo et al., 2010). Striatally, methylphenidate 
blocks the DAT and thus the reuptake of DA, hereby influencing both cognitive and 
motor behaviour via the direct and the indirect pathway through D1 and D2 receptors 
(Volkow et al., 2001). In the PFC, effects on executive functions are likely to be 
mediated by raising DA and NE through a comparable blockage of the NE transporter 
(NET), which is more abundant there and MPH also possesses an affinity for 
(Bymaster et al., 2002).  
 
Indications for the gene’s involvement in the aetiopathogenesis of ADHD 
come from several lines of evidence. In addition to hints from the mechanisms of 
action of stimulant drugs commonly used for the treatment of ADHD (Faraone et al., 
2004, Volkow et al., 2005), genetic association studies link the above-mentioned 
VNTR to the disorder, although - similar to COMT - findings regarding the association 
of DAT with ADHD are heterogeneous ]for an overview, see the meta-analysis by 
(Rommelse et al., 2008a)]. As a model organism, DAT knockout mice display a 
pronounced motorically hyperactive phenotype, thus supporting the gene’s 
involvement in ADHD pathogenesis (Gainetdinov and Caron, 2000). Interestingly, 
there seem to be developmental effects, as the risk allele changes with age. The 10R 
allele is considered a risk allele for childhood ADHD [meta-analysis by (Faraone et al., 
2005)], and carrying two copies of the 10R allele confers an increased risk for 
impaired cognitive functioning in this age group (Loo et al., 2003, Cornish et al., 
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2005), although there are also reports in the opposite direction (Barkley et al., 2006b, 
Karama et al., 2008). For adult ADHD, the 9R allele and the 9/9 genotype seem to be 
the risk variants, interfering with optimal performance (Franke et al., 2010). Cheon et 
al., (2005) reported homozygous 10R carriers to respond less favourably to MPH. Left 
caudate volumes were smaller for the 10/10 genotype and in ADHD subjects, but the 
two factors did not interact (Cheon et al., 2005). This structure is crucial for inhibition 
(Shook et al., 2011), speaking to the role of DAT in response control. Cornish and 
colleagues (2005) found homozygous carriers of the DAT 10R allele to have higher 
ADHD scores and performance impairments in tasks requiring response inhibition 
and selective attention, but not working memory. High scorers were generally out-
performed by low scorers in tasks on attention, inhibition and working memory.  
 
Age differences between samples might partly explain inconsistent findings 
concerning the connection between DAT and ADHD. Further contributing to practical 
ramifications of DAT genotype might be the nature of the task. More cognitive 
(prefrontal, executive) tasks are largely independent of DAT genotype, while those 
involving a motor response are more influenced due to involvement of striatum. Also, 
the relatively low frequency of 9R makes pooling of 9/9 and 9/10 probands 
necessary, and this might obscure some effects. 
 
1.3.3 Latrophililin-3 (LPHN3) 
Latrophilin-3 (LPHN3) is a member of a large family of adhesion G-protein coupled 
receptors (adhesion GPCR).  It possesses seven trans-membrane domains and a large 
extracellular site (Sugita et al., 1998). While LPHN 1 and LPHN2 bind latrotoxin – the 
venom of the black widow spider – with differing affinity, the exact function of LPHN3 
as well as its endogenous ligand remain elusive. Putative functions include the 
negative regulation of axonal growth and protection against oxidative stress. It is 
presumably involved in processes of cell adhesion, synaptic plasticity and signal 
transduction. The protein is predominantly expressed in cerebral cortex, cerebellum, 
amygdala and caudate nucleus, but has also been found in putamen, hippocampus, 
corpus callosum, frontal and temporal lobe, occipital pole (Arcos-Burgos et al., 2010). 
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In addition to being heavily in expressed in the striatum, LPHN3 is associated with 
changes in dopaminergic brain circuitry, as animals models recently were able to 
demonstrate. (Wallis et al., 2012) succeeded in generating a LPHN3 knock-out mouse 
model. These animals – aside from a pronounced phenotypical hyperactivity – 
displayed elevated levels of DA and serotonin (5-HT) in the dorsal striatum, 
furthermore receptors and transporter molecules for those neurotransmitters were 
altered, indicating a profound interaction of LPHN3 and the dopaminergic system. 
Also, the animals lacking LPHN3 showed a heightened sensibility to the stimulating 
effects of cocaine. The more ecologically plausible zebrafish knock-down model 
(Lange et al., 2012) sheds some light on potential changes occurring in humans with 
the less active LPHN3 haplotype. Even in this intermediate state, the decreased levels 
of LPHN3 interfere with dopaminergic architecture in the central diencephalon in the 
form of more sparsely distributed and spatially misplaced DA-positive neurons. Drugs 
commonly used for the treatment of ADHD are capable of an effective phenotypical 
rescue of the motorically hyperactive animals. The authors speculate that the variants 
of the gene leading to a decrease in LPHN3 levels might contribute to the hyperactive 
phenotype, whereas different variants might be involved in the pathogenesis of 
Parkinson’s disease. The connection between ADHD and LPHN3 has first been 
described by Arcos-Burgos et al. (2004) in a genome-wide linkage study on a 
Columbian population isolate (Arcos-Burgos et al., 2004).  In this population, the 
highly prevalent ADHD was linked to a risk variant in the region around the LPHN3 
gene, which could be mapped to a locus at 4q13.2 in subsequent investigations. This 
finding has since been replicated in European and US samples (Arcos-Burgos et al., 
2010, Ribases et al., 2011). The authors identified a risk haplotype comprising 3 SNPs 
- rs6551665 (G), rs1947274 (C) and rs2345039 (C) – belonging to a common linkage 
disequilibrium (LD) block. In a region-of-interest analysis  of brain chemistry using 
Proton magnetic resonance spectroscopy (1H-MRS), the risk haplotype carriers 
displayed decreased activity in left lateral and medial thalamus as well as the right 
striatum, and an increase in the cerebellar vermis (Arcos-Burgos et al., 2010). 
Interestingly, one of the risk SNPs comprising the risk haplotype (G allele for 
rs6551665) was also associated with better response to stimulant medication. 
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1.4   Candidate Endophenotypes 
1.4.1 Response Inhibition 
1.4.1.1 Behavioural Correlates of Response Inhibition 
The capability for response inhibition describes the successful interruption of 
prepared responses, requiring an active suppression of behaviour. This marker meets 
the aforementioned endophenotype criteria, as quantitatively measurable correlates 
of response inhibition deficits are associated with the disorder in ADHD patients 
(Wodka et al., 2007) and it has also been found to be compromised in unaffected 
siblings (Slaats-Willemse et al., 2003, Bidwell et al., 2007). Furthermore RI possesses a 
distinct genetic component (Goos et al., 2009). A number of meta-analyses [(Schachar 
et al., 1995, Oosterlaan et al., 1998, Willcutt et al., 2005) on the whole confirm a 
higher prevalence of inhibitory deficits in ADHD samples, however not all patients 
showed this particular difficulty.  The two major tasks for the study of response 
inhibition are the Continuous Performance Test (CPT) and the Stop Signal Task (SST) 
and variants thereof. As the SST however presents with some theoretical and 
methodological issues and furthermore could not be analysed with regard to 
electrophysiological correlates of prefrontal functioning, a Go/NoGo paradigm was 
chosen to assess response inhibition. The CPT as a response inhibition task is very 
well suited for the examination of ADHD, as it very basic, has high explanatory value 
as an endophenotype for many behavioural symptoms and provides access to both 
dimensions of ADHD by means of errors of impulsiveness (errors of commission; False 
Alarm) and inattention (errors of omission; Miss) as well as response time variability 
(RTV; operationalized by the standard deviation of reaction times). The task has 
proven to be particularly sensitive in identifying ADHD cases compared to healthy 
children and adolescents. In a recent meta-analysis, the majority of studies on CPT 
performance in ADHD found patients to perform worse than controls - mainly 
manifesting in increased errors of commission, as this is the most direct indicator of a 
lack of inhibitory control (Willcutt et al., 2005). Pre-school children aged 3 to 7 years 
were classified into a high- and a low-risk group for ADHD and tested with a 
combined CPT –Go/NoGo task. High-risk children made more errors of both types in 
the CPT, and frequency of errors as well as mean RT and RTV was negatively related to 
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age. Furthermore, mean and variability of reaction times was higher in the risk group 
(Berwid et al., 2005). Generally, more errors of commission as indicators of 
impulsivity and omission as the consequence of inattention (Barkley et al., 2001, 
Fallgatter et al., 2004, Berwid et al., 2005, Wodka et al., 2007), longer reaction times 
and more variable responses have been reported in ADHD populations (Banaschewski 
et al., 2003, Fallgatter et al., 2004, Berwid et al., 2005, Wodka et al., 2007). It has to 
be noted however, that results are not unequivocal, and a number of studies could 
not confirm the aforementioned behavioural deficits in ADHD (Fallgatter et al., 2004, 
Lawrence et al., 2005). 
 
MPH can successfully counteract the impact of ADHD on error rates in a 
variety of tasks, particularly the rate of false alarms as a correlate of impulsivity 
[(Broyd et al., 2005, Lawrence et al., 2005); for a review on stimulant effects 
specifically on CPT outcome, please see (Riccio et al., 2001)]. The beneficial effect of 
psychostimulants on ADHD related impulsivity seems to be somewhat specific when 
distinguishing between different kinds of the broad impulsivity construct. DeVito and 
colleagues (2009) found ADHD children to improve under stimulant medication in 
terms of impulsivity when it is defined as inhibition of prepotent motor responses, 
but medication did not influence reflective impulsivity in terms of rash decision-
making without evaluating all available information (DeVito et al., 2009). If errors of 
commission are viewed as indicative of action impulsivity, then the unmedicated 
ADHD group should be outperformed by their medicated counterparts as well as 
healthy children.  
 
1.4.1.2 EEG correlates of Response Inhibition 
The most commonly studied event-related potential (ERP) components in response 
inhibition paradigms are the negative fronto-central N200 (200-300 ms) and the 
positive centro-parietal P300 (300-700 ms). Additionally, the CPT as a Go/NoGo task 
allows for the assessment of an electrophysiological correlate of prefrontal inhibitory 
functioning – the NoGo-Anteriorization or NGA (Fallgatter et al., 1997).  
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1.4.1.2.1 Event-Related Potentials  
The origins of both N200 and P300 have been traced back to the anterior cingulate 
cortex or ACC (Strik et al., 1998, Bekker et al., 2005). The proposed functions of the 
P300 range from orienting and perceptual evaluation to closure and resource 
allocation (Brandeis et al., 1998), and the target P3b plays a role in event 
categorization (Kok, 2001). Both have been presumed to reflect inhibitory effort, 
and the debate particularly regarding the role of the frontally maximal N200 is on-
going [inhibition (Lavric et al., 2004); conflict monitoring (Nieuwenhuis et al., 2003, 
Donkers and van Boxtel, 2004)], however especially the NoGo-P3 seems to reflect 
inhibitory effort (Tekok-Kilic et al., 2001, Freitas et al., 2007), as this component has 
been proven to be more susceptible to manipulations of probability of inhibitory 
demands than the N2 (Smith et al., 2007). However, since N2 amplitudes have been 
found to be higher for NoGo compared to Go trials, it no doubt is involved in the 
inhibitory process in some form (Johnstone and Clarke, 2009). Indeed, Pliszka et al. 
(2000) found the N2 amplitude to be strongly correlated with inhibitory 
performance, and greater amplitude for successful as compared to failed inhibitions 
for N2 and NoGo-P3 only in controls underlines these components’ importance in 
response control and the suppression of unwanted reactions (Pliszka et al., 2000). 
The increase in N2 amplitude for successful inhibitions was only present in control 
subjects, indicating abnormal preparatory processes in ADHD (Liotti et al., 2007).  
 
Response inhibition (NoGo) trials normally elicit higher N2 amplitudes than 
response execution (Go) trials. In healthy subjects, no latency differences between 
Go and NoGo-N2 emerged (Johnstone & Clarke, 2009). However, the magnitude of 
N2 responses is related to being a good vs. bad inhibitor in terms of errors of 
commission (Falkenstein et al., 1999). Groom and colleagues (2010) confirmed 
previous reports of higher amplitudes for both inhibition- associated components 
(N2 and P3) during NoGo (inhibition demanding) as compared to Go trials (Groom et 
al., 2010, Fisher et al., 2011). They furthermore compared electrophysiological 
correlates of response control between ADHD patients and healthy controls, and 
found the magnitude of N2 and P3 to be diminished in patients in both conditions. 
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Methylphenidate was able to normalize amplitudes of both components in the 
ADHD group, and furthermore added motivational incentives were also beneficial 
for electrophysiological response. N2 amplitudes are lower in ADHD compared to 
controls (Johnstone & Clarke, 2009). This less strong N2 response in patients has 
been found numerous times (Strandburg et al., 1996, Overtoom et al., 1998, Pliszka 
et al., 2000, Bokura et al., 2001, Johnstone et al., 2001, Broyd et al., 2005, Liotti et 
al., 2007, Wild-Wall et al., 2009), but there are also contradicting reports of an 
increase in N2 amplitudes in the ADHD population [adults (Prox et al., 2007) and 
children (Rubia et al., 2005)]. ADHD patients have been found to show a delayed N2 
when inhibition is required compared to trials requiring a response (Johnstone & 
Clarke, 2009), however there are also reports of shorter latencies for NoGo 
compared to Go in this population (Smith et al., 2004).  
 
In NoGo trials in a study by Fisher et al. (2011), ADHD was associated with 
longer latencies for N2 and P3, with lower P3 amplitudes and more errors of 
commission in comparison to controls. During the Go condition, patients missed 
more targets and had greater N2 responses compared to controls. During a cued 
CPT, the increase of N200 amplitudes from Go to NoGo was greater in ADHD, and 
they also showed shorter NoGo-N200 latencies (Smith et al., 2004). Frontal N2 and 
posterior P3 amplitudes to target stimuli were diminished in ADHD, and stimulant 
medication administered for a second experimental session had a normalising effect 
on ERPs during a cued CPT. Reaction times during Go trials did not distinguish 
between groups, and differences in error rates during the first session were 
remedied by methylphenidate as well (Lawrance et al., 2005, see also Fallgatter et 
al., 2004 for diminished NoGo-P3). A subsequent study by the same group found the 
same effects on N2 and P3, but distinguishing between types of errors revealed that 
methylphenidate selectively diminished false alarms, while a higher rate of omission 
errors persisted (Broyd et al., 2005).  
 
In healthy individuals, P3 amplitudes are higher in NoGo compared to Go 
trials (Fisher et al., 2011; Groom et al., 2010). Summing up the vast P300 literature, 
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a review on P300 in childhood ADHD largely describes longer latencies and higher 
amplitudes as characteristic of the disorder (Barry et al., 2003), while in adult ADHD 
a recent meta-analysis reported diminished amplitudes in patients (Szuromi et al., 
2011). Electrophysiological studies using versions of the CPT have reported generally 
reduced P300 amplitudes in ADHD children (DeFrance et al., 1996, Strandburg et al., 
1996, Overtoom et al., 1998). Differentiating between response inhibition and 
execution trials, ADHD patients have lower P3 amplitudes for both conditions (Broyd 
et al., 2005; Fallgatter et al., 2004; Fisher et al., 2011; Groom et al., 2010; Lawrance 
et al., 2005). Contrary to normally developing control children, patients suffering 
from ADHD did also show deficits in their allocation of processing energy, as the 
usual habituation of P300 strength to standard stimuli was absent in ADHD 
(Karayanidis et al., 2000) and there was a less clear amplitude difference between 
targets and standards. This could be interpreted as investing an unnecessary 
amount processing capacity and energy, possibly due to difficulties with 
distinguishing in terms of relevance. Research on P300 latencies is less consistent. 
Some studies find faster responses in unmedicated ADHD (Taylor et al., 1997), while 
others report delayed P300 peaks that could also be counteracted with stimulant 
medication (Strandburg et al., 1996, Sunohara et al., 1999). 
 
1.4.1.2.2 Topographical parameters: NoGo-Anteriorization 
NGA describes a shift in the positive electrical field of the brain during the P300 
window from posterior to more anterior areas whenever a prepared motor 
response has to be inhibited (NoGo condition) as compared to executed (Go 
condition). A coordinate system ranging from 1 to 5 is superimposed onto the 
topographical brain maps and the weighted centroid location for Go and NoGo 
along this axis is calculated. By subtracting the location of the NoGo centroid from 
the Go centroid, the resulting NGA constitutes an individual quantification of the 
magnitude of this shift for each participant. Higher NGA values signify better the 
inhibitory control from the PFC. Fallgatter and colleagues established this 
topographical parameter as an electrophysiological correlate of prefrontal response 
control (Fallgatter et al., 1997, Fallgatter and Strik, 1999) and have shown the NGA 
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to possess great long-term reliability and intra-individual stability (Fallgatter, 2001, 
Fallgatter et al., 2002a). As it appears to be largely independent of gender and age 
(Fallgatter et al., 1999), impairments in NGA could be a promising marker for 
monitoring executive dysfunction during the course of a disorder. Source localization 
via functional Magnetic Resonance Imaging (fMRI) and Low Resolution 
Electromagnetic Tomography (LORETA) traced the origins of the NGA or rather the 
activation during the NoGo condition back to the anterior cingulated cortex (ACC) 
(Fallgatter et al., 2002b, Ford et al., 2004). 
 
NGA in ADHD In a study by Fallgatter et al., (2004) looking into inhibitory 
mechanisms in ADHD, only affected boys (N=16; aged 7-11) and healthy male 
controls (N=19; aged 8-11) were included. The authors observed a dampened 
central NoGo P3 for the ADHD group, which corresponded to lower ACC activation 
during inhibition trials. Behaviourally, ADHD children had longer reaction times and 
made more omission errors, but did not differ in the number of false alarms. 
Controls had higher fronto-central P3 amplitudes during NoGo compared to Go, and 
higher parietal P3 amplitudes during Go- compared to NoGo-trials. ADHD children 
displayed higher Go amplitudes both at Cz and Pz with generally longer latencies. 
Regarding the N2, no group effects on amplitude were found, but this peak is more 
negative during Go-trials and the difference between conditions is most pronounced 
at Cz. Longer latencies in ADHD group could only be observed during NoGo trials at 
Cz.  
 
Banaschewski et al. (2004) reported on a sample aged 8 to 14 with assessed 
with a cued CPT, where ADHD children showed most pronounced problems in the 
cue condition (to the warning stimuli). Strikingly, the expected anteriorization of 
brain activity for NoGo could only be found in the hyperkinetic group (Banaschewski 
et al., 2004). It has to be noted though that no NGA as such was calculated. The 
inhibitory NoGo-P300 shows earlier maturation in control children, whereas this 
component emerged later in the young ADHD patients. However the target P300, 
which normally decreases in amplitude with age, showed the opposite pattern in 
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ADHD and thus speaks more to a deviation from normal development in terms of 
response execution (Doehnert et al., 2010). The authors followed a small group of 
ADHD patients (N = 11, age at baseline Ø 10.9 years) diagnosed in childhood over 
the course of 11 years (Doehnert et al., 2012) and assessed them at four time points 
(baseline, T2 = 1.1 years, T3 = 2.4 years and T4 = 11 years) with a CPT / Go-NoGo 
paradigm, looking both at preparatory and inhibition-related processes. The 
absence of group by time interactions suggest that none of the parameters deviated 
from the typical developmental trajectory, the direction of change over time was 
the same for ADHD and controls. Behavioural parameters (RT, RTV, errors of 
omission) and preparatory potentials (Contingent Negative Variation CNV, Cue P300) 
decreased over time, with ADHD patients having higher RTV and lower Hit rate and 
magnitudes of Cue-P300 and CNV at single measurement points. Interestingly, the 
CNV was the only marker to be consistently diminished, lending support to its 
suitability as a stable candidate endophenotype present even in patients no longer 
meeting full ADHD criteria. NoGo global field power amplitude decreased with age, 
but was higher in ADHD compared to controls at T3. Adult ADHD patients present 
with decreased NGA and GFP amplitudes and a less substantial increase in fronto-
central P300 from Go to NoGo compared to controls, however one has to bear in 
mind that the probands were out-patients of the forensic section all diagnosed with 
a personality disorder and an incidental and not conclusively verified cADHD 
(Fallgatter et al., 2005). 
 
A reduced NGA has been observed in other clinical populations as well 
(Fallgatter and Muller, 2001, Fallgatter et al., 2003) and thus is not specific for ADHD. 
MPH has a normalising effect on P3 amplitudes, which were diminished in ADHD 
boys following both Go and NoGo stimuli (Seifert et al., 2003). Interestingly, the NGA 
has proven clinically useful as it shows a predictive value for medication response in 
schizophrenia, facilitating treatment decision.  A good initial NGA corresponded with 
a more favourable response to typical antipsychotic medication, whereas a low 
initial NGA predicted a better response to atypical antipsychotics (Ehlis, 2008). So 
this parameter might have clinically highly relevant implications which warrant 
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following up patterns of impairment and interactions with additional risk factors 
such as genotype of catecholaminergic genes. 
 
1.4.1.3   Genetic Modulation of Response Inhibition 
COMT  A study by Fallgatter et al. (2009) on adult ADHD observed that subjects 
with Val/Val genotype had smaller NGA values irrespective of diagnosis (ADHD vs. 
controls), but patients per se did not differ from controls in NGA. Upon closer 
inspection of an interaction of diagnosis and COMT, the genotype effect was 
limited to the patient group with better NGA for Met/Met carriers, while COMT did 
not play a role for healthy controls. Both centroids were located more anteriorly 
for ADHD patients and homozygous Val carriers, however in the ADHD group, only 
Go centroids were located more anteriorly for Val/Val. Surprisingly, testing more 
subjects and re-analysing the data only confirmed more anterior centres for the 
positive brain electric field for NoGo and patients, respectively. None of the 
interactions or the effects involving COMT genotype could be replicated. The 
authors could not identify any sample characteristics differing between the 
preliminary and the final sample (Fallgatter et al., 2009).  
 
In a group of schizophrenic patients examined by Ehlis et al. (2007), 
Met/Met carriers showed increased NoGo amplitudes and NGA values compared 
to Val/Met, while performance outcome was the same for all genotype groups. 
There was a clear dosage effect for the disadvantageous Val allele, as the small 
Val/Val group - included for exploratory analyses - showed a further decrease in 
NGA and NoGo-P3 amplitude compared to Val/Met. For amplitude and latency 
comparisons, the P300 peaks at Cz (NoGo) and Pz (Go) were used. Differences 
between genotype groups were found exclusively in the NoGo condition, making 
dysfunctions during the inhibition process the basis for NGA differences. Only high 
doses of the favourable Met allele seemingly permitted for the formation of a 
stable NoGo potential (Ehlis et al., 2007). The influence of COMT genotype on 
prefrontal functioning follows an inverted U-Shape, where for healthy individuals 
the heterozygous (Val/Met) genotype is at the apex of the curve and thus has 
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optimal prefrontal catecholaminergic metabolization for a range of cognitive tasks. 
The extent of the genotype influence however depends hugely on baseline 
functioning. So while in healthy controls the added benefit of the Met allele might 
be limited, it may elevate prefrontal catecholamine levels of psychiatric 
populations with known catecholaminergic pathology into the lower end of the 
normal spectrum. Healthy Val homozygotes on the other hand show performance 
impairments, which can be remedied by amphetamine administration (Mattay et 
al., 2003).  
 
DAT   According to Loo et al. (2003) performance in a vigilance task (CPT) 
was better for carriers of at least one 9R allele compared to 10/10 carriers 
regardless of ADHD status in a sample of children. Furthermore, the authors 
reported more errors of commission for 10R carriers, indicating deficient response 
control on a behavioural level. Among ADHD adolescents, the 10/10 group 
displayed higher activity related to inhibition in left striatum, right dorsal premotor 
cortex and bilaterally in the temporo-parietal junction in a response inhibition task 
despite identical behavioural performance (Bedard et al., 2010), which suggests 
they were able to compensate potential underlying deficits through an increase in 
effort, or rather: they had to activate more strongly to keep up with the non-risk 
genotype group. Dresler et al. (2010) confirmed lower NGA values in adult ADHD 
patients to be tied to the 9R allele, with no genotype effect emerging in healthy 
controls (Dresler et al., 2010). However seeing that the risk genotype switches 
from 10R in cADHD to 9R in adult ADHD, this could also be the case for the 
relationship with this electrophysiological marker of inhibitory functioning. 
Previous studies looking into the relationship between the DAT VTNR and P300 
elicited in in a conflict processing or an auditory oddball task (Tsai et al., 2003, Han 
et al., 2010) did report no association between genotype and event-related 
potential. 
 
LPHN3  A pilot study by Fallgatter et al. (in press) classified subjects 
into a high-  and a low-risk group according to a haplotype comprising four SNPs 
  
30 
 
(rs2305339 - rs734644 - rs1397547 - rs1397548; risk haplotype: A-G-C-C). ADHD 
subjects carrying two copies risk haplotype showed smaller NGA due to a more 
anterior Go centroid. Behaviourally, these individuals committed more errors of 
inattention (miss), but no differences in false alarms or reaction times emerged. 
 
1.4.2 Working Memory 
Working memory describes the ability to temporarily hold information online and 
manipulate it for later use in the absence of external cues (Baddeley, 1992, Goldman-
Rakic, 1996). This makes working memory a prerequisite for almost any kind of 
cognitive operation, whether it is to discriminate between response inhibition and 
executions cues, or adjusting current behaviour for the attainment of a future goal. 
 
Baddeley & Hitch (1974) proposed one of the most influential models of 
working memory to date (Baddeley and Hitch, 1974). According to this model, 
working memory comprises separate storage systems with severely limited capacity 
depending on the modality of the stimulus to be encoded. Speech-based information 
is stored by means of circulation in the so-called phonological loop, thus keeping it 
active. Visual information is transferred to a visuo-spatial sketchpad, where it also can 
be manipulated. The integration of different modalities and orchestration of working 
memory operations is provided by a central executive. This central executive in turn 
has its own short-term storage, where information can be combined. In 2000, the 
authors introduced the episodic buffer as the central executive's storage component 
(Baddeley, 2000). Both contents from long-term memory as well as information from 
phonological loop and visuo-spatial sketchpad can be downloaded into this store in 
order to be manipulated and updated, making the episodic buffer a temporary 
interface between the working memory slave systems. 
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Figure 2:  Modified model of working memory (Baddeley, 2000) 
 
Both tonic and phasic DA levels in striatum and PFC are involved specific 
aspects of working memory. Hazy et al. (2006) proposed a computational model 
according to which phasic striatal DA release mediates the updating of working 
memory upon presentation of new material, and tonic DA levels in the PFC are crucial 
for the maintenance of information within the network e.g. holding information on-
line during delay periods of a task [(Hazy et al., 2006), see also (Bilder et al., 2004)]. 
The n-back task taps into verbal and spatial working memory processes (Meegan et 
al., 2004) and activates a working memory network comprising dorsolateral (DLPFC) 
and ventrolateral PFC (VLPFC) dorsal cingulate, lateral premotor cortex, medial 
premotor cortex, PFC, frontal poles and medial and lateral posterior parietal cortex 
(Owen et al., 2005). 
 
1.4.2.1 Behavioural Correlates of Working Memory 
Working memory performance is a primary deficit in ADHD (Martinussen et al., 2005; 
Willcutt et al., 2005), and unaffected siblings are impaired on an intermediate level 
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(Bidwell et al, 2007), it is heritable [43-49 %; (Ando et al., 2001)] and can be 
translated to quantitative measures. Different aspects of working memory have been 
found to be compromised in ADHD on a behavioural level (Martinussen et al., 2005, 
Keage et al., 2008) and in terms of underlying electrophysiological correlates (Barry et 
al., 2003; Keage et al., 2008). ADHD children might not have a generalized impairment 
in verbal or spatial working memory, but instead have difficulties pertaining to 
functions of the central executive that becomes especially relevant when faced with 
more complex tasks e.g. requiring switching between modalities (Karatekin, 2004). 
Behavioural abnormalities reflected by errors and reaction times during working 
memory operations can successfully be countered with psychostimulants (Kempton 
et al., 1999, Mehta et al., 2004). Importantly, working memory and response 
inhibition do not seem to represent aspects of one integrated phenotype, but it has 
been argued that inhibitory problems might be a consequence of working memory 
impairments (Schecklmann et al., 2012), although working memory has been found 
to be the link between abnormal performance in the Stop Signal Task and ADHD 
(Alderson et al., 2010). Working memory relies heavily on the integrity and the 
interplay of fronto-striatal regions as well as the cerebellum (Bunge et al., 2001, 
Gottwald et al., 2003, Kondo et al., 2004, Lewis et al., 2004).  
 
DA and NE are potent modulators of working memory functioning (Arnsten, 
2001, Goldman-Rakic et al., 2004), and they are the main agents of neuronal activity 
in frontal and striatal regions subserving working memory. Conversely, structural and 
functional abnormalities in those transmitter systems as well as fronto-striato-
cerebellar pathways are intricately implicated in the aetiopathogenesis of ADHD 
(Seidman et al., 2005). The relationship between DA levels and prefrontally based 
functions follows an inverted U-shape, making those functions susceptible to both 
too high and too low doses of the transmitter (Arnsten, 1997, Vijayraghavan et al., 
2007). Hence, working memory impairments in ADHD may be explained in terms of 
catecholaminergic dysregulation of in fronto-striato-cerebellar networks (Levy and 
Swanson, 2001). Improvement of working memory performance can be achieved via 
the administration of drugs with DA-agonistic effects (Mehta et al., 2004). As a 
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consequence, genes involved in Dopaminergic and noradrenergic neurotransmission 
in those areas are likely to exert an influence on performance and neurophysiological 
correlates in a working memory task. A recent observation of additive effects of 
COMT and DAT for working memory underlines the importance of these regions’ 
interaction (Caldu et al., 2007). Importantly, no individual effects of COMT or DAT on 
performance or brain activation could be found 
 
1.4.2.2 EEG correlates of Working Memory 
In venturing to explain the above-mentioned error-proneness of ADHD patients in 
working memory tasks, EEG is an excellent tool, since its high temporal resolution 
allows researchers to identify the stage at which differences first arise. It allows for 
the attributions of performance deficits indicated by errors to either early more 
sensory processes involved in stimulus perception and discrimination, or late more 
cognitive processes such as allocation of processing capacity or attention. To this end, 
early and late ERP components during target- and non-target trials were used for 
analysis. In response to non-target stimuli indicating a need for updating processes, 
we studied N100, P150, N300 and P450. Target trials were examined for differences in 
P100 and P300 amplitudes and latencies. 
 
1.4.2.2.1 Non-Target related ERP components in ADHD  
The frontally maximal N100 indicates early stimulus discrimination (Vogel and 
Luck, 2000). The fronto-central P150 is a sign of fronto-central networks preparing 
for impending change (Clark et al., 1998). The N300 peak at frontal and central 
sites is evoked when retrieving content from long-term storage (Friedman, 1990). 
The P450 describes a specific non-target evoked centro-parietal P300 response, 
observed when transferring information to the respective working memory store 
and thus updating working memory content (Clark et al., 1998). In addition to that 
function, it seems to be involved in the process of comparing the new stimulus 
with the preceding one (Watter et al., 2001).  
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Previous research looking into working memory updating related ERPs reports 
delayed frontal N100 and P150 responses in ADHD samples compared to controls 
when a stimulus necessitates updating of working memory content. Those early 
components can be indicators of impairment on a more basic perceptual level. 
Longer N300 frontal latencies (Karayanidis et al., 2000) and decreased amplitudes 
over central regions were present in ADHD (Sartory et al., 2002). Furthermore, 
ADHD patients exhibit prolonged P450 latencies (Strandburg et al., 1996) and they 
did increase P450 from frequent to rare stimuli to a greater degree than healthy 
controls (Karayanidis et al., 2000).  
 
Keage and colleagues (2008) were the first to comprehensively assess 
electrophysiological responses of ADHD patients in non-target trials requiring only 
updating of working memory without demands for a motor response. Without 
medication, numerous differences between combined type ADHD children and 
adolescents and matched controls emerged. Central P450 amplitude attenuation 
was observed in unmedicated ADHD patients of both the young and adolescent 
age group in comparison with healthy controls, and this was completely remedied 
by psychostimulants. This marker only remained significantly impaired in the 
inattentive sub-sample, which indicated different underlying deficits in this 
particular symptom group. As the only direct effect of medication on EEG 
parameters within the ADHD sample, in the children group medication effected a 
depression of P450 amplitudes. Surprisingly, no other direct influences of 
psychostimulants on ERPs were observed despite previous reports of normalizing 
effects (e.g. Seifert et al., 2003; Sunohara et al., 1999). The most robust finding 
was the amplitude attenuation of the P450 component, which was present across 
age groups and ADHD subtypes. This could speak to those children being less well 
able to integrate newly relevant information into the working memory image. 
Interestingly, no differences between the inattentive and the combined subtype 
were observed in terms of electrophysiological or behavioural parameters, which 
the authors interpreted as supporting evidence for the two subtypes lying on the 
same continuum instead of constituting two separate clinical entities. 
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Behaviourally, combined type ADHD came with a greater number of errors of 
commission and omission in children and additionally higher RTs and RTV in 
adolescents. Stimulants only influenced behaviour in the combined subgroup 
across the age spectrum, ameliorating RTV and omission errors, whereas it had no 
effect on inattentive ADHD. The lack of deviation from normal controls with regard 
to N100 and P150 as correlates of early stimulus processing is in line with a 
majority of the literature [e.g. (Sergeant and van der Meere, 1990, Lopez et al., 
2006).  
 
Taking into account potential developmental effects, arousal may be affected 
differently across the lifespan according to observations regarding hyper-arousal in 
cADHD and hypo-arousal after entering adolescence (Satterfield et al., 1984). This 
could be related to vigilance regulation, which has been found to be compromised 
in ADHD. Specifically the stability of vigilance states over time is affected (Sander 
et al., 2010) in all subtypes, which is in line with the variability of responses 
discussed previously. 
  
Figure 3:  Scalp distribution of non-target components during working memory  
task 
 
1.4.2.2.2 Target ERP components in ADHD   
To mirror the examination of both early and late processes performed with non-
target trials, we analysed the more perceptually based visual P100 at occipital sites 
along with the previously described parietal target P300. Abnormalities in early 
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ERP components pertaining to the integrity of the visual system in ADHD have 
been observed in a variety of tasks. As a correlate of early visual processing, 
Kemner and colleagues (1996) reported that while the strength of P100 responses 
to novel stimuli was intact in ADHD, standard and deviant stimuli elicit lower P100 
amplitudes in ADHD compared to controls (Kemner et al., 1996). Altered P100 
emerged for ADHD subjects in a variety of tasks, although the direction is not clear 
[e.g. reduced amplitude in visual search (Woestenburg et al., 1992), increased 
amplitudes in stimulus-response compatibility task (Yong-Liang et al., 2000)].  
Nazari et al. (2010) observed lower amplitudes of visual P100 specifically in NoGo 
trials of a cued CPT and longer latencies in both Go and NoGo for ADHD compared 
to controls. Investigating behavioural implications of P100 timing and strength, 
correlational analyses showed that in the total sample, P100 latency was positively 
correlated with errors of omission and commission. Further significant 
relationships with performance parameters were limited to healthy controls, 
where positive correlations of P100 amplitude with RTV and errors of commission 
as well as a negative relationship with number of hits were reported. In controls, 
higher amplitudes were associated with a greater error-proneness, and a decrease 
in P100 strength was linked to better attentional focusing and less errors. These 
two factors were however uncoupled in the ADHD group, implying that ADHD 
patients don’t benefit from lower P100 amplitudes in terms of performance the 
way healthy individuals do (Nazari et al., 2010). Regarding the timing of this early 
visual response, delayed occipital P100 (Yong- Liang et al., 2000) along with later 
N200 have been found in a cued CPT (Nazari et al., 2010). As a putative mechanism 
behind these deficits an impaired capacity for focusing attention in ADHD has been 
postulated.  
 
Gomarus et al. (2009) reported P300 amplitude to be inversely related to 
working memory demands in healthy volunteers, indicating that an increase in 
load and thus difficulty is accompanied by a decrease in amplitude (Gomarus et al., 
2009).  Kok and colleagues (2001) provided an overview of the literature and 
discussed various explanations for this relationship with regard to working 
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memory operations (Kok, 2001). This modulation by load was absent in patients 
suffering from schizophrenia, another psychiatric disorder prominently featuring a 
dysregulation of Dopaminergic neurotransmission and fronto-striatal pathways 
(Gaspar et al., 2011). Overall, studies frequently report lower P300 amplitudes in 
ADHD (see Barry et al., 2003 for a review).  
 
Sunohara et al. (1999) investigated working memory components in a sample of 
ADHD children aged 10-12 and matched controls. ADHD children performed the 
task multiple times under different MPH doses (placebo – low - high) to allow for 
direct comparisons of pharmacological effects within subjects. The paradigm used 
for this study was a modified CPT (double task) that basically functions like a 1-
back task, where repeated letters are the signal for a motor response. During 
successful response execution trials, controls had longer N2 and shorter P3 
latencies than unmedicated ADHD patients, whereas those parameters were 
normalized in the medicated patient group. Interestingly, latencies of N2 and P3 
were correlated in unmedicated patients, but this relationship lost strength with 
increased MPH dosage and was completely absent in optimally medicated ADHD 
children and healthy controls. No amplitude effects were evident on P2, N2 or P3. 
 
  
Figure 4: Scalp distribution of target components during working memory task 
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1.4.2.3 Genetic Modulation of Working Memory 
COMT  Taking into account the anatomical distribution of COMT, this gene is 
expected to exert a bigger influence on tonic aspects of working memory and the 
maintenance of information (Bilder et al. 2004). Behaviourally, COMT genotype did 
not modulate performance on an n-back task with varying load level in healthy 
adults (Blanchard et al., 2011). This was also observed in a simple n-back task; 
however in this case COMT in combination with DAT did affect performance and 
brain activation (Caldu et al., 2007). The gene seems to predominantly have an 
effect on more complex operations that require both storage and manipulation of 
working memory content in a study comparing different working memory tasks 
(Bruder et al., 2005). Comparing schizophrenia patients and their unaffected siblings 
with matched controls, homozygous Met carriers’ n-back performance was superior 
to that of individuals with the Val allele. This effect was independent of load or 
diagnostic group, and siblings showed an intermediate degree of impairment 
(Goldberg et al., 2003). COMT genotype furthermore predicts working memory 
related brain activation (Egan et al., 2001), as increasing number of Met alleles 
corresponding to attenuated task related activity during the n-back in DLPFC. In 
healthy children and adolescents, the met allele boosted working memory 
performance and related activity in right inferior frontal gyrus and intraparietal 
sulcus (Dumontheil et al. 2011). The Met/Met genotype showed more focused 
activity when engaging working memory networks indicated more efficient resource 
allocation (Bertolino et al., 2006). Being homozygous for the met allele meant lower 
working memory-related activity and connectivity within the DLPFC and higher 
activity and connectivity in the VLPFC compared to the other genotype groups 
(Sambataro et al., 2009). Finally, Yue et al. (2009) directly assessed the functional 
relationship between COMT genotype and event-related potentials in a 3-back task 
in healthy adults. Homozygous Val-carriers had better behavioural performance, 
higher P300 amplitudes and shorter latencies then subjects carrying at least one 
Met allele. The authors interpreted this finding a suggestive of superior updating 
ability and concurrent deficient maintenance of working memory content associated 
with the Val allele. Heterozygous genotypes corresponded to worst performance as 
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well as weakest and most delayed P300 responses.  Behavioural outcome was 
furthermore correlated with P300 amplitude at parietal sites (Yue et al., 2009). The 
beneficial effect of the met allele on working memory manifests around the age of 
10 (Dumontheil et al., 2011), which suggests that in the present study most subjects 
should already show a genotype effect for COMT. 
 
DAT  Normally (i.e. in healthy children), when dealing with high working 
memory loads, performance and fronto-striatal pathways activation are superior 
with 9R allele compared to 10/10, whereas DAT genotype does not play a role for 
low load tasks (Stollstorff et al., 2010). In contrast to this, DAT and COMT genotypes 
– separately or combined - had no behavioural effects on performance in a spatial n-
back even with high loads (Blanchard et al., 2011). One study performed by Karama 
et al. (2008) investigating working memory in childhood ADHD with regard to DAT 
genotype found the opposite pattern, namely an advantage of being 10/10 (Karama 
et al., 2008). It has to be considered thought that the paradigms used in this study 
taps into other functions besides working memory and might thus be influenced in a 
different way by Dopaminergic genes. However, it fit with functional findings that 
brain activity in the working memory network is more focused in homozygous 10R 
carriers of the DAT variable number tandem repeat (Bertolino et al., 2006). In adults, 
using the same set-up and load condition no DAT influence on working memory 
have been observed (Bertolino et al., 2006, Bertolino et al., 2009), but maturation of 
the brain might mean those are no longer equally demanding as they are for 
children. Thus, the importance of DAT for working memory performance (until 2-
back) should decrease with age. In healthy adult volunteers (18-22, males and 
females) there were additive effects of COMT and DAT on brain functioning during 
working memory task (fMRI during n-back), where having the Val allele (COMT) plus 
the 9R allele (DAT) was associated with higher brain activation despite equal 
performance. Individually, the 10R carriers had faster RTs and more false alarms and 
the Val allele corresponded to more false alarms and perseverative errors (Caldu et 
al., 2007). 
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1.4.3  Sensory Gating 
Sensory gating describes the pre-attentional filtering of incoming sensory input to 
prevent an overload of higher cortical areas due to concurring or excessive 
stimulation. If presented with two stimuli in short temporal succession, processing 
of the second stimulus is blocked to ensure adequate processing of the initial 
stimulus. Especially the acoustically evoked P50 as a very early component appears 
to be beyond psychological control mechanisms, as increasing the relevancy of the 
second stimulus did not alter the suppression of the second P50 wave (Jerger et al., 
1992). It is largely independent of pre-stimulus alertness and gender (Cardenas et 
al., 1997, Lijffijt et al., 2009b). P50 amplitudes vary with stimulus intensity, however 
anything short of startle-evoking intensities do not influence the gating ratio 
(Griffith et al., 1995). This makes it a relatively pure indictor of the fundamental 
neuronal rather than higher order psychological foundations of information 
processing and thus speaks for the suitability of this parameter as an 
endophenotype in its own right. Still, the pre-attentional nature of the P50 has been 
called into question, as without further instruction wakeful alertness as indicated by 
pre-stimulus beta-power did not influence gating (Cardenas et al., 1997), whereas 
explicit directions to attend to the first or the second stimulus could shape the 
amplitudes and the ratio of those components in a sample of schizophrenic patients 
(Yee et al., 2010). Furthermore, special physiological states such as pain or (Johnson 
and Adler, 1993) or stress (Yee and White, 2001) modulate sensory gating. 
However, these constitute extreme situations with high evolutionary significance, 
putting the whole organism in a state of alert.  In this context it makes sense to 
lower the bar for stimuli to be passed on to higher cortical areas, as they warrant 
heightened scrutiny for potential significance relating to the source of the stress or 
pain, respectively. Using a variant of the CPT with healthy participants, Lijfijt et al. 
(2009) described that P50 suppression was negatively related to errors of 
commission, and stronger gating resulted in longer reaction times. Good N100 
gating also contributed to performance. The efficiency of this control mechanism 
proved to be diminished in a range of psychiatric conditions such as bipolar 
disorder, schizophrenia, post-traumatic stress disorder or panic disorder (Ghisolfi et 
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al., 2006, Karl et al., 2006, Patterson et al., 2008, Lijffijt et al., 2009c). A deficit in this 
domain would consequently lead to the flooding of higher cortical areas with 
irrelevant information, thus potentially contributing to the ADHD associated 
distractibility and disorganisation. 
 
Olincy and colleagues (2000) were the first to compare a sample of 16 
unmedicated adult ADHD patients to a matched group of healthy controls in terms 
of P50 sensory gating (Olincy et al., 2000). Neither conditioning or testing 
amplitudes nor the P50 ratio could distinguish between the two groups, however 
the P50 difference score was greater for controls indicating better sensory gating at 
p = .050. None of the reported markers were correlated with ADHD symptom 
severity. A lack of suppression was observed in 25 % of patients, but this was not 
statistically different from the 10% of non-suppression seen in healthy probands. 
Feifel and colleagues (2009) confirmed intact gating in a prepulse inhibition 
paradigm, again in an adult ADHD population (Feifel et al., 2009). In contrast to this, 
ADHD children and adolescents had compromised P50 suppression compared to a 
matched control sample (Durukan et al., 2011). The observed differences in P50 
gating ratios were attributable to altered testing responses, as those were found to 
be both delayed and of higher in amplitude in ADHD children, whereas reactions to 
conditioning stimuli were identical. Administering MPH to the same group before a 
second session led to a decrease in amplitude and latency of testing responses, 
furthermore conditioning responses were also speeded up. Unfortunately the 
authors did not report on comparisons between the medicated ADHD sample and 
controls, but by visual inspection all parameters seem to have been returned to 
normal levels. Conversely, prepulse inhibition in a young sample with ADHD was 
impaired and could again be remedied by stimulant administration (Hawk et al., 
2003). A possible explanation for the discrepant observations in young vs. adult 
populations could be that sensory gating improves with age (Marshall et al., 2004, 
Brinkman and Stauder, 2007), suggesting a development effect especially in ADHD 
patients who are characterised by a delay in cortical maturation (Shaw et al., 2007). 
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Figure 5:  Sensory gating mechanism. The black triangle represents the P50 
response to S1, the red triangle represents the weaker P50 response to S2 
representing successful suppression. 
 
Regarding the proposed mechanism of P50 deficit in ADHD, the prime suspect is an 
altered catecholamine balance. Catecholamines play an important role for sensory 
gating, and Adler et al., (1988) were able to demonstrate that the administration of 
amphetamine – a drug that enhances dopaminergic neurotransmission primarily in 
striatum and reward-related areas - interfered with suppression of the second 
stimulus, and this could be countered with the DA antagonist and antipsychotic 
haloperidol. Furthermore, amphetamines effected a P50 response to the 
conditioning stimulus that was decreased in amplitude and latency, which again 
could be returned to normal with haloperidol (Adler et al., 1988). According to this 
line of evidence, high DA levels seem to actually be counterproductive with respect 
to the filtering of surplus information.  
 
Genetic Modulation of Sensory Gating 
COMT Dopaminergic signalling is essential for intact sensory gating. Prepulse 
inhibition of the startle reflex is enhanced in homozygous Met carriers and 
inhibitory power decreasing with increasing number of Val alleles (Roussos et al., 
2008, Quednow et al., 2009). Studies on P50 sensory gating in schizophrenia 
patients found either an advantage for Val/Val genotypes (Lu et al., 2007) or no 
association of COMT and gating potential (Shaikh et al., 2011), while in healthy 
controls there was a consistent lack of association. Majic and colleagues (2011) 
replicated the independence of P50 gating from COMT genotype in a large sample 
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of healthy adults. Both P50 and P100 capture aspects of sensory gating, but P50 is 
less dependent on psychological variables and reflects comparatively pure pre-
attentional processes. Interestingly, while P50 suppression was not modulated by 
the Val158Met polymorphism, gating ratios of the N100 were found to be stronger 
in Val/Val carriers (Majic et al., 2011). In light of the fact that stronger gating is 
usually indicative of better cognitive functioning, and subjects with at least one Met 
allele have an advantage in various cognitive operations, this result is surprising. 
 
DAT  To our best knowledge, Millar and colleagues (2011) were the first to 
investigate the modulation of sensory gating by DAT genotype in healthy volunteers 
(18-40 years). They found the carrying of at least one 9R allele - associated with 
lower gene expression - to be related to better filtering abilities. Only in this 
genotype group could gating be further enhanced with nicotine (Millar et al., 2011). 
Taken together with the fact that nicotinic acetylcholine (nACh) neurotransmission 
interacts with expression and function of the DAT (Li et al., 2004, Parish et al., 
2005), and activation of presynaptic nACh receptors supports striatal DA release 
(Grady et al., 2002), the importance of a functional variant within the DAT gene for 
sensory gating needs to be further explored.  
 
1.4.4 Response Time Variability 
Response time variability (RTV) expresses the degree to which reactions vary in their 
speed within one person across tasks. It is common for healthy individuals to develop 
a characteristic and stable response speed as reflected by mean reaction time, with 
the standard deviation as an indicator of RTV becoming smaller. Support for this 
comes e.g. from Rommelse et al. (2008), who could show that response time 
variability decreases with age in healthy controls (Ø 11.6 ± 3.2 years 5-19), and 
reaction times more or less settle to an individual level with comparatively little 
variance (Rommelse et al., 2008d). However, this can of course be disrupted by 
factors like a transient change in the state of alertness or effects of various kinds of 
drugs.  
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Instead of a linear decline of attention and focus over time, ADHD is more 
characterized by patients’ inability to adequately regulate their energetic state, which 
provokes frequent lapses in attention (Sergeant, 2005). One possible explanation is 
intrusions of the Default Mode Network (DMN) associated with rest and interfering 
with task-related activation (Sonuga-Barke and Castellanos, 2007). The term DMN 
describes a distributed set of functionally strongly connected brain structures 
comprising the ventral medial PFC, posterior cingulate cortex and precuneus, which is 
active at rest and attenuates its activity when the brain shifts into task mode (Raichle 
et al., 2001). The degree of deactivation increases with task difficulty (Singh and 
Fawcett, 2008) and is correlated with performance (Weissman et al., 2006, Li et al., 
2007). Although results are still inconclusive with regard to the exact nature of the 
disturbance in ADHD, various studies found compromised functional connectivity in 
ADHD within the DMN, as well as between DMN and other regions (Castellanos et al., 
2008, Tian et al., 2008). Peterson and colleagues demonstrated that the excess DMN 
activity at the expense of speed and accuracy observed in ADHD can be partly 
remedied with MPH (Peterson et al., 2009). One compelling explanation for ADHD-
related deficits comes from the default mode interference hypothesis by Sonuga-
Barke and Castellanos (2007), which postulates that the brain fails to adequately 
attenuate the task-negative DMN when faced with a cognitive task, and this rest-
associated activity then interferes with performance by means of periodic lapses of 
attention (Sonuga-Barke and Castellanos, 2007). ADHD patients have consistently 
been shown to display slower reaction times along with a higher variability [e.g. 
during CPT (Borger et al., 1999, Heinzel et al., 2012); during basic motor task 
(Rommelse et al., 2008d). Additionally, a greater increase of variability along with a 
faster deterioration of performance (on-task behaviour, omission errors did not 
increase as the task went on, even though that type of error was more frequent in 
ADHD children) over time could be observed in the ADHD groups as compared to 
controls (Borger et al., 1999). This variability was shown to be related to most 
symptoms of ADHD (Epstein et al., 2003) and highly heritable (Kuntsi et al., 2006). 
Furthermore, non-affected siblings score between that of controls and their affected 
siblings (Uebel et al., 2010), speaking to the suitability of RTV as an endophenotype 
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for ADHD. RTV can be decreased by stimulant administration, suggesting the 
catecholaminergic regulation of intra-individual variability (Nandam et al., 2011). 
Interestingly, this effect is independent of stimulant effects on performance (SSRT). 
 
Genetic Modulation of RTV 
COMT  In healthy individuals, RTV in a CPT proves to be largely unaffected by 
COMT or DAT genotype, either singly or in combination (Bender et al., 2012, Heinzel 
et al., 2012). Heinzel and colleagues (2012) also included an ADHD group, which 
despite having a higher mean RTV mirrored the genotype-independence of the 
variability of reaction times in controls. Contrasting these negative results, Stefanis et 
al. (2005) found the met allele to be favourable for the stability of RTs in a large of 
young male adults (Stefanis et al., 2005). 
 
DAT  Higher RTV has been found to be related to Dopaminergic system 
genes such as DRD4 (Kebir and Joober, 2011). Looking at comparisons between ADHD 
and healthy controls, high-risk (10/10) ADHD children had more variable RTs than 
controls (Bellgrove et al., 2005), whereas low risk ADHD patients with at least one 
compensatory 9R allele did not differ from controls. Within an ADHD sample, being 
homozygous for the10R corresponds to having even more variable RTs than those 
patients with at least one 9R allele (Loo et al., 2003). In contrast to these reports, in a 
sample of Korean boys with ADHD, the DAT VNTR did not influence reaction times or 
RTV (Oh et al., 2003). Finally, widening the scope to additional functional variants 
within the DAT gene, several SNPs in the DAT gene were implicated in RTV, however 
the two included VNTRs came up negative (Cummins et al., 2012). 
 
1.4.5 Outlook: Developmental course of the candidate endophenotypes  
A few lines of evidence led to our including an exploratory catamnestic part re-
examining a small subset of participants after approximately three years to take a 
closer look at developmental effects on response inhibition, working memory and 
response time variability. 
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Since developmental lag rather than a fundamental deviation from normal 
developmental templates has emerged as the leading explanation for ADHD-related 
deficits (Kinsbourne, 1973), and normal cortical development is prominently altered 
in patients, it is vital to monitor changes in ADHD-associated behavioural and 
electrophysiological deficits related to maturational processes as patients grow up. 
Shaw et al. (2007) found ADHD specific abnormalities in the speed of cortical 
maturation, while the normal temporal sequence of regions reaching full maturity 
was preserved. The motor cortex reached peak cortical thickness earlier in ADHD, 
whereas in those children prefrontal areas necessary for regulating motor behaviour 
lagged approximately 5 years behind normal controls. Stimulant medication exerted a 
normalising effect on ADHD-related deviant cortical thickness (Shaw et al., 2009a). On 
average, cortical thickness was reduced in prefrontal and temporal areas in ADHD 
compared to controls, and worse clinical outcome was linked to thinner cortices in 
those two regions. Longitudinally, ADHD children with better clinical outcomes also 
showed a normalisation of cortical thickness in the parietal but not the motor cortex 
by late adolescence (Shaw et al., 2006). Typically developing children on average 
attained a higher mean prefrontal thickness before entering the thinning phase, and 
they furthermore reached that point of peak thickness faster than ADHD children 
(Shaw et al., 2007). The subsequent process of cortical thinning obliterating surplus 
connections was entered into earlier by healthy controls, this this group reached the 
fully mature state of the cortex at a younger age than  their ADHD peers.  
Unmedicated ADHD patients showed an abnormally slow rate of cortical thinning 
(Shaw et al., 2011), and thinner prefrontal cortices in ADHD were furthermore 
associated with more severe clinical outcomes (Shaw et al., 2006). Support for the 
dimensional nature of ADHD comes from findings that this slowed cortical thinning 
can also be observed in normally developing children depending on their level of 
hyperactive traits (Shaw et al., 2011). Since most ADHD patients receive stimulant 
medication over long periods of time, Shaw and colleagues investigated the influence 
of those substances on the developing cortex, and reported excessive thinning in 
unmedicated ADHD children in comparison to controls of the same age, which was 
slowed to normal levels with medication (Shaw et al., 2009). This contradictory 
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finding might be due to the separate analysis of medicated and unmedicated ADHD 
groups, which were not distinguished in the previous study. The COMT gene has also 
been implicated in this process of cortical shaping during development. The number 
of Met alleles was positively related to cortical thickness in the right inferior frontal 
cortex and temporal areas, the former of which is prominently associated with 
response inhibition (Shaw et al., 2009b).  
 
Behavioural parameters Attentional functions and response time variability are 
time-dependent to varying degrees, with differences between ADHD and controls 
fluctuating during the transition from childhood to adolescence (Drechsler et al., 
2005). Biederman and Faraone (2009) postulated that cognitive and executive 
functioning (e.g. working memory, flexibility) was largely independent of the clinical 
outcome of ADHD symptoms, as both patients in remission and with a persistent 
ADHD performed worse than controls (Biederman et al., 2009). A meta-analytic 
review of studies pertaining to response inhibition and memory impairments in adult 
ADHD patients confirmed the persistent nature of executive dysfunction (Hervey et 
al., 2004). Although ADHD symptoms, particularly of the hyperactive domain, tend to 
decline with age (Faraone et al., 2006), inhibitory deficits associated with childhood 
ADHD are also present in adult patients (Boonstra et al., 2010). In normally 
developing individuals, errors tend to decrease and reaction times speed up with age, 
while ADHD deficits remained stable.  In fact, performance of ADHD children was 
comparable to that of younger controls, supporting the developmental lag hypothesis 
(Doehnert et al., 2010). Reaction times stabilise at an individual level in adulthood, 
accordingly RTV is diminishes with age (Rommelse et al., 2008). While a recent meta-
analyses comparing younger and older adults report an age-related increase in RTV 
(Dykiert et al., 2012), a study examining children and adolescents found a 
pronounced linear decrease in RTV with age (Tamnes et al., 2012). 
 
Response inhibition  Electrophysiologically, Doehnert et al., (2010) observed 
reduced cue P3a and P3b in the ADHD group; this along with a persistently reduced 
NoGo-P300 was a largely stable deficit over the 2.5 years covered. In sum, these 
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authors’ findings are mixed, partially supporting the developmental lag model and 
partially being more compatible with a deviation from normal development. There 
remains the possibility of the aforementioned lag being too great to be caught up 
within the critical period, thus making it permanent. Ultimately, Doehnert et al. 
(2012) followed a group of 11 ADHD patients (Ø 10.9 years) diagnosed in childhood 
over the course of 11 years and assessed them at four time points (baseline, T2 = 1.1 
years, T3 = 2.4 years and T4 = 11 years) with a CPT / Go-NoGo paradigm, looking both 
at preparatory and inhibition-related processes. The absence of group by time 
interactions suggest that none of the parameters deviated from the typical 
developmental trajectory, the direction of change over time was the same for ADHD 
and controls. Behavioural parameters (RT, RTV, errors of omission) and preparatory 
potentials (Contingent Negative Variation CNV, Cue P300) decreased over time, with 
ADHD patients having higher RTV and lower Hit rate and magnitudes of Cue-P300 and 
CNV at single measurement points. Interestingly, the CNV was the only marker to be 
consistently diminished, lending support to its suitability as a stable candidate 
endophenotype present even in patients no longer meeting full ADHD criteria. NoGo 
global field power amplitude decreased with age, but was higher in ADHD compared 
to controls at T3. Early studies looking into developmental changes in event-related 
potentials specifically to visual language stimuli noted a speeding up of N2 with a 
minimum in adolescence and P3 with shortest latencies in adulthood (Taylor and 
Williams, 1988). The adult group in the study by Taylor ranged only from 20 to 29 
years, so later potential reversals of changes in timing and strength of the ERPs could 
not be ruled out.  Indeed, for the P300 there seems to be a subsequent increase in 
latencies throughout adult life, and this latency lengthening with age seems to be a 
stable phenomenon [see meta-analysis by (Polich, 1996)]. P300 amplitudes are 
decreased in ADHD, and this attenuation with regard to healthy controls grows 
stronger with age (Szuromi et al., 2011). In a study employing a large adult age range 
(20-88 years), amplitude was negatively and latency was positively correlated with 
age for visual P3a and P3b to target and distractor stimuli (Fjell and Walhovd, 2004). 
Looking at P3b in more detail, the relationship appears more complex, with 
amplitudes decreasing from childhood into late adolescence and increasing again in 
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later life (Stige et al., 2007). Taylor on the other hand pinpointed the turning point at 
around 11 years of age (Taylor, 1988). In healthy people, better cognitive abilities 
have been linked to greater P300 amplitudes, indicating a performance augmenting 
effect of this additional recruitment of resources (Daffner et al., 2006). I the 
consequence, higher amplitudes in ADHD subjects might be a marker for a successful 
compensation of underlying deficits. Findings regarding N200 are mixed, depending 
on the subtype of the component. There is little to no influence of age on visual and 
auditory MMN, while visual oddball N2b latency is decreased in older subjects. In 
their review Patel & Assam (2005) concluded that N2b latency increases and 
amplitude decreases with age throughout adulthood (Patel and Azzam, 2005). Similar 
to P300, a U-shaped course over the whole lifespan meant that while in a younger 
sample [7-24 years (Van der Stelt et al., 1998)] latencies decreased with age, the 
opposite pattern was true for a samples covering the adult lifespan (Amenedo and 
Diaz, 1998, Falkenstein et al., 2002). 
 
Topographically, while both centroids shift towards frontal areas with age, the 
NGA as the difference measure of the two remains unaffected (Fallgatter et al., 1999). 
In adulthood, NGA is a very stable marker with high test-retest-reliability (Fallgatter et 
al., 2002a). However so far no study has established the age at which NGA first 
emerges. So while we do not expect to find differences in NGA between 
measurements, the location of both centroids should shift towards more frontal areas 
in controls and this anteriorization should be weaker in the unmedicated ADHD 
group. However, depending on the peak age, ADHD children who show low initial 
NGA might very well improve as the PFC matures, and the distance to healthy 
individuals might become smaller. ADHD patients should display dampened ERPs 
owing to a general state of hypo-arousal due to unstable vigilance regulation, and this 
should be countered by psychostimulant action (Sander et al., 2010). Lower 
amplitudes particularly on late components are expected to persist across both 
measurements in the unmedicated ADHD group. Along those lines, N200 and P300 
should decrease in amplitude and latency between measurements for healthy 
controls and remain lower respectively delayed in unmedicated ADHD. 
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Working memory Approaching the question of developmental effects on working 
memory on a behavioural level, Lamkbek & Shevlin (2011) conducted a study 
assessing response inhibition as well as verbal and spatial working memory with the 
objective to establish whether these were changing independently during normal 
development. Children and adolescents aged 7 to 16 showed a marked improvement 
i all three domains with age, which furthermore proved to be linked despite being 
clearly distinguishable factors (Lambek and Shevlin, 2011). This improvement seems 
to be attributable to the intensified recruitment of crucial frontal, striatal and parietal 
areas subserving working memory (Bunge and Wright, 2007). In later life working 
memory capacities deteriorate, and this process is particularly pronounced for spatial 
compared to verbal working memory (Myerson et al., 1999). Correspondingly, ERP 
studies on working memory described an increase in amplitude for early auditory and 
visual components like P100 (Pelosi and Blumhardt, 1999) and P200 (McEvoy et al., 
2001). P300 responses in working memory tasks have been found to decrease in 
magnitude and slow down in older subjects (McEvoy et al., 2001). This could point to 
the recruitment of different areas in different stages of life (parietal in early life to 
frontal in later life). Indeed, young adolescents rely on both hippocampus and PFC, 
while late adolescence marks the start of a period where hippocampal regions loose 
importance until in adults they are only additionally employed for highly demanding 
tasks (Finn et al., 2010). Regarding ADHD specific development, Keage and colleagues 
(2008) compared children (Ø 10.4 years) and adolescents (Ø 14.9 years) of combined 
and inattentive subtype with matched controls, and those mean ages are mirrored in 
the two measurement points of the present study. Both age groups had lower P450 
activation (see also Strandburg et al., 1996 for age-independence of P450 
attenuation), however ADHD children had dampened and ADHD adolescents had 
delayed N300 responses. Early potentials arising from perceptual processes were 
normal in ADHD patients irrespective of age and subtype. N300 and P450 as largely 
endogenous potentials were altered, indicating difficulties with incorporating new 
information into working memory storage. So while we expect healthy control 
children to follow those developmental trajectories, ADHD patients should lag behind 
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in terms of speeded up and more efficient processing as indicated by shorter 
latencies and decreasing amplitudes and remain impaired at T2. 
 
Candidate genes  Decreasing basal DA levels with age and the PFC becoming 
more important in most cognitive operations are both already effective during 
adolescence, thus making this period likely to be marked by changing modulating 
influence of out candidate genes. Most executive functions are known to be in in the 
process of maturation well into early adulthood (De Luca et al., 2003). COMT 
metabolism gains significance with the progressive maturation of the PFC as its main 
site of action throughout adolescence and early adulthood. Dumontheil and 
colleagues (2011) reported on behavioural and functional implications of COMT 
genotype on working memory. The performance advantage associated with carrying a 
Met allele only set in after the age of 10, and corresponding lower frontal and parietal 
activation with age compared to homozygous Val carriers. If this is an incremental 
effect, met carriers should differ from the Val/Val to a greater degree at T2. Age has 
been found to exacerbate the moderating effects of COMT on cognitive functioning, 
with the Val allele corresponding to impaired cognitive flexibility and slower 
responses in a spatial working memory especially in older versus younger adults 
(Nagel et al., 2008). DAT genotype also gains relevance in adolescence, since DA levels 
are known to be inversely related to age (Barkley et al., 2006b) and should 
predominantly benefit striatally mediated functions since DAT is the main modulator 
of Dopaminergic transmission. This is supported by a study by Bäckmann et al. (2000) 
showing that cognitive functioning and decline in cognitive abilities with age is 
mediated by striatal DA metabolism (Backman et al., 2000). 
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Figure 6:  Study design 
 
1.5 Research Objectives and Hypotheses 
1) Does ADHD negatively influence behavioural performance on tasks assessing 
response inhibition and working memory? 
1.1  Influence of diagnostic status on behavioural parameters 
 produce more errors of omission and commission across tasks. 
 show prolonged and more variable reaction times across tasks. 
1.2  Modulation by candidate genes 
 For COMT, carriers of at least one Met allele should perform better 
since this variant is associated with better cognitive functioning 
 For DAT, homozygosity for the 10R allele should confer impaired 
cognitive performance. 
 For LPHN3, not having the risk variants leads to superior performance. 
 
2) Do ADHD patients differ from healthy controls in behavioural and electrophysiological 
parameters pertaining to response inhibition? 
2.1  Influence of diagnostic status on response inhibition 
The unmedicated ADHD group is expected to  
 commit more false alarms across tasks. 
 show reduced NGA and more posterior centroids in the CPT. 
 have lower amplitude and longer latency for N200 and P300. 
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2.2  Modulation by candidate genes 
 For COMT, the risk Met allele should confer stronger NGA and more 
posterior Go centroids in ADHD, while it should be of less importance 
in healthy controls. 
 For DAT, the homozygous 10R group is expected to show lower NGA in 
ADHD, but not in controls. 
 For LPHN3, ADHD patients with the risk haplotype have a lower NGA 
due to more anterior Go centroid. 
 
3) Is working memory negatively affected by ADHD? 
3.1  Influence of diagnostic status on working memory  
Unmedicated ADHD patients are expected to show 
 prolonged latencies for N100, P150 and N300; P100.  
 dampened P450 activity reflecting weaker working memory updating. 
 lower P100 and P300 amplitudes reflecting impaired vigilance and 
event categorization. 
3.2  Modulation by candidate genes 
 For COMT, the Met allele evokes P100 and P300 of lower amplitude 
and longer latency due to lower task related activation of the working 
memory network. 
 For DAT, 10R/10R carriers have lower amplitudes and delayed 
latencies since individuals with this genotype display more focused 
working memory network activation 
 
4) Is Sensory Gating impaired in ADHD patients? 
4.1 Influence of diagnostic status on sensory gating 
Without stimulant medication, ADHD patients should display  
 weaker rates of suppression compared to healthy controls. 
 delayed and enhanced testing P50. 
4.2  Modulation by candidate genes 
 For COMT, Met carriers should show compromised suppression rates. 
 For DAT, the 9R allele produces better gating and higher suppression. 
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5) Response Time Variability  
5.1 Influence of diagnostic status on RTV 
 In unmedicated ADHD patients, we expect to find increased RTV in 
compared to controls due to disturbed state regulation 
5.2  Modulation by candidate genes 
 For COMT, the Met allele is associated with less variable responses. 
 For DAT, homozygous 10R children display higher RTV. 
6) Does ADHD affect maturational effects on behaviour, response inhibition and working 
memory as evidenced in the exploratory longitudinal examination of a subsample or 
patients and controls? 
From the first measurement point (T1) to the second examination (T2) 
 NGA should improve and reflect maturation of the PFC 
 amplitudes and latencies should decrease. Target P300 decreases in controls 
with age, whereas ADHD patients show the opposite pattern. 
 RTV should decrease especially in controls, since reaction times become more 
stable with age, and differences to ADHD should be magnified at T2. 
 differences between COMT genotypes should get bigger, since beneficial 
effects of the Met allele begin to show around age 10. 
 differences in relation to DAT genotype should be diminished as the ADHD risk 
allele for DAT switches with age. 
 
7) Administration of psychostimulants is expected to remedy deviations owing to ADHD. 
 
2 Methods 
2.1 Sample characteristics and procedure 
Patients diagnosed with cADHD from the in-patient and out-patient facility of the 
Department for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, 
University Würzburg as well as children and adolescent from the department’s control 
subjects pool were approached and briefly informed about the purpose of the study. If 
they expressed an interest in participating, they were thoroughly briefed about the aims 
and the exact study procedure. Providing informed consent, they answered a selection 
of questionnaires and came in for an appointment of approximately 2 hours duration for 
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electrophysiological testing, at the end of which a compensation of 30 Euros was 
provided. For participants under the age of 18, additional informed consent was 
obtained from the parents. Psychopathology was extensively assessed by means of a 
semi-structured clinical interview [KIDDIE-SADS-PL, (Kaufman et al., 1997); German 
version by Deutsche K-SADS-Arbeitsgruppe, 2001]. Current ADHD was confirmed by a 
clinically trained observer using both patient and parents as information sources 
(parental version of the KIDDIE-SADS-PL without medication and DSM-IV criteria for < 
18; DSM-IV criteria only for > 18). Additionally, the presence of other psychiatric and 
behavioural problems was assessed with the Child Behaviour Checklist [CBCL; 
(Achenbach and Edelbrock, 1983); German adaptation by Döpfner and colleagues 
1998)], which can further distinguish between externalizing and internalizing symptoms. 
Exclusion criteria were IQ below 70 or presence of conditions that would prevent the 
recording of a sufficiently clean electroencephalogram (e.g. Tourette Syndrome). The 
main criterion for control subjects was absence of psychiatric disorders. Comorbidities 
observed in the ADHD sample included conduct disorder (N=5), oppositional defiant 
disorder (N=22), depression (N=8) and anxiety disorders (specific phobia N=4, 
separation anxiety N=1), enuresis (N=12) and encopresis (N=1), tics (N=6) and obsessive 
compulsive disorder (N=1). Patients receiving medication for their ADHD were either 
asked to discontinue pharmacological  treatment for at least 48 hours prior to testing 
(unmedicated ADHD) or to follow their normal routine (medicated ADHD). The 
predominantly male sample (male-to-female ratio of 1.8 at T1 and 1.4 at T2) thus 
comprised two ADHD groups (unmedicated ADHD or ADHDunmed and medicated ADHD or 
ADHDmed) and matched healthy controls, since we were interested in both performance 
under presumably optimal conditions and in a natural state in ADHD as well as normally 
developing children. The unmedicated ADHD group also included medication naive 
subjects. Mean age of the total sample was 10.55 ± 0.26 (SE) years at T1 and 13.52 ± 
0.40 (SE) years at T2. For a details on the sample, please refer to Table 1. 
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  ADHDunmed ADHDmed Controls p 
Age  mean  
(SE) 
10.14  
(0.39) 
10.81  
(0.43) 
10.73  
(0.51) 
.509 
Gender (male /female) 26/16 29/7 22/19 .043 
Subtype Inattentive 
Combined 
6 
37 
4 
32 
- .748 
CBCL Sum 
Internalizing 
Externalizing 
12 (1.20) 
18.32 (1.81) 
47.37 (3.3) 
13.27 (1.6) 
20.52 (2.09) 
55.94 (4.87) 
4.05 (0.59) 
2.03 (0.44) 
5.34 (1.04) 
Controls < ADHDmed 
                < ADHDunmed 
DSM Inattentive 
Hyperact-imp 
7.29 (0.36) 
7.08 (0.35) 
7.67 (0.29) 
7.84 (0.24) - 
.425 
.089 
Medication  
type 
MPH 
Atx 
AMPH 
MPH + Atx 
- 
30 
1 
4 
1 
- 
  
  42 36 41 
Table 1: Sample description at measurement point T1 
 
All experiments were conducted in a quiet and darkened room with a constant 
temperature in the Department of Psychiatry, Psychosomatics and Psychotherapy 
Würzburg. Participants were seated in front of a computer screen at a distance of 
approximately 1.2 meters and instructed to move as little as possible during the 
recording. For the sensory gating paradigm, a fixation cross attached to the screen 
served as a visual orientation aid. The neuropsychological test battery probed response 
inhibition with the CPT (Rosvold et al., 1956), working memory with the n-back task in 
two load conditions (1-back and 2-back) and sensory gating with an auditory double-
click-tone paradigm (Adler et al., 1982). All procedures involved were approved by the 
university’s ethics committee and in accordance with the latest version of the 
declaration of Helsinki. 
 T1 T2 
CPT 105 38 
n-Back           targets 
                       non-targets 
95 
111 
45 
44 
P50 46 - 
Out of total 119 50 
Table2: Participants with > 15 valid EEG epochs 
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2.2 Electrophysiological recording 
Twenty-one EEG channels were recorded using a 32-channel DC amplifier (Brain-Star 
System, Erlangen) and the software VisionRecorder (Brain Products GmbH, Hamburg, 
Germany) with a sampling rate of 1000 Hz, a bandpass between 0.1 to 100 Hz and a 
50Hz notch filter to compensate for external electrical influences. The ground 
electrode was located between Fz and Fpz, the recording reference between Fz and Cz. 
The 21 data electrodes were placed in accordance with the international 10-20 system 
(Jasper, 1958) at frontal (Fp1 Fpz, Fp2, F3, F4, Fz, F7, F8), central (C3, Cz, C4), temporal 
(T3, T4, T5, T6) and posterior (P3, Pz, P4, O1, Oz, O2) sites as well as right and left 
mastoids. Additional electrodes were located at the outer canthi of both eyes for 
horizontal and under the right eye (recorded against Fp2) for vertical eye movements. 
Offline data analysis was performed with the Brain Vision Recorder software (Brain 
Products, Munich, Germany). 
After application of task-appropriate filter settings, the data was re-referenced and 
segmented into epochs of 850 ms length including a 150 ms pre-stimulus baseline. For 
detection of blink artifacts, the algorithm developed by Gratton & Coles (1989) was 
employed. Segments containing signals exceeding ± 100 µV were automatically 
rejected. Additionally, all kept segments were visually inspected. If less than 15 artifact 
free epochs remained for any test subject, individual channels were excluded if they 
were not relevant for the components of interest and constituted the sole source of 
interference. Peak detection was performed in a semi-automatic manner and the 
investigator confirmed each identified peak. 
 
2.3      Neuropsychological Test Battery 
2.3.1   Response Inhibition 
2.3.1.1 Continuous Performance Test  
A cued CPT was employed to study response inhibition capabilities. Stimuli for this 
task consisted of eleven letters: nine distractors (A through G, J and L), a primer (O) 
and the go-signal X. Participants were instructed to press the space bar as quickly as 
possible whenever the letter O was followed directly by the letter X (Go-trials), but 
to not react to any other combination of stimuli. In the case of the go-signal X 
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appearing after any other letter than the primer, it was also treated as a facultative 
distractor (DisX). NoGo trials were those specifically designed to assess the capacity 
for inhibition of a prepared motor response and consisted of the primer stimulus O 
being followed by one of the distractors. Seeing the primer puts participants in a 
state of vigilance and has them involuntarily preparing for a button press, so 
refraining from executing it requires inhibitory control from the PFC and deficits 
should be reflected in the number of false alarms in the behavioural output (errors 
of commission). Failing to respond to the go-stimulus constitutes an error of 
omission and is thought to reflect inattention. All stimuli were present for 200 ms, 
with an inter stimulus interval (ITI) of 1650 ms. 
 
2.3.1.2 EEG specifications 
Offline, the signal was bandpass-filtered between 0.1-50 Hz and re-referenced to an 
average reference. Data was segmented into Go- and No-Go epochs (850 ms with a 
150 ms baseline) and those segments were averaged. A semi-automatic peak 
detection algorithm was applied in order to identify N200 (250-350 ms) and P300. 
For further analyses, the mean N200 amplitudes and latencies of all electrodes 
where this peak was scored (Fz and Cz) were used. P300 was scored at Pz for Go-
trials (265-420 ms) and at Cz for NoGo-trials (325-475 ms). For calculation of the 
NGA, the P300 peaks of the Global Field Power (GFP) are identified in identical time 
windows, and the centre of the positive electrical field of the brain at this peak time 
is then mapped onto a spatial coordinate system ranging from 1 (anterior) to 5 
(posterior). The NGA as the difference between the centroid location in Go- versus 
NoGo-trials represents the condition-specific anteriorization of the brain’s 
activation focus. Additionally, peaks at individual electrode sites (Cz and Pz) were 
subjected to the same procedure. 
 
2.3.2 Working Memory 
2.3.2.1 n-Back task  
Working Memory was assessed with an n-back task in two load conditions. For each 
condition, a total of 216 letters (J, B, C, D, E, F, G. H, L) including 54 target stimuli 
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were presented for 200 ms each, with an ITI of 1650 ms. Subjects were required to 
press a button whenever the letter on screen was identical to the last (1-back) or 
second-to last (2-back) letter. The two conditions were presented in separate 
blocks.  
 
2.3.2.2 EEG specifications 
Signals between 0.1 – 25 Hz were re-referenced to linked mastoids and segmented 
into target and non-target trials. Two kinds of trials were used for analysis of 
corresponding brain activation, namely trials when subjects made a correct 
response to a target stimulus (target trial) or when no response occurred after a 
distractor (non-target trial). Non-target ERPs included a minimum of 20 epochs. For 
non-target ERPs, we looked at four components reflecting the different stages of 
working memory operations: the N100 at frontal sites (F3, Fz, F4) reflecting early 
discrimination was defined as the most negative peak between 50 and 150 ms. 
P150 (implicated in the selection of material) and N300 (associated with memory 
retrieval) were analyzed at frontal and central sites (F3, Fz, F4, C3, Cz, C4) within a 
timeframe of 120 – 300 ms and 200 – 400 ms, respectively. P450wm (involved in 
working memory updating) was defined as the mean activity at central and parietal 
sites (C3, Cz, C4, P3, Pz, P4) between 440-460 ms post-stimulus. For target trials, 
fronto-polar electrodes were excluded prior to artefact rejection to increase the 
number of trials going into the averaged ERP. The most negative peak at occipital 
electrodes (O1, Oz, O2) within 70-150 ms post-stimulus represented the P100 (early 
visual processing). P300 (event categorisation and evaluation) was defined as the 
most positive parietal peak (P3, Pz, P4) within the classical timeframe between 250 
and 400 ms.  
 
2.3.3   Sensory Gating 
2.3.3.1 Dual-Click paradigm 
To elicit the P50 response and induce sensory gating in the form of suppression of a 
temporally close interfering stimulus, pairs of auditory click tones with an inter-
stimulus interval of 500 ms and an inter trial interval of 1750 ms were used, with a 
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volume calibrated for the tones to be clearly audible but not of startle-inducing 
magnitude. Two blocks of forty click-pairs were presented via headphones, with a 
break of 30 seconds between blocks. The ratio of P50 amplitude to the second 
(testing) to the first (conditioning) stimulus was multiplied by 100 and the result 
subtracted from 1 to calculate the individual percentage of suppression:   [1 - 
(
𝑆1
𝑆2
) ∗ 100] (e.g. Durukan et al., 2011). 
 
2.3.3.2 EEG specifications 
The tip of the nose served as recording reference. Offline, after applying a bandpass 
filter (10-45 Hz) and correction of blink artefacts, the data were segmented into 
conditioning and testing epochs of 400 ms including a 100 ms baseline. After 
excluding epochs containing activity exceeding 50 µV, a minimum of 20 segments 
were averaged. Peaks in the P50 window (40-70 ms) were detected semi-
automatically at Cz, since the component has a well-known fronto-central 
distribution, and exported after visual inspection. 
 
2.4 Genotyping 
2.4.1 Catechol-O-Methyl-Transferase 
DNA was extracted from whole blood. Standard PCR protocols were used for the 
genotyping of the COMT Val158Met variant using the forward primer 5' GGG GCC 
TAC TGT GGC TAC TC and the reverse primer 5' TTT TTC CAG GTC TGA CAA CG. A 
reaction volume of 25µl containing 2.5 µl buffer solution, 25 nM MgCl2, 2.5 nM of 
each nucleotide, 10 pmol of each primer, 0.5 µl Taq DNA polymerase and 50-100 ng 
of genomic template DNA was used at an annealing temperature of 58°C (35 cycles). 
Products were digested for 3 hours at 37°C with NLA III and separated on a 5% 
agarose gel. The G allele corresponds to the high-activity aminoacid Val and has a 
fragment size of 114 bp; the A allele has a fragment size of 96 + 18 bp and leads to 
the integration of the low-activity aminoacid Met. 
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2.4.2 Dopamine Transporter 1 
For genotyping of the 40 bp DAT/SLC6A3 3’ UTR VNTR, the primers were 5´- TGT GGT 
GTA GGG AAC GGC CTG AG (forward) and 5´- CTT CCT GGA GGT CAC GGC TCA AGG 
(reverse). The reaction volume of 25µl contained 2.5 µl of buffer solution, 15 nM 
MgCl2, 2.5 nM of each nucleotide, 10 pmol of each primer, 0.5 µl Taq DNA 
polymerase and 50-100 ng of genomic DNA. Annealing temperature was 67.5°C (38 
cycles). Products were visualised on a 3% agarose gel. Depending on the number of 
repeats, fragment lengths were 316 bp (6R), 396 bp (8R), 436 bp (9R), 476 bp (10R) or 
516 bp (11R). 
 
2.4.3 Latrophilin-3 
A reaction volume of 25µl containing 2.5 µl buffer solution, 15 mM MgCl2, 2.5 mM of 
each nucleotide, 10 pmol of each primer, 0.5 µl Taq DNA polymerase and 50-100 ng 
of genomic template DNA was used. 
 For rs2345039 primers used were 5’-CTTGGCTTTTCTCCACTCCCTTCTC 
(forward) and 5’-AAAACTATACTGGCAGCAGGGGGA (reverse). Annealing 
temperature was 60°C (40 cycles). Products were digested over night at 37°C 
with BseRI and separated on a 3% agarose gel. G/G has a fragment size of 184 
+ 283 + 733 bp, G/C leads to fragments of the sizes 36 + 148 + 184 + 283 + 733 
bp, and C/C has 36 + 148 + 283 + 733 bp. 
 For rs6551665, primers used were 5’-CAGCATGCAGTAGCCCTCTCAC (forward) 
and 5’-TGACTTTTCTAGGGCAGACAGGCT (reverse). Annealing temperature was 
65°C (35 cycles). Products were digested for 3 hours at 37°C with HphI and 
separated on a 3% agarose gel. G/G has a fragment size of 64+ 97 + 735 bp, 
G/A leads to fragments of the sizes 64+ 97 + 735 + 799 bp, and A/A has 97 + 
799 bp. 
 rs1947274 was analysed by sequencing from the reverse primer (5’-
GCATGTGACACAGAAGAGGGGTCA).  Variants were either C or A. 
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2.4.4 Hardy-Weinberg-Equilibrium and Group Differences 
For seven participants, no genotyping data were available. Due to the relatively low 
sample size, we stratified genotypes in order to get comparable group sizes, so for 
COMT we compared the group with at least one risk allele (Val/Met and Met/Met; N 
= 72) with homozygous Val/Val carriers (N = 39). COMT genotypes were in Hardy-
Weinberg-Equilibrium (HWE) in (Ӽ² = .34, p = .56). There were no differences in 
binary genotype frequencies (at least one Met allele vs. no Met allele) between 
groups (Ӽ² = .96, p = .672). Regarding DAT, we looked at homozygous risk allele 
carriers (10/10; N=55) versus carriers of less than two risk alleles (9/9 and 9/10; N = 
58). Genotype distribution was in Hardy-Weinberg-Equilibrium (Ӽ² = .036, p = .85). No 
differences in binary genotype frequencies (10/10 vs. other) between diagnostic 
groups were observed (Ӽ² = .492, p = .782).  For LPHN3, genotypes for the three 
investigated markers rs6551665 (Ӽ² = 1.349, p = .245), rs2345039 (Ӽ² = 1.999, p = 
.157) and rs1947274 (Ӽ² = .866, p = .352) were in HWE. Comparing carriers of all risk 
SNPs vs. other genotypes, no differences between diagnostic groups were observed 
(Ӽ² = .794, p = .672).   
 
2.5 Statistical analysis  
All statistical analyses were carried out with the software SPSS 18. For non-normally 
distributed behavioural parameters (errors of commission and omission, reaction 
times and response time variability), we used Kruskal-Wallis tests for general group 
comparisons and Mann-Whitney U-tests for post-hoc pair-wise comparisons. Due to 
the relative robustness of Analyses of Variance (ANOVA) to non-normal data 
distribution, we applied this test procedure to all electrophysiological data. For all 
electrophysiological data, parallel analyses were conducted for all three candidate 
genes, since the sample size was too small to study gene-by-gene interactions. Owing 
to low cell counts in the homozygous minor-allele carriers, we treated genotypes as 
binary variables. For COMT, we compared individuals carrying at least one Met allele 
with homozygous Val/Val carriers. For DAT, the group of homozygous 10R/10R carriers 
was tested against those with at least one 9R allele. With respect to LPHN3, subjects 
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were categorized into carriers of the risk variants at all SNP sites (risk haplotype 
carriers) versus individuals with any other constellation of variants (no risk haplotype). 
NGA and P50 suppression ratios were entered as dependent variables in univariate 
ANOVAs, with the between factors ’diagnostic group’ (3) and ‘genotype’ (2). For post-
hoc comparisons, univariate ANOVAs and t-tests for paired and independent samples 
were used. Centroids in the CPT and all peaks in the n-back paradigm were subjected to 
repeated measures ANOVAs with the within factor ‘condition’ (2; Go vs. NoGo for the 
CPT and 1-back vs. 2-back for the n-back task) and the between factors ‘diagnostic 
group’ (3) and ‘genotype’ (2). For post-hoc comparisons, univariate ANOVAs and t-tests 
for paired and independent samples were used. Only effects with a nominal p>.05 and 
trends of interest will be reported in the body of the text. For all other discovered 
trends, please see the appendix. 
 
3    Results 
3.1 Behavioural Parameters 
We expected unmedicated ADHD patients to perform worse than medicated patients 
and controls, manifesting in more errors of omission and commission, longer reaction 
times and greater response time variability across all tasks. Furthermore, carriers of 
the risk genotypes (COMT, DAT) or haplotype (LPHN3) were expected to commit more 
errors. For this reason, only targeted group comparisons were performed with Mann-
Whitney U-tests for all behavioural parameters and the reported p-values reflect one-
sided significances. 
 
Diagnostic Group Non-parametric Mann-Whitney-U tests showed a greater 
number of omission errors in unmedicated compared to medicated patients (CPT: p = 
.018; 1-back: p < .001; 2-back: p = .008) and controls (CPT: p = .009; 1-back: p = .008; 2-
back: p = .007) across tasks. Furthermore, they had more variable reaction times 
compared to medicated patients (CPT: p = .040) or controls (1-back: p = .032). 
 
Genotype effects  In the CPT, carriers of at least one COMT Met allele had higher 
RTV (p = .016) and more False Alarms (.013) than those without Met allele. Individuals 
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with the LPHN3 risk haplotype committed more False Alarms than the non-risk group, 
(p = .022). In the 1-back condition, homozygous carriers of the 10R variant in the DAT 
gene had a greater RTV than the other genotypes (p = .029), whereas for 2-back they 
showed longer reaction times (p = .045). 
 
3.2 Response Inhibition 
Regarding the direction of the main effects for COMT, carriers of at least one Met 
allele always showed more posteriorly located centroids. Main effect for condition 
always indicated that the NoGo centroid was located more anteriorly than the Go 
centroid (for details, see Table x). 
 
3.2.1 NoGo-Anteriorization 
The NGA is a stable phenomenon, risk genotypes bring about worse NGA (DAT) and 
more posterior centroids (COMT) in all diagnostic groups or only in unmedicated 
ADHD patients (LPHN3). 
 
a)  COMT 
Genotype affects location of both centroids (risk = more posterior).  Looking at 
diagnostic groups individually shows negative impact of genotype in unmedicated 
ADHD patients. 
 
NGA and COMT  The ANOVA with the factors COMT genotype and group found 
a trend level interaction effect for diagnostic ‘group x genotype’ (F2, 94 = 2.965, p = 
.056). Follow-up tests did not find any further effects for group or COMT, all ps > 
.113.  
 
Centroids and COMT The repeated measures ANOVA confirmed a stable 
main effect of condition, with NoGo centroids (3.81 ± .07) being located more 
anteriorly than Go centroids (4.08 ± 05), F1, 94 = 17,840, p < .001. Furthermore, we 
found a trend level main effect for COMT genotype (F1, 94 = 3.270, p = .074), with 
carriers of one or more Met alleles having more posterior centroids in both 
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conditions (Go = 3.95 and NoGo = 3.69 for no Met, Go = 4.15 and NoGo = 3.87 for 
Met).  
 
Additionally, we observed a trend level interaction ‘condition x group x COMT 
genotype’ (F2, 94 = 2.965, p = .056). Following up this interaction by condition, in Go 
trials carrying at least one Met allele led to more posterior centroids (4.15 vs. 3.95) 
compared to Val/Val, p = .029. No genotype effects were observed in the NoGo 
condition, all ps > .126. Stratifying subjects by genotype, both genotype groups 
showed a main effect of condition (p = .012 for no Met; p = .001 for Met). Lastly, 
separate analyses for each diagnostic group returned main effects of condition and 
COMT genotype for the unmedicated sample, with p = .011 and p = .033. In the 
control group, only a main effect of condition was observed, p < .001. For 
medicated patients, neither COMT genotype nor condition significantly affected 
centroid locations.   
 
Figure 7:  Modulation of centroid location from anterior to posterior by COMT 
genotype and diagnostic status 
 
 
 
* 
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b)  DAT 
Without risk genotype, medicated patients have more anterior centroids than 
unmedicated ADHD patients  
 
NGA and DAT   The genotype by group ANOVA returned a main effect 
of DAT genotype (F 1, 95 = 5.854, p = .017), indicating a better anteriorization in non-
homozygous as compared to homozygous carriers of the 10R allele in the sample.  
 
Centroids and DAT  Comparing centroid locations with a repeated 
Measures ANOVA, we found a main effect ‘condition’ (F 1,95= 20.581, p < .001) 
indicating more posterior Go centroids.  
The interaction ‘condition x genotype’ (F2, 95 = 5.854, p = .017) was further explored 
with t-tests comparing Go and NoGo centroids within each DAT genotype group and 
confirmed a more anterior NoGo centroid compared to the Go location in both 
genotype groups. However, this effect was more pronounced in the non-
homozygous 10R group, p < .001 and p = .043, respectively. 
Following up the interaction ‘group x genotype’ (F2, 95 = 3.637, p = .030), for 10/10 
carriers no differences between diagnostic groups emerged.  Only among non-
homozygous 10R carriers, medicated patients had more anteriorly located centroids 
compared to unmedicated patients (p = .024) and controls (p = .072). 
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Figure 8:  Modulation of centroid location from anterior to posterior by DAT 
genotype and diagnostic status 
 
c)  LPHN3 
While Go centroids were negatively influenced by genotype, during NoGo only 
having the risk haplotype brought out more posterior centroid locations in 
unmedicated ADHD 
 
NGA and LPHN3   For NGA, an interaction ‘Group*LPHN3’ (F 2, 91 = 3.401, 
p = .038) was further explored. Among risk variant carriers, a trend level group 
effect (F 2, 48 = 2.596, p = .085) indicated tendentially lower NGA values in members 
of the unmedicated ADHD group compared to medicated patients (p = .072), 
whereas no group effect emerged in subjects without the risk SNPs. Comparing the 
genotypes within each diagnostic groups reveals LPHN3 to only moderate NGA in 
both unmedicated (p = .055) and medicated (p = .050) ADHD patients, where the 
risk haplotype conferred higher NGA. 
 
* 
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Centroids and LPHN3 Regarding centroid location, the interaction of LPHN3 
genotype, group and condition (F 2, 91 = 3.401, p = .038) meant that for Go trials risk 
carriers had more posterior centroids (F 1, 91 = 4.686, p = .033), while only during the 
NoGo condition unmedicated patients with the risk genotype had also more 
posterior centroids compared to the medicated group (p = .014).  
 
Figure 9:  Modulation of centroid location from anterior to posterior by LPHN3 
genotype and diagnostic status 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
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Figure 10:  Topographical maps of mean Go and NoGo ERPs at P300 peak 
time in individuals carrying the LPHN3 risk haplotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11:  Topographical maps of mean Go and NoGo ERPs at P300 
peak time in individuals without the LPHN3 risk haplotype 
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3.2.3 N200 
 
NoGo elicits higher amplitudes regardless of genotype; Go longer latencies than 
NoGo (COMT), unmedicated ADHD patients delayed in both conditions (DAT), risk 
haplotype delayed NoGo N200 (LPHN3) 
 
a) Amplitudes   
The most significant finding regarding N200 amplitudes in the CPT was a main effect 
of condition regardless of included candidate gene,  all ps < .001 (F1, 93 = 60.390 for 
COMT; F1, 94 = 63.049 for DAT; F 1, 91 = 62.130 for LPHN3). As expected, the elicited 
response was always greater for NoGo compared to Go trials. 
 
b) Latency   
COMT  Including COMT genotype into the analysis, we only observed trend 
level effects for N200 latency, again for condition (Go > NoGo with F1,93 = 3.284 , p = 
.073) and an interaction of condition and group that was not further explored (F2, 93 =  
2.404, p = .096).  
 
DAT  With DAT genotypes, a trend level main effect for group (F1, 94 = 2.826, 
p = .064) meant that unmedicated patients had more delayed N200 compared to the 
medicated ADHD group (p = .047). This effect was qualified by the interaction 
‘condition’ x ‘group’ (F2,94 = 2.932, p = .058). Following Go stimuli, unmedicated had 
longer latencies than medicated ADHD patients (p = .047), while in the, whereas in 
the NoGo condition, unmedicated patients were delayed in comparison to controls (p 
= .083).  
 
LPHN3  The interaction of ‘LPHN3 x condition’ (F 1, 91 = 4.865, p = .030) 
signified that the risk group had higher mean NoGo N200 latencies than that without 
the risk haplotype (p = .029), whereas LPHN3 genotype did not play a role for Go 
latencies (p =.945). Marginal group differences with regard to N200 latencies (F 2, 91 = 
2.704, p = .072) suggest longer latencies in unmedicated compared to medicated 
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ADHD patients (p = .078), and longer latencies in NoGo compared to Go on a trend 
level (F 1, 91 = 3.822, p = .054). 
 
3.2.4 P300  
a) P300 and COMT  
NoGo amplitudes (Cz) smaller for unmedicated ADHD patients compared to 
controls, while for Go only unmedicated patients without risk had lower amplitudes 
(Pz) than both other groups. Only without risk genotype could medication decrease 
latencies for both conditions (at electrodes) below level of controls. 
 
GFP The main effect of condition for P300 amplitude and latency, with p = .009 
and p < .001, respectively signified that in the Go condition, higher P300 amplitudes 
and shorter latencies compared to NoGo were observed.   
 
Electrodes A main effect of condition indicted - that similar to the GFP results - 
Go stimuli generated higher amplitudes with shorter latencies compared to NoGo 
stimuli (both ps < .001). 
To further elucidate the trend-level interaction of ‘condition’ x ‘group’ x ‘COMT 
genotype’ (F2, 94 = 3.064; p = .051) for P300 amplitudes, separate ANOVAs for Go and 
NoGo were performed. The main effect ‘group’ in the NoGo condition (F2, 94 = 3.223, 
p = .044), indicated that unmedicated ADHD patients had marginally lower 
amplitudes than controls (p = .075). In the Go condition, an interaction of ‘group’ x 
‘COMT genotype’ (F2, 94 = 2.649; p = .073) was observed. Among subjects without met 
allele, unmedicated ADHD patients had lower P300 amplitudes compared to both 
medicated patients (p = .096) and healthy controls (p = .020). For Met carriers, 
diagnostic group status had no effect on P300 amplitudes.  
Regarding P300 latency at individual electrodes, there was an interaction of ‘group’ x 
‘COMT’ (F2, 94 = 3.595, p= .031). Subjects without Met allele showed no group 
differences, whereas among carriers of at least one Met allele medicated ADHD 
patients had shorter P300 latencies than both unmedicated patients (p = .010) and 
controls (p = .018). 
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b) P300 and DAT   
Risk genotype (10/10) longer Go and shorter NoGo latencies in Global Field Power 
 
Main effects of condition indicated shorter latencies and higher amplitudes for Go 
compared to NoGo for Global Field Power peaks and the peaks at the respective 
electrode sites, with p = .006 for GFP amplitude, all other p-values < .001. 
 
GFP  For GFP latency, the significant interaction ‘condition’ x ‘DAT 
genotype’ (F1, 95 = 9.868, p = .002) meant that for Go stimuli, homozygous 10R 
carriers had the longest latencies (p = .040) compared to other genotypes, whereas 
this effect was reversed for NoGo (p = .073). 
 
Electrodes  Looking at the latencies at electrode sites, we observed a trend-level 
group effect (p = .091), which was due to longer latencies in unmedicated patients 
compared to controls (p = .090). 
 
c) P300 and LPHN3  
NoGo peaks have smaller amplitude and longer latencies compared to Go peaks 
 
For P300 peaks both scored according to global field power and individual electrode 
sites, main effects of condition signified that NoGo P300 peaks were of smaller 
amplitude (GFP: F 2, 91 = 7.215, p = .009; electrodes: F 2, 91 = 34.802, p < .001) and 
longer latency than Go amplitudes (GFP: F 2, 91 = 64.749, p < .001; electrodes: F 2, 91 = 
176.649, p < .001).  
 
Electrodes A trend-level three-way interaction ’Condition*Group*LPHN3’ (F 2, 91 = 
2.411, p = .095) for P300 latency at Cz and Pz was not further explored, and a 
marginal group main effect (F 2, 91 = 2.499, p = .088) did not return significant group 
differences in post-hoc tests. 
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a)          b) 
           
Figure 12:  Grand Average ERPs during CPT for a) Go (at Pz) and b) NoGo (at Cz) 
trials, black curves are from healthy control subjects 
 
3.3    Working Memory 
3.3.1 COMT 
 
Non-targets Met allele carriers had delayed N100; P150 later in unmedicated 
compared to medicated ADHD; controls with Met allele elicit higher 
P450 than those without Met 
 
COMT modulated N100 timing, as Met allele carriers had delayed N100 peaks 
compared to non-Met carriers (F1, 99 = 5.265, p = .044).  
 
P150 latencies were longer in unmedicated compared to medicated patients (p = 
.023), as a main effect for group (F2, 99 = 3.263, p = .042) confirmed.  
 
Analysis of P450 mean activity returned a significant group x COMT interaction (F2, 99 
= 3.705, p = .028). Further exploration of this interaction with respect to COMT and 
group effects only returned a trend level genotype influence in controls (p = .079), 
with Met allele carriers having higher mean amplitudes than those without Met 
allele, all other ps > .219.  
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Main effects of condition could be observed for P150 (F1, 99 = 6.570, p = .012; 1b > 2b) 
and N300 latencies (F1, 99 = 22.109, p < .001; 2b > 1b) as well as for P450 (F1, 99 = 
16.182, p < .001; 1b > 2b) and P300 amplitude (F1, 84 = 6.064, p = .016; 2b > 1b). 
 
Figure 13: Mean P450 activity in interaction with COMT genotype, diagnostic status 
and condition 
 
3.3.2 DAT 
 
Non-targets For P150 under high load, unmedicated patients had the longest 
latencies. For low load additional genotype influence: only in risk 
genotype group had medicated ADHD the fastest response. 
Genotype differences only in controls (risk > no risk). 
Targets Genotype had only an effect in unmedicated patients, where risk 
carriers had higher P100 and P300 amplitudes. Group differences 
emerged in the low risk genotype, where unmedicated patients had 
lower amplitudes for both components (P100 < medicated ADHD 
patients and controls; P300 < medicated ADHD patients). In the high-
risk group, unmedicated ADHD had greater P300 than controls. 
 
* 
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Non-targets   P150 latencies differed between conditions (F1, 100 = 8.863, p = 
.004; 1b >2b) and diagnostic groups (F2, 100 = 4.289, p = .016; unmedicated ADHD > 
medicated ADHD with p = .013). A three-way interaction of condition, group and DAT 
genotype (F2, 100 = 4.110, p = .019) was observed. Looking separately at the two load 
levels, main effects of group were evident in both conditions: During 1-back trials, 
medicated patients had faster responses than the unmedicated group (p = .025). For 
2-back, unmedicated patients had slower responses than both medicated patients (p 
= .0) and healthy controls (p = .048). In the low load condition, the main effect was 
qualified by an interaction of group and DAT (F2, 100 = 3.253, p = .043). Group 
differences only existed among the homozygous 10R carriers, where ADHD patients 
receiving stimulant medication had faster P150 responses than unmedicated patients 
(p = .062) and controls (p = .015). Conversely, genotypes only affected latencies in 
healthy controls, where the 10/10 genotype went along with delayed peaks (p = 
.015).  
 
For non-targets, additional effects of condition on N300 latency (F1, 100 =24.097, p < 
.001; 1-back < 2-back) and P450 amplitude (F1, 100 = 13.720, p < .001; 1-back > 2-back) 
were observed.  
 
Figure 14:  P150 activity in interaction with DAT genotype, diagnostic status and 
condition 
 
* * 
* 
* 
* 
* 
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Targets   Group and DAT genotype shaped P100 amplitudes in an 
interactive way (F2, 85 =3.833, p = .025). While diagnostic groups did not differ if 
homozygous for the 10R allele, without risk genotype unmedicated patients had 
lower amplitudes than medicated patients (p = .010) and a trend in the same 
direction compared to controls (p = .092). If splitting the sample by diagnostic group, 
genotype effects were only evident in unmedicated ADHD patients, where 10R/10R 
carriers had greater responses (p = .003).  
 
Similar to findings regarding P100, the homozygous 10/10 group also had greater 
P300 amplitudes (F1, 85 = 4.101, p = .046). This relationship was further qualified by 
the interaction of DAT genotype and group (F2, 85 = 5.191, p = .007). Again, differences 
were only present in non-homozygous 10R probands, where unmedicated patients 
had lower P300 amplitudes than the medicated group (p = .014). On a trend-level, 
unmedicated patients with the risk genotype however had higher P300 amplitudes 
compared to controls (p = .051). Genotype effects were limited to the unmedicated 
ADHD group, with 10/10 carriers having greater amplitudes (p = .003). 
 
Figure 15:  P100 and P300 responses to target stimuli (1-back and 2-back) in 
interaction with DAT genotype and diagnostic status  
* 
* * 
* 
* 
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3.3.3 Latrophilin-3  
 
Non-targets P150 delayed for unmedicated compared to medicated ADHD 
patients, N300 stronger for risk haplotype 
 
Non-targets N300 amplitudes were greater for carriers of the LPHN3 risk haplotype 
(F1, 96 = 4.969, p = .028), whereas P300 amplitudes were only dependent on condition 
(F1, 81 = 4.578, p = .035), with responses being greater for 2-back. For P150 latency, 
main effects of condition (F1, 96 = 7.356, p = .008) and group (F2, 96 = 3.854, p = .025) 
signified delayed responses for 1-back compared to 2-back and unmedicated 
compared to medicated ADHD patients (p = .020). The reverse effect of condition 
could be found for N300 latencies, where 1-back elicited a faster reaction (F1, 96 
=21.490, p < .001). 
 
3.4  Sensory Gating 
Separate ANOVAs with factors ‘group’ and ‘genotype’ were performed for each 
candidate gene. Subsequent correlational analyses between P50 suppression rate 
and behavioural output from CPT and n-back task should be regarded as strictly 
exploratory, as the cell counts were very low. 
 
a) Sensory Gating Ratio 
 
LPHN3 risk haplotype beneficial for gating in controls and medicated ADHD 
patients, opposite pattern for unmedicated ADHD patients 
 
Analyses of the influence of the LPHN3 risk haplotype on sensory gating returned an 
interaction ‘Group by LPHN3’ (F2, 53 = 5.849, p = .005). Subjects with the risk 
haplotype showed a main effect for group (F2, 26 = 6.312, p = .006), indicating a more 
effective P50 suppression in medicated compared to unmedicated patients (p = .004). 
No such difference was observed in participants without risk haplotype (p = .352). 
Among unmedicated patients, those without risk haplotype had more efficient 
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sensory gating than risk carriers (p = .014), whereas the exact opposite was observed 
in controls (p = .023) and medicated ADHD (p = .042), where those with the risk 
haplotype showed better suppression.  
 
For medicated patients without LPHN3 risk haplotype, exploratory correlational 
analyses showed better P50 suppression comes with more errors of omission in the 
n-back task (r = .990, p = .010), while risk carriers without medication have a negative 
relationship between suppression rate and errors of omission (r =- .770, p = .043). 
 
For COMT and DAT, no significant effects on P50 suppression were observed, all ps > 
.254.  
 
Figure 16:  Mean P50 suppression rate in interactio with LPHN3 genotype and 
diagnostic status 
 
b) P50 Amplitudes and latencies  
 Having at least one Met allele means lower conditioning amplitudes 
Individual comparisons for conditioning and testing amplitudes and latencies with the 
factors ‘group’ and ‘genotype’ (COMT, DAT and LPHN3) returned a main effect for 
COMT genotype on conditioning amplitudes across all diagnostic groups (F1, 53 = 
3.995, p = .051). Met allele carriers had smaller amplitudes in response to the first 
stimulus than probands without Met allele. Exploratory inclusion of sex instead of 
* 
* 
* 
* 
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genotype as a factor returned only a trend-level interaction effects of ‘group by sex’ 
for conditioning amplitudes (F1, 61 = 5.107, p = .072) and testing latencies (F1, 61 = 
3.160, p = .080), which were not further explored. 
 
3.5 Exploratory catamnestic analysis 
Seeing that only 50 subjects returned for the catamnestic part of the study, we 
reduced the number of factors used for analysis in order to avoid low cell counts. So 
we conducted Repeated Measures ANOVAs with the within factor ‘condition’ and 
one between factor at a time. The included between factors were ‘group’, ‘COMT 
genotype’, ‘DAT genotype’ or ‘LPHN3 genotype’.  
 
 
 
 
 
 
Table 3: Sample description at measurement point T2 
 
Reaction times decreased over time in all tasks, while this was only true for RTV and 
omission errors in CPT and 2-back. False alarms only showed a time-dependent 
decline in the CPT. For details, see Table x. 
 
 Variable p  
CPT RT .026 
T1 > T2 
SD < .001 
miss .019 
False Alarms < .001 
1-back RT < .001 
2-back RT .013 
SD .036 
Miss .002 
Table 4: Changes in behavioural parameters from T1 to T2 
 
 
 
  ADHDunmed ADHDmed Controls p 
Age  mean  
(SE) 
13.86 
(0.73) 
14.94 
(0.62) 
12.16 
(0.64) 
.012 
Gender (male /female) 6/8 13/4 10/9 .141 
Subtype inattentive 
combined 
1 
13 
3 
14 
- .607 
  14 17 19  
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3.5.1 Changes in Response Inhibition from T1 to T2 
 
N200 amplitudes were higher for T1 and NoGo trials. Latencies were always longer 
at T1, however the delay for Go responses was only observed at T2. P300 responses 
quickened and decreased in strength from T1 to T1. Go stimuli elicited faster 
responses than NoGo commands. 
 
N200   When including the factor time into the repeated measurement 
ANOVAs, for both amplitudes and latencies we only found main effects of time and 
condition as well as interactions of the two factors. Amplitudes were higher at T1 and 
for Go trials. Responses at T1 were both of larger magnitude and more delayed 
compared to T2, and Go stimuli evoked reactions of smaller amplitude with longer 
latencies. Since genotype and diagnostic group did not play a role for the 
development of N200 amplitudes or latencies and the main effects all pointed in the 
same direction, we followed up the interactions of condition by time in a separate 
analyses without the factor genotype. N200 amplitudes were bigger for Go compared 
to NoGo at both time points, and higher at T1 for both conditions. Latencies were 
only greater for Go at T1, however faster responses were observed at T2 in both 
response inhibition and execution trials. For details, see table supplementary table 
S6-M. 
 
A main effect of DAT genotype (F1, 28 = 9.488, p = .005) indicating dampened 
N200 amplitudes for homozygous 10R carriers was qualified by the interaction of 
condition and DAT (F1, 28 = 4.614, p = .041). Follow-up t-tests confirmed that this was 
only true for the Go condition (p = .006). However both genotype groups showed 
increased amplitudes for NoGo compared to Go. N200 latencies were modulated by 
an interaction of time and DAT genotype (F1, 28 = 5.730, p = .024). Only at the second 
measurement probands homozygous for the 10R allele had slower N200 latencies (p 
= .013). But again both genotype groups showed the overall quickening of responses 
from T1 to T2 (all ps < .003) 
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NGA and P300 For NGA, no developmental effects were found. Exploratory 
analyses with both genotype and diagnostic group as factors despite small cell counts 
and shift in NGA as dependent variable did not return any significant results. 
 
Centroids showed the familiar more anterior location for the Go condition 
regardless of diagnostic group or genotype (with p = .045 for DAT, p = .044 for LPHN3, 
p = .083 for group and p = .062 for COMT). A main effect for COMT was indicative of 
more posteriorly located centroids in probands carrying at least one Met allele (F1, 29 
= 6.316, p = .018).  
 
P300 amplitudes both in terms of Global Field power and at individual electrode 
sites were larger at T1, all ps < .019. Additionally, at Cz and Pz main effects of 
condition indicated larger P300 amplitudes for NoGo, all ps <.001. NoGo responses 
were always later than Go responses for Global Field power and at individual 
electrode sites, all ps < .001. The peaks at Cz and Pz were delayed at T1 compared to 
T2, all ps < .001. 
 
 GFP Electrodes 
 
P300 Amplitude 
 
m.e. time 
 
m.e. time 
 
m.e. condition 
Group F1, 28 = 7.272, p = .012 F1, 28 = 10.161, p = .004 F1, 28 = 17.368, p < .001 
COMT F1, 27 = 6.205, p = .019 F1, 27 = 9.891, p = .004 F1, 27 =16.879, p < .001 
DAT F1, 27 = 7.313, p = .011 F1, 29 = 10.822, p = .003 F1, 29 = 22.093, p < .001 
LPHN3 F1, 27 = 9.478, p = .005 F1, 29 = 11.489, p = .002 F1, 29 =16.879, p < .001 
 
P300 Latency 
 
m.e. condition 
 
m.e. time 
 
m.e. condition 
Group F1, 28 = 27.253, p < .001 F1, 28 =22.381, p < .001 F1, 28 =102.549, p < .001 
COMT F1, 27 = 27.630, p < .001 F1, 27 =21.143, p < .001 F1, 27 = 89.538, p < .001 
DAT F1, 29 = 28.713, p < .001 F1, 29 =23.269, p < .001 F1, 29 = 100.29, p < .001 
LPHN3 F1, 29 = 28.077, p < .001 F1, 29 = 27.511, p < .001 F1, 29 = 89.538, p < .001 
Table5:  Developmental Effects on Response Inhibition Related Components  - P300 
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3.5.2  Changes in Working Memory from T1 to T2 
3.5.2.1 Development of working memory in interaction with COMT 
 
Non-targets Genotype effect on P150 amplitude at T1 (risk > no risk); 
unmedicated ADHD delayed N300 only under high load (T1 and T2) 
Targets  Decrease in P100 and P300 amplitude (unmedicated and medicated 
ADHD) and P100 latency over time only in patients; controls show 
weaker P300 responses than either patient group at T2 
 
Strong effect of time on all amplitudes and latencies were the most prominent 
findings, with T1 responses being both larger and later than at T2 (see Table x). 
Additionally, main effect of condition for N100 amplitude (F1, 34 = 4.387, p = .044), 
N300 latency ((F1, 34 = 8.998, p = .005 and P450 amplitude (F1, 34 = 21.256, p < .001) 
emerged. 
 
Non-targets 
     N100 An interaction of condition and time (F1, 34 = 5.8824, p = .021) 
indicated that only at T1 were N100 amplitudes higher for 2-back compared to 1-
back (p = .017). However, amplitudes decreased from T1 to T2 in both conditions 
(all ps < .001).  
 
The timing of this component was also altered by an interaction of time, 
group and COMT (F1, 25 = 5.824, p = .021. Further probing of this interaction only 
returned effects for time (T1 > T2) within both COMT genotype groups (p = .039 and 
p = .019 for “no Met” and “Met”, respectively) as well as unmedicated ADHD 
patients and controls. 
 
     P150 For P150 latency, we found a Time by COMT interaction (F1, 34 = 4.135, 
p = .050). Post-hoc tests showed a marginal effect for COMT at T1 (p = .082; no Met 
> Met), whereas this effect was absent at T2 (p = .517). Again the factor time 
significantly influenced both genotype groups (p ≤ .001).  
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     N300 The Condition by Group interaction for N300 latency (F2, 34 = 3.671, p = 
.036) illustrated that only for 2-back did unmedicated patients show longer 
latencies than controls (p = .002). Looking individually at the diagnostic groups, 
medicated patients (p = .045) and controls (p = .011) have longer latencies for 2-
back compared to 1-back. 
 
Targets  
     P100  Exploring a Time*Group interaction for P100 amplitudes (F 2,25 = 4.145, 
p = .028), a group effect at T2 (F2, 32 = 7.444, p = .002) indicated that controls 
responses were less strong than those of unmedicated (p = .003) or even medicated 
ADHD patients (p = .011). Both patient groups had higher P100 amplitudes at T1 
compared to T2, all ps ≤ .001.  
 
For P100 latencies on the other hand, the interaction Time*Group (F2 26 = 
5.663, p = .009) showed that in unmedicated patients, latencies at T1 were longer 
than at T2 (p = .016), all other follow-up ps > .077. A further Time*COMT interaction 
(F1, 26 = 4.565, p = .042) additionally confirmed slower responses at T1 compared to 
T2 for both COMT genotype groups (p = .047 for “no Met” and p = .031 for “Met”). 
 
     P300  Analysing P300 amplitudes, we observed a three-way interaction of 
Condition*Time*Group (F1, 25 = 4.602, p = .020). In addition to main effects for time 
in both conditions (p = .004 for 1-back and p > .001 for 2-back), a Time*Group 
interaction in 2-back (F1, 28 = 4.122, p = .027) indicated greater P300 responses at T2 
in controls compared to unmedicated patients (p = .031) and a tendency for the 
same effect in the medicated ADHD group (p = .079). Both ADHD patients on (p 
=.041) and off medication (p =.010) show a decrease in P300 amplitudes from T1 to 
T2. The exploration of a Condition*Time*COMT interaction (F1, 25 = 5.198, p = .031) 
only confirmed the time effect in 1-back and 2-back (T1> T2), but did not show any 
further effects with p < .05. 
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3.5.2.2 Development of working memory in interaction with DAT 
 
Non-targets At T1 the risk group displayed faster N100 in high load compared to 
low load. Only controls have higher P150 amplitudes to low 
compared to high load. P150 latency was dependent on load in 
controls and Medicated ADHD patients. 
Targets Patient groups displayed shortening of P100 latency between 
measurements; medicated (T1) and unmedicated (T2) ADHD had 
higher 1-back than 2-back P300; under high load controls highest 
P300 amplitudes 
 
Non-targets 
     N100 The main effect of condition on N100 amplitudes (F1, 34 = 4.925, p = 
.033; a-back > 2-back) was qualified by the interaction of condition and time (F1, 34 = 
5.865, p = .021), whereby both conditions showed stronger reactions at T1, but only 
at T1 could 2-back elicit higher responses than 1-back. 
 
N100 latency was modulated by a Condition x Time x DAT interaction (F1, 34 
=5.233, p = .029). Follow up tests found a main effect of time for 1-back (p = .001; 
T1 > T2). Only at T1 there was a further interaction of condition and DAT genotype 
(F1, 39 = 5.006, p = .031), which signified that only risk variant carriers (10/10R) 
differentiated between load in terms of N100 timing (p = .028; 1-back > 2-back). 
 
     P150 The interaction of group and condition (F2, 34 = 3.669, p = .036) meant 
that only control subjects had higher P150 amplitudes for 1-back compared to 2-
back (p = .046). 
 
     N300 The main effect of condition on N300 latency (F1, 34 = 11.099, p = .002) 
was further explained by an interaction of condition and group (F1, 34 = 3.346, p = 
.031). In the high load condition, unmedicated ADHD patients had faster responses 
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than controls (p = .002). However, only medicated patients (p = .045) and controls 
(p = .011) had faster responses in 1-back compared to 2-back trials. 
 
     P450 The low load condition evoked greater mean activity in the P450 
window than the high load condition (F1, 34 = 21.147, p = .0) 
 
Targets 
     P100 Amplitudes were modified by an interaction of the factors group and 
DAT genotype (F2, 25 = 3.832, p = .035). Follow-up tests failed to return any 
significant effects in either genotype or diagnostic group. 
 
 Analysis of P100 latency returned an interaction effect of condition by time by 
diagnostic group (F2, 26 = 4.384, p = .023). Follow- up tests by condition found an 
effect of time for 1-back (F1, 30 = 8.599, p = .006; T1 > T2), by time a marginal group 
effect at T1 (p = .079). Looking individually at the diagnostic groups, both patient 
groups had speeded up P100 responses at T2 compared to T1 (p = .016 for 
unmedicated ADHD and p = .080 for medicated ADHD), while latencies in controls 
were not dependent on time. 
 
     P300 Amplitudes were moderated by an interaction of condition, diagnostic 
group and time (F2, 33 = 4.337, p = .024). Both T1 and T2 showed interaction effects 
of condition and group (T1 p = .017; T2 p = .019). Follow-up t-tests showed for T1 
higher 1-back amplitudes compared to 2-back in medicated ADHD patients (p = 
.023), while at the second measurement only the unmedicated ADHD group showed 
this effect (p = .019). Furthermore in the high load condition controls had higher 
amplitudes compared to both ADHD groups (unmedicated ADHD p = .031; 
medicated ADHD p = .079) at T2. 
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3.5.2.3 Development of working memory in interaction with LPHN3 
 
Non-targets Higher amplitudes and longer latencies for all components at T1; 
P150 delayed in unmedicated ADHD risk carriers and N300 greater 
for risk haplotype and compared to medicated ADHD patients 
 
All amplitudes and latencies were subject to development, as ubiquitous main 
effects of time indicated (for details, see Table x). Main effects of condition (F1, 32 = 
5.896, p = .021, 2b > 1b) and time on N100 amplitudes were qualified by the 
interaction of condition and time (F1, 32 = 7.968, p = .008). While at T1 there was a 
higher amplitude for 2b compared to 1b (p = .017), this effect was absent at T2. For 
P150 latency, exploration of an interaction group*LPHN3 (F2, 32 = 3.525, p = .041) 
showed that only among carriers of the risk haplotype did unmedicated patients 
show increased latencies compared to controls (p = .033). N300 amplitudes showed 
main effects of time, group (F2, 32 = 3.452, p = .044) and LPHN3 (F1, 32 = 4.386, p = 
.044) indicated that the N300 was of greater magnitude at T1 compared to T2 and 
in risk haplotype compared to non-risk haplotype carriers, and there was a trend for 
greater N300 in unmedicated compared to medicated ADHD patients (p = .052). 
Besides main effects of time and condition (F1, 32 = 13.039, p < .001) on N300 
latency, the interaction of the two factors (F1, 32 = 4.497, p = .042) illustrated longer 
latencies for 2b condition compared to 1b at both measurement points (T1: p = 
.031; T2: p =.004) and a decrease in latencies from T1 to T2 (1b: p < .001; 2b: p = 
.018). Lastly, the main effect of condition (F1, 32 = 17.505, p < .001) on P450 activity 
indicated greater P450 responses for 1-back compared to 2-back. 
Peak Amp (V) / Lat (L) F p Direction of effect 
N100 V F 1,34 = 30.897 < .001 
T1 > T2 
L F 1,34 = 13.678 = .001 
P150 V F 1,34 = 36.753 < .001 
L F 1,34 = 62.012 < .001 
N300 V F 1,34 = 25.606 < .001 
L F 1,34 = 15.764 < .001 
P450 V F 1,34 = 10.013 .003 
P100 V F 1,25 = 37.094 < .001 
L F 1,25 = 17.381 < .001 
P300 V F 1,25 = 14.595 = .001 
Table 6: Effects of time on n-Back components (COMT) 
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Peak Amp (V) / Lat (L) F p Direction of effect 
N100 V F 1,34 = 37.331 < .001 
T1 > T2 
L F 1,34 = 8.321     .007 
P150 V F 1,34 =29.048  < .001 
L F 1,34 = 56.158 < .001 
N300 V F 1,34 = 29.751 < .001 
L F 1,34 = 16.132 < .001 
P450 V F 1,34 = 11.356     .002 
P100 V F 1,34 = 27.241 < .001 
L F 1,34 = 10.655     .003 
P300 V F 1,34 = 12.209   .002 
Table7: Effects of time on n-Back components (DAT) 
 
 
 
 
Peak Amp (V) / Lat (L) F p Direction of effect 
N100 V F1, 32 = 27.271 p < .001 
T1 > T2 
 L F1, 32 = 7.198 p = .011 
P150 V F1, 32 = 30.275 p < .001 
 L F1, 32 = 52.645 p < .001 
N300 V F1, 32 = 25.761 p < .001 
 L F1, 32 = 16.136 p < .001 
P450 V F1, 32 =9.381 p = .004 
Table 8: Effects of time on n-Back components (LPHN3) 
 
 
 
 
Time Gene Peak 
Amp (V) 
/ Lat (L) 
Effect F p 
T1 COMT 
N100 
V condition*group F2, 99 = 2.626 .077 
COMT V group*COMT F2, 99 = 2.751 .069 
COMT P300 V group*COMT F2, 84 = 2.963 .057 
T2 COMT P150 V COMT F1, 36 = 2.969 .093 
COMT N300 V condition F1, 36 = 2.900 .097 
COMT 
P100 
V COMT F1, 33 = 3.341 .077 
COMT L cond*group F2, 34 = 2.874 .070 
COMT P300 V group F2, 33 = 3.011 .063 
T1  T2 COMT 
P150 
V COMT F1, 34 = 4.087 .051 
COMT V cond*group F2, 34 = 3.185 .054 
COMT L condition  F1, 34 = 3.392 .074 
COMT 
N300 
V condition*COMT F1, 34 =3.542 .068 
COMT L cond*time F1, 34 = 3.559 .068 
COMT P450 V COMT F1, 34 = 3.554 .068 
COMT  V cond*time F1, 34 = 3.393 .074 
COMT P300 L time F1,26 = 3.971 .057 
Table 9: Trend level effects for working memory tasks (COMT) 
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Time Gene Peak Amp (V) 
/ Lat (L) 
Effect F p 
T1 DAT 
N100 
V 
condition*group F2, 100 = 2.954 .057 
DAT condition*DAT F1, 100 = 3.350 .070 
DAT L condition*group*DAT F2, 100 = 2.393 .097 
DAT N300 L DAT F1, 100 = 2.798 .098 
DAT P100 L DAT F1, 85 = 3.833 .079 
DAT P300 L condition*group F2, 85 =2.398 .097 
T2 DAT P150 L group*DAT F2, 36 = 3.150 .055 
DAT N300 L group*DAT F2, 36 = 2.980 .063 
DAT P450 V condition*group*DAT F2, 36 = 3.071 .059 
DAT 
P300 V 
group F2, 33 = 2.898 .069 
DAT condition*group*DAT F2, 33 = 2.824 .074 
T1  T2 DAT P150 V condition F1, 34 = 3.668 .064 
DAT L condition F1, 34 = 3.319 .077 
DAT N300 L condition *time F1, 34 = 3.386 .074 
DAT P450 V condition *time F1, 34 = 3.967 .054 
DAT P100 V condition F1, 25 = 4.133 .053 
DAT L condition *time F1, 26 = 3.142 .088 
DAT P300 V condition *group F2, 25 =3.393 .050 
DAT condition *time F1, 25 =3.599 .069 
DAT condition *group*DAT F2, 25 = 3.080 .064 
DAT condition *time*DAT F1, 25 = 3.428 .076 
Table 10: Trend level effects for working memory tasks (DAT) 
 
 
Time Gene Peak 
Amp (V) 
/ Lat (L) 
Effect F p 
T1 LPHN3 N100 V condition*group F2, 96 = 2.944 .057 
LPHN3 P100 L condition*group*LPHN3 F2, 81 = 3.085 .051 
LPHN3 P300 V group*LPHN3 F2, 81 = 2.685 .074 
T2 LPHN3 P150 L Group*LPHN3 F2, 35 = 2.606 .088 
LPHN3 N300 
N300 
V cond F1, 34 = 3.231 .081 
LPHN3 V cond*LPHN3 F1, 34 = 2.911 .097 
LPHN3 P100 
P100 
V cond F1, 31 = 3.400 .075 
LPHN3 L cond*group F2, 32 = 2.976 .065 
T1  T2 LPHN3 P150 
P150 
P150 
V cond*group F2, 32 = 2.784 .077 
LPHN3 L condition F1, 32 = 3.108 .087 
LPHN3 L time*group F2, 32 = 2.495 .098 
LPHN3 N300 
N300 
L group*LPHN3 F2, 32 = 2.664 .085 
LPHN3 L cond*group F2, 32 = 3.254 .052 
LPHN3 P450 V cond*time F1, 32 = 3.634 .066 
LPHN3 P100 
P100 
V cond F1, 23 = 3.627 .069 
LPHN3 V time*group F2, 23 = 2.877 .076 
LPHN3 P300 
P300 
V time*group F2, 23 = 2.764 .084 
LPHN3 V group*LPHN3 F2, 23 = 3.192 .060 
Table 11: Trend level effects for working memory tasks (LPHN3) 
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4 Discussion 
We partly confirmed the predicted behavioural deviations associated with ADHD across 
neuropsychological tasks manifesting in prolonged and more variable reaction times as 
well as a greater tendency towards errors of omission and commission. We replicated 
the ubiquitous finding of more omission errors of unmedicated ADHD patients in Go-
NoGo tasks (Fallgatter et al., 2004; Fallgatter et al., 2009; Fisher et al., 2011) and n-back 
(Keage et al., 2008; Sunohara et al., 1999) both compared to healthy controls and 
medicated patients, pointing towards problems with both inattention and working 
memory. Psychostimulants such as MPH are known to improve inhibition (SSRT) and 
variability of response times in healthy individuals (Nandam et al., 2011), the 
mechanism most likely being increased stimulus salience via enhanced striatal DA 
(Volkow et al., 2004, Volkow et al., 2005). Interestingly, Atomoxetine as an effective 
alternative drug for the treatment of ADHD left those parameters unchanged in the 
same group despite a significant reduction in behavioural ADHD symptoms (see meta-
analysis by Faraone, 2009). The lack of group differences regarding false alarms has 
been observed before with this particular paradigm by Fallgatter et al. (2004) in a 
sample of ADHD boys, however we did not find prolonged reaction times for ADHD 
patients in any of our tests and this goes against most of the previously published 
research on ADHD (Fisher et al., 2011; Fallgatter et al, 2004; Uebel et al., 2010). Risk 
genotype carriers of COMT (Met) and LPHN3 (risk haplotype) committed more false 
alarms in the CPT, indicating difficulties with inhibiting responses, while DAT 
(homozygous 10R) corresponded to longer reaction times in the more taxing working 
memory task. The increased rate of commission errors in the LPHN3 risk haplotype 
could be linked to decreased striatal neuronal activity in the risk group (Arcos-Burgos et 
al., 2010) 
 
4.1 Response Inhibition 
 
NGA  NGA could not distinguish between ADHD patients and healthy control 
children. However, all examined ADHD candidate genes modulated NGA in some way, 
and we could identify differences between diagnostic groups when taking into account 
the individual’s genotype on our ADHD risk genes. While for DAT the 10-repeat allele 
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had a negative influence on inhibitory functioning as reflected in lower NGA, 
Latrophilin-3 only influenced NGA in combination with diagnostic status. Surprisingly, 
one-sided t-tests revealed a positive influence of the LPHN3 risk haplotype on this 
particular index of response control in ADHD patients irrespective of medication, as 
risk carriers of in both patient groups had trend-level higher NGA values. 
 
When discussing NGA results, it is important to note that looking at raw NGA 
values in the present study, the observed mean NGAs (T1: 0.27 ± 0.53) seem small in 
comparison to those reported for adults (e.g. Fallgatter et al., 2009 with mean NGA = 
0.6 ± 0.5 for adult ADHD and 0.7 ± 0.4 for adult controls). The big age range might have 
obscured the fact that a majority of participants were still quite young even at the 
second assessment and hadn’t reached mature degrees of anteriorization; therefore in 
total the mean NGA also appeared unchanged in the longitudinal assessment. 
However, dividing the sample by presence or absence of NGA showed adult level NGA 
values (T1: Ø 0.56 ± 0.47) in the group with at least minimal anteriorization for 
response inhibition. In our case absolute NGA values were not related to participants’ 
age and absence or presence of NGA was independent of diagnostic status. So 
independent of ADHD, a big proportion of participants had not yet mastered that 
crucial step. A considerable number of participants did not show an NGA at T1 (40 %) 
or T2 (43 %); their Go centroids were more frontally located than the NoGo centroids. 
Initial reports on NGA as a marker of prefrontal functioning stressed finding the effect 
in all included subjects; this might have been partly due the selection of adult 
participants (Fallgatter & Strik, 1997; Fallgatter et al., 1999). Absence of NGA in a 
percentage of participants is not an uncommon finding among psychiatric populations 
(e.g. 25% of adult personality disorder with childhood ADHD symptoms and 0% of 
healthy controls in Fallgatter et al., 2005) Among healthy individuals, this has also been 
reported for a sample of children and adolescents despite general independence of 
NGA and age already in this young sample (Renner, 2007). Approximately half of our 
control children had not yet developed an NGA; hence it is likely that their NGA will 
improve over time as they enter adulthood, whereas this might not be the case in the 
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ADHD groups. This would ultimately manifest in the aforementioned decreased NGA 
findings for adult ADHD patients. 
 
Centroids and COMT  While NGA was independent of COMT genotype, having 
at least one Met allele moved both centroids more towards posterior areas on a trend 
level, thus putatively facilitating or influencing response execution rather than 
inhibition. Behavioural observations support this idea, since Met carriers had more 
errors of commission as well as more variable responses. So while they did not miss 
cues and thus did not differ in the rate of omission errors, they had trouble inhibiting 
responses.  This also fits with the preliminary results from Fallgatter et al. (2009), 
although here more posterior Go centroids with Met were only observed in the ADHD 
group. They furthermore found a genotype main effect on NGA in adult ADHD patients 
indicating homozygous Val carriers had smaller NGA values, but COMT did not 
modulate this parameter in healthy controls. Nevertheless, NGA did not differentiate 
between ADHD and controls either, in accordance with our own results. After adding 
more patients, the only stable findings of Fallgatter et al.’s study were the presence of 
an NGA in all groups, and generally more anterior centroids in ADHD individuals, while 
all effects involving COMT genotype vanished. This suggests more difficulties with 
response execution rather than inhibition since Go centroids are more anterior, and 
indeed the ADHD group predominantly showed elevated rates of omission errors, 
although false alarms were more frequent in patients on a trend level as well. In 
contrast to our own negative reports for COMT and NGA, Ehlis et al. (2007) identified a 
beneficial effect of Met on NGA in a schizophrenic sample. In contrast to our ADHD 
sample, in the schizophrenic population it was the NoGo centroid, which was affected 
by COMT and carried the effect. So in disorders involving dopaminergic 
neurotransmission, the Met allele is in some cases beneficial for prefrontal functioning 
as captured by NGA. Taken together however, the relationship of both the COMT 
Val158Met polymorphism to ADHD and COMT activity to prefrontal functioning, as 
indicated by NGA is not a stable phenomenon in our sample, hence findings remain 
inconclusive. 
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Centroids and DAT  Not being homozygous for the childhood risk allele 10R 
meant better NGA. These results regarding implications of DAT for NGA fit with 
indications of poorer neuropsychological functioning of homozygous 10R carriers 
among childhood ADHD populations (Loo et al., 2003), whereas this pattern seems to 
be reversed in adult ADHD where the 9R allele confers the risk of a diminished NGA 
(Dresler et al., 2010). Interestingly, even though t-tests examining genotype effects 
within each diagnostic group did not turn out significant, the differences between 
genotypes was most pronounced in the medicated ADHD group in the expected 
direction (9R < 10R) and virtually absent in controls, which fits with previous research 
(Dresler et al., 2010). Having at least one 9R allele allowed for psychostimulant 
medication to lead to an anteriorization of the brain electric field both during executed 
and inhibited reactions. The lack of group difference in the 10/10 genotype group has 
to be interpreted in the light of the small degrees of anteriorization in this high-risk 
genotype, which might make genotype effects hard to detect with this small sample 
size. 
 
Centroids and LPHN3  During successful response execution, the LPHN3 risk 
haplotype was associated with more posterior centroids irrespective of diagnostic 
group or medication. So while more posterior Go centroids might be beneficial for 
swift motor responses this also might facilitate unwanted behaviour resulting in false 
alarms. Indeed risk carriers regardless of diagnosis did commit more errors of this kind, 
i.e. failed inhibition. During inhibition trials, unmedicated patients with the Latrophilin-
3 risk variants had more posterior centroids than those receiving medication. This is in 
line with the fact that the NGA was also lower – albeit on trend level – in unmedicated 
ADHD compared to medicated patients with the risk variants. In the case of LPHN3, the 
combination of carrying a genetic risk and being without the support of medication 
ultimately could be seen in a lower NGA as an electrophysiological indicator of 
response control, and this was caused by a shift in the surface recorded potential 
reflecting response inhibition. Supporting this, the combination of SNPs defined as risk 
haplotype in the present study has been found to confer a decrease in activity in 
striatum, cerebellum and thalamus (Arcos-Burgos et al., 2010) – putatively in the 
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inhibitory loop. Even though the component responsible for the NGA phenomenon 
originates in the ACC, cross-talk between regions and top-down inhibitory commands 
to motor areas in the striatum contribute in a vital way to a successful inhibition of on-
going or prepared responses. 
 
P300 amplitudes and latencies  DAT modulated P300 GFP latencies in 
interaction with condition. For inhibition trials, homozygous 10R carriers had 
significantly faster responses; this effect was reversed in the response execution 
condition where having two copies of the 10R meant longer latencies. When including 
COMT genotypes into the analyses, we found a trend suggesting that when inhibition 
of a response was required (NoGo), control subjects had higher P300 amplitudes than 
unmedicated patients, while during Go trials this held only true for probands without 
Met allele. In this genotype group, stimulant medication also led to higher amplitudes 
compared to unmedicated ADHD. On the whole, methylphenidate is known to have a 
normalizing effect on P300 amplitudes (Zillessen et al., 2001, Seifert et al., 2003, 
Groom et al., 2010). Furthermore, among Met carriers, latencies were faster for 
unmedicated patients with respect to both other groups. So COMT genotype 
predominantly modulated the strength of the Go P300. Go amplitudes were only 
diminished in unmedicated ADHD if they had no Met allele. This fits with previous 
findings that - following the inverted U-shape description of prefrontal functioning - 
only ADHD patients with the Val/Val genotype lie clearly outside of the normal range. 
Having a Met brought unmedicated patients up to normal levels, whereas without Met 
support of stimulant medication was required to achieve normal responses. Regarding 
the proposed mechanism behind normalising psychostimulant effects on inhibition-
related ERP components, stimulants like methylphenidate primarily support target 
detection by making the relevant stimuli more salient. In the case of the CPT this 
would be the NoGo signal, commanding the interruption of the prepared response. 
Crucial to this beneficial action is their supporting striatal DA availability, which might 
make up for the prefrontal disadvantage of having a Val allele.   
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4.2 Working Memory 
 
Early and mid-latency working memory components  Our study echoes 
previous work in that it largely could not identify sensory deficits in ADHD (Lopez et al., 
2006; Sergeant and van der Meere, 1990). Early visual stimulus discrimination as 
indicated by the N100 peak was comparable between ADHD children irrespective of 
medication status and healthy controls. This is supported by the absence of a pre-
attentive auditory processing deficit in the P50 paradigm. Responses to the first 
auditory stimulus (conditioning P50) necessitate no sensory gating, thus strength and 
timing of this mid-latency auditory component can be interpreted as an indicator of 
the functioning of the primary auditory cortex regardless of gating success. Since there 
were no group differences between ADHD and controls regarding conditioning P50 
amplitudes or timing, it is in line with the finding of normal early visual processing. 
Karayanidis et al. (2000) did report increased N100 latencies in ADHD boys; however 
their sample had a much narrower age range (6-10 years) where development is still 
on-going to a  greater degree, and they had all been medication naïve before testing. It 
is conceivable that previous treatment with psychostimulants or after-effects of 
discontinued medication for the experiment may have normalised stimulus 
discrimination. COMT genotype was the only factor modulating early sensory 
potentials in non-target trials the form of timing of the N100. Met carriers had longer 
latencies, hinting at a delay for visual information to be routed on to higher processing 
centres and processed. This is surprising considering the Met allele is associated with 
impulsivity and would thus be more readily able to explain latency decreases. In the 
working memory task, where this was observed, there were however no overt 
behavioural consequences of this delay. So the functional Val 158Met polymorphism 
starts to exert its influence resulting in performance differences or overt behaviour 
very early on, at the stage of stimulus discrimination.  
 
Looking at ERPs to target stimuli, we could however see impairments in 
unmedicated ADHD in the occipital P100 as a correlate of comparatively early visual 
processing. Exploring the interaction of group and DAT genotype, separate analyses by 
diagnostic group found that being homozygous for the 10R allele was only associated 
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with larger P100 responses in unmedicated ADHD, whereas it was of no consequence 
for early visual processing of target stimuli in medicated ADHD or control subjects. 
Without the risk genotype however, unmedicated patients had the smallest P100 
responses. In conclusion, having the ADHD associated DAT risk genotype 10R/10R 
brought out enhanced P100 responses in unmedicated ADHD patients, who otherwise 
had dampened P100 amplitudes. Target stimuli are more resource and attention 
demanding than non-target stimuli, since they constitute a signal that the initiation of 
a more or less complex behavioural response is required. Conversely, in this area 
ADHD patients show the most consistent deficits. Errors of omission (i.e. non-
responsiveness to target stimuli) were elevated in unmedicated patients across tasks, 
whereas false alarms (i.e. erroneous reactions to non-target stimuli) were independent 
of diagnostic group.  
 
  ADHD patients differed in their P150 response reflecting fronto-central 
networks preparing for impending change. A main effect for diagnostic group 
consistently showed longer P150 latencies in unmedicated compared to medicated 
ADHD patients. This is in line with findings by Karayanidis et al. (2000) and extends ERP 
differences identified by Keage et al. (2008) in their investigation of non-target 
components in ADHD. The latter authors did not find ADHD patients on or off 
medication to differ from controls in P150 responses. Karayanidis (2000) did not 
require subjects to update working memory, and instead had them perform a motor 
response to every stimulus. Keage (2008) on the other hand used only a simple load 
condition (1-back) while at the same time requiring a more complicated motor 
response to targets; also they differentiated between ADHD subtypes and children vs. 
adolescents for their analyses while for our study we merged those four categories.   
 
DAT genotype interacted with diagnostic group and load level in shaping P150 
timing. When cognitive load was low, medication only normalised P150 latencies and 
thus presumably material selection in the presence of a genetic risk conferred by the 
10/10 genotype. Without risk genotype, ADHD subjects showed normal responses. No 
differences in performance emerged. This does not fit with reports of particular 
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importance of DAT genotype under high load conditions, also in absence of 
compromised performance (Stollstorff et al., 2010). It was surprising to find that DAT 
genotype did not play a role for 2-back as opposed to Stollstorff et al. (2010), since in 
our study unmedicated patients had prolonged P150 latencies irrespective of DAT 
genotype. In adults the 10R/10R genotype was shown to be associated with more 
focused activation during working memory operations (Bertolino et al., 2009), faster 
reactions and more errors of commission (Caldu et al., 2007). Seeing that in children 
the DAT risk genotype is reversed, the prolonged P150 latencies for homozygous 10R 
carriers would go with longer and more variable reaction times and might be indicative 
of less focused activity in the working memory network. Stimulant medication speeded 
up electrophysiological responses corresponding to the selection of material or 
preparation for impending change and supports those processes in ADHD children.   
 
For N300, no ADHD specific impairment in memory retrieval was found, similar 
to Keage et al., 2008, but contrasting findings of decreased N300 amplitudes in ADHD 
patients (Sartory et al., 2002). The LPHN3 risk haplotype came with stronger N300 
responses indicative of better memory retrieval. Indeed, N300 amplitudes were 
correlated negatively with almost all behavioural parameters, indicating faster and less 
variable reactions and fewer errors of both types in subjects with greater N300 
amplitudes. This finding is surprising in light of the fact that the haplotype is more 
common in ADHD, but may be explained by more resources being invested in the 
retrieval process to achieve normal levels of functioning. Also this effect only being 
present in controls, the changes associated with LPHN3 genotype might interact with 
altered cortical architecture in ADHD and be detrimental only in combination with 
those alterations.  
 
Late working memory components  More endogenous components indica-
tive of higher-order cognitive control were used to assess the categorisation of targets 
(P300) and non-targets (P450).  P300 and DAT. A similar pattern as for P100 was seen 
for the target P300 peaks, where diagnostic group modulated the response in 
interaction with DAT genotype. Again, under the low load condition patients without 
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medication and without risk genotype were less responsive and had lower P300 
amplitudes than the medicated group. Carrying the risk genotype meant tendentially 
higher amplitudes in unmedicated patients, whereas without genetic risk, they had the 
lowest P300 amplitudes. Indeed, DAT genotype effects only manifested in this 
unmedicated group in the shape of higher amplitudes in 10R/10R individuals. 
However, high P300 amplitudes have been linked to better working memory span 
(Nittono et al., 1999) and there are reports of better cognitive functioning for 
homozygous risk allele carriers in ADHD (Barkley et al., 2006b; Karama et al., 2007), 
although the opposite pattern has also been found. So it is feasible that the 10R allele 
with higher DAT activity could have a compensatory effect through better phasic DA 
release at the cost of more variable responses, whereas the normally beneficial 9R is a 
disadvantage in terms of certain forms of cognitive performance for ADHD. This effect 
might be absent in medicated ADHD since their Dopaminergic transmission has 
probably not yet returned to pre-treatment levels. P300 latency has been reported to 
be associated with performance on working memory tasks (Polich et al., 1996), but in 
our study we could not confirm latency differences in any of the target components 
despite higher error rates in for ADHD children and adolescents. 
 
P450 and COMT Additionally, COMT also interacted with ADHD status on the 
late P450 component indicative of working memory updating. Upon closer inspection, 
only the control group had higher activation associated with the Met allele, whereas 
genotype was not relevant with respect to P450 in individuals with ADHD. This 
contradicts findings in healthy controls that Val/Val individuals display heightened and 
faster P300 responses (Yue et al., 2009). Since stronger P450 signifies a more capacities 
for the accommodation of new information (Clark et al., 1998), this is in line with 
reports of better cognitive functioning healthy Met carriers. The presence of a Met 
allele is associated with dampened activity and connectivity in some parts of the 
working memory network (DLPFC in Sambataro et al., 2009) and higher activation in 
others (VLPFC in Sambataro et al., 2009; right inferior frontal gyrus and intra-parietal 
sulcus in Dumontheil et al. 2011), so resources might be used in a more focused and 
efficient manner. Concerning the lack of COMT effects in ADHD patients, COMT is 
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mainly relevant for prefrontally mediated functions. Since maturational processes in 
the PFC go on well into early adulthood, and the majority of our sample was still quite 
young, COMT genotype might gain importance at a later point during development. 
Controls already show first indications of COMT effects, but since ADHD children are 
known to lag behind in normal development, this gene’s influence has likely not yet 
taken hold. 
 
4.3 Sensory Gating 
 
COMT  Regarding COMT, diagnostic groups without Met allele did not differ, 
whereas having a Met allele brought about worse sensory gating in unmedicated 
compared to medicated ADHD patients. Without Met allele, even patients without 
medication perform equal to controls, medication brings no additional benefit. The 
absence of an overall genotype (main) effect rules out that this is due to a floor or 
ceiling effect in either genotype group. This is in line with the study by Majic et al. 
(2011), who also did not find a main effect for COMT genotype on P50 gating ratios in a 
large sample of healthy subjects. However, the weaker suppression in unmedicated 
patients with Met allele compared to Val/Val homozygotes is mirrored by findings by 
Majic et al. (2011), who confirmed stronger N100 gating in their Val/Val group of 
healthy individuals, although the P50 peak captures a different aspect of sensory 
gating. In animal models receiving stimulant doses comparable to those administered 
to humans with ADHD, lead to an increase in prefrontal NE as well as DA (Berridge and 
Stalnaker, 2002). NE levels are associated with executive functioning and 
impulsiveness (Kieling et al., 2008, Hess et al., 2009) and more DA in the PFC enhances 
signal-to-noise ratio via eliminating background noise through stimulation of D1 
receptors and making the cell less responsive to irrelevant stimulation (Vijayraghavan 
et al., 2007), but balance is crucial: both too much NE (Birnbaum et al., 2004) and too 
much DA (Vijayraghavan et al., 2007) disrupt PFC and cause the cells to cease firing 
altogether. The Met allele of the COMT gene slows down the degradation of 
catecholamines (DA and NE) in PFC and stimulants increase extracellular levels of DA 
and NE via transporter inhibition (also in the PFC), so the combination should bring the 
best results in terms of phasic prefrontal activity, whereas both too low levels (in 
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unmedicated ADHD) and too high levels (in controls) can interfere with targeted 
activity necessary for sensory gating. Stimulant medication put them just at the right 
end of the inverted U-shaped curve of optimal prefrontal catecholamine levels. 
 
In both patient groups with at least one Met allele, greater degrees of 
suppression were associated with more false alarms in neuropsychological tests (e.g. 
CPT). This might be counter-intuitive seeing that the Met allele has frequently been 
found to be favourable for cognitive performance (e.g.  Mattay et al., 2003), and intact 
sensory gating is a prerequisite for higher cognitive processing (Wan et al., 2008, Lijffijt 
et al., 2009a, Yadon et al., 2009). However, this apparent contradiction of the often 
observed better cognitive functioning in Met/Met carriers and worse suppression of 
potentially interfering sensory information might be explained in terms of a generally 
higher capacity for the processing of sensory information in the PFC. It is feasible that 
the PFC areas involved in sensory gating might purposefully reduce the suppression 
rate to take advantage of those resources. Alternatively, the nature of the tasks 
involved might mediate the relationship between sensory gating, genotype and 
performance. As the direction of the relationship between sensory gating and 
cognitive performance appears heterogeneous, task complexity might to be an 
important moderator. While it could be beneficial to have low filter settings for 
sensory information during some cognitive operations (e.g. interference in Stroop task, 
Yadon et al. 2009), it might be disadvantageous during others (e.g. Attention Network 
Test, Wan et al., 2008; inhibition in a Go/NoGo task, Yadon et al. 2009). Another 
possible explanation are the low cell counts in this tentative correlational analysis, 
especially since the relationship between False Alarm rate and P50 suppression was 
inverted in the n-back task in the medicated ADHD group (r = -.914, p = .030). It is also 
possible that despite a higher mean P50 suppression, patients could overall display 
more variable gating behaviour, as ADHD has been associated with increased 
variability in state regulation (Sergeant, 2005), and this would result in stretches of 
poor gating bringing about false alarm responses. Furthermore, studies  uncovering sex 
as a mediating variable (Barnett et al., 2007: in healthy sample only COM effect in 
boys) or not finding any interactions between genotype and performance in executive 
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function tasks (Mills et al., 2004) illustrate the complex nature of the relationship 
between genotype and phenotype. 
 
DAT  Our finding that carriers of the DAT 9R allele in all diagnostic groups 
showed better gating is in line with the study by Millar et al. (2011), where these 
individuals were not only superior to homozygous 10R carriers but also were the only 
group where gating could be enhanced with nicotine, which downstream feeds into 
the same mechanisms as stimulant drugs. Findings that tobacco consumption led to an 
improvement of deficient sensory gating in schizophrenic patients (Millar et al., 2011) 
combined with the knowledge that one of the effects of nicotine is the release of DA 
(Grady et al., 2002) provided hints towards the involvement of the Dopaminergic 
system in sensory gating.  Indeed, the authors observed a main effect of genotype on 
the P50 gating measure (9R > 10R) along with an effect for drug (nicotine > placebo). 
Lower expression of DAT in the 9R carriers signifies greater availability of DA in the 
striatum (Fuke et al., 2001) and thus better dopaminergic tone. Striatal DA levels are 
also crucial for prefrontal functioning as the striato-thalamo-cortical loop regulates 
cognitive and motor behaviour and impulsivity, and the DAT 3’ VNTR modulates 
prefrontal activation in healthy individuals (Bertolino et al., 2006, Caldu et al., 2007, 
Yacubian et al., 2007). Potentially the lower suppression rate in homozygous 10R 
carriers masked any improvements medication might have had, even though better 
responses to methylphenidate have been reported for the 10R (Kirley et al., 2003, 
Stein et al., 2005). On the other hand having at least one 9R allele brought out 
differences between medicated and unmedicated patients, possibly due to a higher 
baseline suppression capacity. Kooij (2008) found that carriers of one 10R - the risk 
allele for childhood ADHD (Franke et al., 2010) - responded better to stimulants than 
10/10 (Kooij et al., 2008), which makes sense since for stimulants to be considered 
effective, at least 50% of striatal DAT needs to be blocked, and that’s harder to 
accomplish when there is a higher expression of DAT. DAT density and its affinity for its 
substrates DA und NE determine striatal Dopaminergic functioning. Within the DAT 
gene, the 10R allele confers increased availability of DAT in the striatum compared to 
the 9R (Heinz et al., 2000). It follows that DA and NE are cleared from the synaptic cleft 
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at a much quicker pace and this might contribute to impaired sensory gating, as the 
neurotransmitters are being made available for the initiation of subsequent action 
potentials (e.g. P50 to the second stimulus in the paired click-tone paradigm). Adler et 
al. (1988) found an increase in the NE metabolite 3-methoxy 4-hydroxyphenylglycol 
(MHPG) indicative of greater amounts of degraded NE to go along with impaired P50 
suppression in acute mania, and treatment normalising plasma MHPG levels 
corresponded to a normalisation in gating. Stimulants can normalise gating, as they 
block the reuptake and thus degradation of DA and NE, which leads to less 
neurotransmitter agents in the pre-synapse and smaller likelihood of a second action 
potential. So our finding that stimulant medication improves sensory gating only in the 
non-homozygous 10R group fits with previous research. 
 
LPHN3  Notably, we found an interaction of LPHN3 genotype with diagnostic 
group. Unmedicated patients who had the risk haplotype were impaired in terms of 
sensory gating, while for controls this very same haplotype actually promoted better 
gating ratios. As exploratory correlational analyses showed, better sensory gating led 
to more errors of omission in medicated ADHD and this relationship was reversed in 
patients without medication, where better gating was accompanied by less errors of 
omission in the n-back task. When receiving stimulant medication, having the LPHN3 
risk haplotype laid the ground for a negative relationship between gating capacity and 
false alarms (CPT), whereas having not having all risks SNPs meant better gating went 
along with more errors of omission (n-back). Among control children, those without 
the risk haplotype showed a positive relationship between P50 suppression and speed 
and variability of reaction times: The better the gating the slower and less consistent 
the responses, i.e. more variable. The thalamus as the brain’s most important relay 
station, where decisions about what will be passed on to higher sensory association 
areas and what will be blocked are made, is one of the generators of the P50 response 
(Tregellas et al., 2009, Williams et al., 2011). LPHN3 is expressed in thalamic nuclei and 
the risk haplotype has been found to be associated with decreased neural activity in 
thalamus and striatum and an increase in the cerebellar vermis (Arcos-Burgos et al., 
2010). So better suppression rates in carriers of the risk haplotype might be explained 
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by less activation of thalamic areas, which in turn exert less stimulating influence on 
higher auditory cortical areas. 
 
4.4 Response Time Variability 
ADHD children without medication had an increased variability of responses only in 
comparison to patients receiving psychostimulants, since those showed a slightly 
attenuated RTV even compared to controls. Medication seems to decrease RTV to 
below-normal levels, and this suggests stimulants drugs help with poor state 
regulation, even though the difference to controls did not reach statistical significance. 
This is in line with previous reports on improved RTV under psychostimulants in 
healthy individuals (Nandam et al., 2011) and ADHD samples (Uebel et al., 2010). 
Uebel et al. (2010) studied a range of behavioural parameters in a non-cued go/NoGo 
task with a comparable age range. ADHD children and adolescents had more variable 
but slower responses than controls, while unaffected siblings had intermediate scores 
in terms of RTV and both error types. In an exploratory manner, we additionally looked 
at changes in RTV over time. Arranging the tasks by their order in our investigation and 
adding diagnostic group as a factor, we did however only find a general increase in 
variability over the course of one session that was not more pronounced in ADHD. 
Response time variability was increased for homozygous 10R carriers (DAT) and 
carriers of at least one Met allele (COMT). This has been reported previously in ADHD 
children (Bellgrove et al., 2005; Loo et al., 2003). Two other studies did not find any 
implications of the DAT VNTR on variability of responses (Cummins et al., 2011; Oh et 
al., 2003), however Oh  (2003) investigated a sample of Korean boys, and there are 
well-known differences in different ethnicities, which might explain the divergent 
findings. And Cummins (2011) compared SD of Go reaction times in the SSRT between 
in healthy young adults, and this age group might have been on the cusp of DAT risk 
genotypes switching.  
 
4.5 Exploratory catamnestic analysis 
The overarching finding when looking for the effect of time on electrophysiological 
parameters was a marked decrease in amplitude combined with a quickening of 
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responses, i.e. shorter latencies at the second measurement. We could prove that 
there was a No-Go-Anteriorization at the second measurement.  Unfortunately the 
subsample returning for the second wave of testing was too small for a meaningful 
study of interactions between diagnostic group and genotype. However, one would 
expect DAT to become less important for the ADHD phenotype with age, as it is mainly 
expressed in the striatum and might thus be more relevant for the motor hyperactivity, 
decreases with age. This might be indicative of compensatory mechanisms taking 
effect, possibly due to better prefrontal control, as this structure only fully matures by 
late adolescence. At the second measurement point, only condition and group 
modulated centroid locations, with the centre of the positive brain electric field being 
more at frontal sites during inhibition compared to response execution trials, thus 
confirming the existence of NGA at T2. Receiving stimulant medication went along with 
more anterior inhibitory activity as well as faster and less variable reactions compared 
to unmedicated ADHD.  
 
N200 amplitudes did show an attenuation over time, as the strength of the 
response was smaller at the second measurement point. In addition to being smaller in 
magnitude, latencies also decreased, potentially paving the way for faster signalling of 
response conflicts. These effects were independent of condition and diagnostic group, 
both Go and NoGo amplitudes decreased to a similar extent in patients and controls. 
NoGo signals led to an earlier N200. This could however not be found at T2 and 
potentially hints towards higher processing demands of response execution commands 
in younger children. Of our candidate genes, only DAT exerted an influence on the 
development of the N200. Homozygous 10/10 carriers had lower Go amplitudes 
compared to people with at least one 9R allele at both T1 and T2. Latencies were 
delayed for homozygous 10R carriers at T2. The overall acceleration of N200 over time 
and the greater NoGo amplitude could be found for all DAT genotypes. 
 
We could confirm the existence of an NGA at both measurement points in terms 
of centroid location, however there was no difference between T21 and T2, nor did the 
diagnostic groups develop along different paths. It is possible that the catamnestic 
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time frame was either too short or didn’t capture a critical developmental period. 
Relatively low NGA values compared to previous publications speak to that (e.g. 0.36 
for ADHD and 0.50 for controls in Dresler et al., 2010; 0.59 for ADHD and 0.67. for 
controls in Fallgatter et al., 2009). For P300, we looked both at Global Field Power and 
values at the respective peak sites – Cz for NoGo and Pz for Go. Both kinds of P300 
amplitudes showed a decrease between measurement points. When comparing peaks 
at individual electrode sites, it also emerged that Go stimuli evoked faster reactions 
than NoGo signals, and those were also greater in magnitude. 
 
Response Inhibition During response inhibition, this held true for N200 and P300 
peaks both in terms of Global Field Power and at individual electrode sites during the 
response inhibition task. Amplitude decrease with age fits with previous research 
findings for target P300 (Fjell & Walhovd, 2004), whereas the negative relationship of 
age and P300 latency is in stark contrast with these authors’ findings.  It does however 
fit with the study by Stige et al., (2007), who also observed a quickening of P300b 
responses in addition to extending the known development of P300 amplitudes by 
identifying an increase in later life following the initial attenuation of the evoked 
response.  The same U-shaped course has previously been described for P300 latencies 
as well, with latencies starting to increase again in early to late twenties [(e.g. (Mullis 
et al., 1985). Faster and more efficient responses from childhood to adolescence could 
be indicative of the fact that the demands of a given task subjectively decrease with 
brain maturation, until after a switch point in adult life age again necessitates the 
recruitment of to achieve comparable results. Neither the Go nor the NoGo centroid 
locations showed developmental effects in comparisons between measurement points 
as a two; consequentially the NGA also remained unaffected by time. This corresponds 
well to reports on the relative independence of age on NGA (Fallgatter et al., 1999), 
however we were hoping to gain insight into the age at which NGA first emerges as a 
stable phenomenon. To this end, we conducted additional nonparametric correlational 
analyses between the two parameters. We did not find significant correlations 
between age and NGA, neither in the total sample nor in the individual diagnostic 
groups. We could however replicate the negative relationship between age and 
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locations of both Go and NoGo centroids at T1. Differences in P300 amplitudes   were 
no longer identifiable at T2 in our study, which is in contrast with Doehnert et al., 
(2010) postulating the temporal stability or rather progressive nature of a reduced 
NoGo- P300 in ADHD. This was not the case in our sample, where NoGo amplitude was 
unrelated to age in control and ADHD patients, regardless of whether medicated and 
unmedicated cases were examined independently or grouped together. However, 
differences in age composition of the samples and catamnestic period (3.5 years in the 
present study vs. 2.5 years in Doehnert et al., 2010) might have contributed to the 
divergent results. 
 
Working memory  For the working memory task, only interactions of time and 
diagnostic groups will be discussed, since we were primarily interested in diverging 
developmental paths between ADHD children and healthy controls, and potential 
modifying effects of stimulant medication. In longitudinal analyses involving COMT 
genotype as a factor, timing of N100 was moderated by an interaction of time, 
diagnostic group and COMT genotype: While both genotype groups showed the 
expected latency decrease, individual analysis within each diagnostic group revealed 
that only unmedicated ADHD patients and healthy controls speeded up their N100 
responses over time. Psychostimulants seem to interfere with early responses involved 
in stimulus discrimination getting more automated and thus faster with age. To 
conclusively determine the underlying mechanism, future research need to address 
this question with a within-subject comparison on and off medication. In a previous 
study on early auditory and visual potentials in working memory tasks (Pelosi & 
Blumhardt, 1999), no age effects on latency were observed in healthy adults (aged 19-
71), which suggest that medication might delay this adaptive process that reaches a 
plateau at the end of adolescence. At the second measurement point controls had 
lower amplitudes P100 than either ADHD group, while the latency decrease from T1 to 
T2 was only present in unmedicated patients. Regarding P300 amplitudes, differences 
between diagnostic groups were limited to T2, where controls responded more 
strongly than ADHD patients.  
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4.6 Limitations  
There were several limitations to the present study. As is common practise in 
examinations of ADHD populations, the sample comprised considerably more males 
than females, and patients were only of the combined subtype. For better 
generalizability and to compare the distinct phenotypical manifestations of ADHD on 
an electrophysiological level, it is necessary to invest in the recruitment of a more 
diverse sample of sufficient size. Correspondingly, for analyses of genetic contributions 
to electrophysiological endophenotypes, a bigger sample is better suited to elucidate 
interactions between diagnostic status, sex and genotype, which was not possible 
within the framework of this study. It would have been interesting to check for sex 
differences both in the developmental trajectories and moderating effects of this 
variable on genotype. In particular, we would have been interested in looking into 
gene-by-gene interactions as well, as previous studies have shown genes e.g. of the 
Dopaminergic system to act in concert to modulate phenotypes and underlying 
neuronal processes. Bertolino et al. (2006) demonstrated additive effects of COMT and 
DAT on working memory related brain activity with functional brain imaging methods 
functional magnetic resonance imaging and near-infrared-spectroscopy, hinting at 
more focused and thus efficient activation of the respective areas. It would be 
interesting to see how this affects Event-Related Potentials. The main issues regarding 
longitudinal questions were the small sample size at T2 and inhomogeneous intervals 
between measurement points. This neither allowed for the sub-division of the sample 
according to sex nor was it sensitive for genotype effects. 
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Appendix A: Instructions and Questionnaires 
A1:   Information for Participants and Confirmation of Consent 
 
 
DFG - Klinische Forschergruppe 
Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom - Molekulare Pathogenese und 
Endophänotypen im Therapieverlauf  
 
Teilprojekt 1 
Charakterisierung  von Patient/innen mit Aufmerksamkeitsdefizit-
/Hyperaktivitätssyndrom (ADHS) unter Einschluss familiengenetischer 
Untersuchungsstrategien und Längsschnittbeobachtung 
 
 
Sehr geehrte Frau, sehr geehrter Herr............................ 
 
Wir haben uns die Aufgabe gestellt, im Rahmen eines von der deutschen Forschungs-
gemeinschaft (DFG) geförderten Projektes, die Symptome und den Verlauf des  
Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom (ADHS) bzw. des hyperkinetischen 
Syndroms zu untersuchen. Wir möchten Sie herzlich bitten, uns in dieser wichtigen 
Aufgabe zu unterstützen. Sie würden damit einen sehr wertvollen Beitrag zur 
Erforschung des hyperkinetischen Syndroms leisten und mithelfen, die 
Behandlungsmöglichkeiten in Zukunft weiter zu verbessern. Dieses Informationsblatt 
fasst die wesentlichen Aspekte des oben genannten Forschungsprojektes zusammen. Sie 
wurden bereits ausführlich hierzu von einer/m Ärztin/Arzt, die/der an dem Projekt 
mitarbeitet, über das Vorgehen und den Zweck der Untersuchung informiert. Falls Sie 
weitere Fragen haben, wenden Sie sich bitte an Herrn Dr. Romanos mit dem Stichwort 
„Katamnese“ (Tel.: 0931/201- 78600) oder an die Ihnen bekannten Kontaktpersonen.  
 
Die klinischen Untersuchungen werden koordiniert von  
 
Frau PD. C. Mehler-Wex und Herrn Prof. Dr. A. med. Warnke,  
Klinik für Kinder und Jugendpsychiatrie und Psychotherapie der Universität Würzburg 
 
 
Bisherige wissenschaftliche Erkenntnisse zur Erblichkeit des Aufmerksamkeitsdefizit-
/Hyperaktivitätssyndroms 
Bei dem Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom handelt es sich um eine 
Störung, die ca. vier Prozent aller Knaben und ein Prozent aller Mädchen betrifft. An der 
Entstehung dieser Störung wirken sowohl Umwelt- als auch genetische Faktoren mit. 
Man geht davon aus, dass bei gegebener erblicher Veranlagung Umwelteinflüsse die 
Symptomatik verhindern oder aber verstärken können. Die Bedeutung von erblichen 
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Faktoren lässt sich aufgrund von Zwillings-, Adoptions- und Familienstudien nachweisen. 
So sind beispielsweise häufig bei einem eineiigen Zwillingspaar beide Zwillinge, bei 
einem zweieiigen Zwillingspaar hingegen nur ein Zwilling von der Störung betroffen. 
Allgemein ist des Weiteren bekannt, dass Eltern, besonders Väter von Kindern mit 
einem hyperkinetischen Syndrom selbst eine entsprechende Symptomatik in ihrer 
Kindheit hatten bzw. aktuell noch aufweisen. So wissen wir, dass die typischen 
Symptome des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms– motorische 
Hyperaktivität, Aufmerk-samkeitsstörung und Impulsivität – in der Regel nicht über das 
gesamte Leben durchgängig vorhanden sind. Vielmehr treten diese Symptome ganz 
besonders stark im Kindesalter auf. Während die Impulsivität und die 
Aufmerksamkeitsstörung häufig auch noch im Erwachsenenalter anhalten, lässt die 
motorische Hyperaktivität bei vielen Betroffenen im Jugendalter deutlich nach. 
Aufgrund dieser Zusammenhänge ist es wichtig, dass bei einer Untersuchung zur 
Erblichkeit des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms (ADHS) nicht nur nach 
gegenwärtig vorhandenen Symptomen sondern auch nach solchen in der Vergangenheit 
und besonders im Kindesalter gefragt wird.  
 
Ziele der Untersuchung 
Unser Forschungsprojekt dient dem genauen Erkennen und Beschreiben 
(Charakterisierung) der Symptome der Patienten mit ADHS und bei Ihren Eltern. Eine 
Blutentnahme von 20 ml Blut erfolgt zur Erkennung von Erbanlagen, die an der 
Entstehung des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndroms ADHS beteiligt sind. 
Um dies zu ermöglichen, wird die Erbsubstanz (DNA) von den betroffenen Kindern und 
deren Angehörigen untersucht. Sehr vereinfacht ausgedrückt geht es darum, spezifische 
Genvarianten zu identifizieren, die bei von einem hyperkinetischen Syndrom 
Betroffenen häufiger als bei Nichtbetroffenen vorkommen. Darüber hinaus gibt es aber 
auch beispielsweise Familienuntersuchungen, bei denen ermittelt wird, ob bestimmte 
Genvarianten häufiger als erwartet von den Eltern an die Kinder weitervererbt werden. 
Wenn zwei oder mehr Geschwister erkrankt sind, wird untersucht, ob diese überzufällig 
häufig den gleichen DNA-Abschnitt von ihren Eltern ererbt haben. Für solche 
Untersuchungen benötigt man auch eine umfassende statistische Auswertung, da nur 
hierdurch gewährleistet ist, dass tatsächlich die relevanten Varianten identifiziert 
werden können. Weiterhin möchten wir Erkenntnisse über den Verlauf der ADHS 
erhalten, da die Symptome im Erwachsenenalter teilweise abnehmen, zum Teil jedoch 
bestehen bleiben und sich verändern können. Wir werden Sie daher im Abstand von 
mehreren Jahren erneut in unsere Ambulanz einladen, um an den 
Verlaufsuntersuchungen teilzunehmen. Auch die Teilnahme an diesen Untersuchungen 
ist selbstverständlich jederzeit freiwillig. 
 
Untersuchungen in der Klinik und Poliklinik für Kinder- und Jugendpsychiatrie der 
Universität Würzburg 
 
Ausführliche Untersuchung und Diagnostik Ihres Kindes 
Um eine genaue Einschätzung von den Problemen Ihres Kindes zu bekommen, benötigen wir 
eine Reihe von Informationen von Ihnen und Ihrem Kind. Wir möchten Sie deshalb bitten, einige 
Fragebögen über das Verhalten Ihres Kindes auszufüllen und möchten auch eine kurze 
Einschätzung der Symptomatik durch den Lehrer einholen. Ferner werden wir Ihnen Fragen 
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darüber stellen, ob neben dem hyperkinetischen Syndrom noch weitere Auffälligkeiten bei Ihrem 
Kind bestehen. Mit Ihrem Kind werden wir einige Aufgaben, zum Teil am Computer durchführen, 
um eine objektive Einschätzung seiner kognitiven Fähigkeiten und seiner 
Konzentrationsprobleme zu bekommen. Ferner soll Ihr Kind zwei kurze Fragebögen zu seiner 
Stimmung und zu möglichen Ängsten ausfüllen. Da wir in dieser Studie insbesondere an der 
Erblichkeit des hyperkinetischen Syndroms interessiert sind, möchten wir Sie ferner darüber 
befragen, inwieweit Sie in der Kindheit auch unter bestimmten typischen Symptomen gelitten 
haben bzw. ob diese gegenwärtig noch vorhanden sind. Die Untersuchungsdauer Ihres Kindes 
wird ca. 120 Minuten betragen. Für das Ausfüllen der Fragebögen und die Durchführung der 
Interviews (bei zwei betroffenen Kindern) werden wir ca. 2 Stunden Ihrer Zeit beanspruchen. Wir 
werden versuchen, möglichst zeitlich flexibel und parallel Ihre Befragung und die Untersuchung 
Ihres Kindes durchzuführen.  
 
Verlaufsuntersuchung 
Die Familien, welche an der Studie teilnehmen, werden im Abstand von mehreren 
Jahren erneut eingeladen, um an einer Verlaufsuntersuchung teilzunehmen. Die 
Symptome der ADHS können im Laufe der Zeit Veränderungen unterliegen. Bislang ist 
ungeklärt, warum in manchen Fällen einzelne oder alle Symptome bestehen bleiben 
oder abnehmen. Auch können die langfristigen psychosozialen Folgen sehr 
unterschiedlich sein. Für das Verständnis der ADHS und um zukünftig eine optimale 
Therapie gewährleisten zu können, ist es notwendig, die Ursachen für die 
unterschiedliche Entwicklung der Störung zu erkennen. Zu diesem Zweck laden wir die 
teilnehmenden Familien im Abstand von 3 Jahren erneut ein, um erneut eine genaue 
klinische Untersuchung mit den gleichen Untersuchungsmethoden wie bei der 
Erstuntersuchung durchzuführen. Dadurch kann ein eventueller Wandel der 
Symptomatik erfasst werden. Wenn Ihr Kind bereits die Volljährigkeit erreicht haben, 
werden die Verlaufsuntersuchungen durch Teilprojekt 2 (Erwachsenenpsychiatrie) 
durchgeführt werden. Für diesen Fall wird eine gesonderte Einladung und separate 
Aufklärung erfolgen.   
 
Untersuchungen zur funktionellen Molekulargenetik 
Um molekulargenetische Untersuchungen durchführen zu können, benötigt man die 
Erbsubstanz. Diese wird aus den weißen Blutkörperchen gewonnen. Insofern ist es 
erforderlich, dass sowohl bei dem Betroffenen als auch dessen Eltern und ggf. 
betroffenen Geschwistern eine Blutentnahme zur Gewinnung der DNA erfolgt. Hierbei 
werden 20 ml Blut benötigt. Auch für ein Kind ist die Entnahme einer solchen Blutmenge 
unbedenklich. (Ein separates Informations- und Aufklärungsblatt liegen bei). 
 
Untersuchungen zur Neurophysiologie  
Das Elektroenzephalogramm (EEG) erfasst an der Kopfoberfläche die schwachen 
elektrischen Ströme, mit denen das Gehirn arbeitet. Hierfür werden Ihrem Kind 
zunächst mittels einer Paste schmerzfrei Meßelektroden auf die Kopfhaut geklebt. Ihr 
Kind soll dann den „Continous performance Test“ durchführen, bei dem es z.B. auf 
bestimmte an einem Bildschirm dargebotene Buchstaben mit Knopfdruck reagieren 
oder nicht reagieren soll. Die Dauer beträgt 90 min. Nebenwirkungen sind nicht 
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bekannt. (Ein separates Informationsblatt und eine separate Einwilligungserklärung 
erhalten Sie von der neurophysiologischen Abteilung vor der Untersuchung.) 
 
Untersuchung am Institut für Psychologie der Universität Würzburg 
Psychobiologie 
Das ADHS ist häufig verbunden mit der Tendenz auf positive Ereignisse geringere 
Reaktionen zu zeigen. In dem ersten Versuch wird Ihr Kind z.B. kleine Belohnungen 
erhalten für Reaktionen auf nicht relevante Reize, die einem (harmlosen) Schreck 
auslösenden Reiz vorangehen. In einem zweiten Versuch sollen Reaktionen erfasst 
werden auf positiv und negativ besetzte Bilder, die Ihnen, wenn Sie es wünschen, gerne 
vorher gezeigt wurden. Die Dauer beträgt 120 min. Nebenwirkungen sind nicht bekannt. 
(Ein separates Informationsblatt und eine separate Einwilligungserklärung erhalten Sie 
von der biologischen und klinischen Psychologie vor der Untersuchung).  
 
Untersuchungen in der Abteilung für Neuroradiologie des Instituts für 
Röntgendiagnostik der Universität Würzburg 
Funktionelle Magnetresonanztomographie  
Einige wenige Patienten und Probanden sollen mit einem modernen radiologischen Verfahren 
untersucht werden, das nicht nur die Struktur, sondern auch die Funktion umschriebener 
Regionen des Gehirns darstellt. Die Magnetresonanztomographie benötigt für diese Darstellung 
im Gegensatz zu anderen Verfahren keine radioaktiv markierten Substanzen. Ich Kind sieht eine 
Serie von Buchstaben auf einer Leinwand und soll auf eine bestimmte selten vorkommende 
Buchstabenkombination reagieren. Die Dauer der Untersuchung beträgt 40 min. Die 
Strahlenbelastung überschreitet nicht das Maß der radiologischen Routineverfahren. (Ein 
separates Informationsblatt und eine separate Einwilligungserklärung erhalten Sie von der 
Neuroradiologie vor der Untersuchung). 
 
Laboruntersuchung bei medikamentöser Behandlung 
Falls bei Ihrem Kind eine Aufmerksamkeitsdefizit/Hyperaktivitätsstörung vorliegt und Ihr 
Kind mit einem Medikament behandelt werden sollte, sind immer vor Beginn der 
Behandlung die Blutwerte zu untersuchen, nach Beginn der Behandlung werden die 
Blutwerte in größeren Abständen kontrolliert, um Nebenwirkungen ausschließen zu 
können. Im Rahmen dieser Blutuntersuchungen, würden wir gerne bei den ersten 3 
Kontrolluntersuchungen einen kleinen Teil der Blutabnahmen (jeweils 5 ml) abtrennen, 
um weitere mögliche Nebenwirkungen untersuchen bzw. ausschließen zu können.  
Zusätzliche Blutentnahmen sind dafür nicht notwendig. 
 
Ablauf 
Die Untersuchungen erfolgen während der stationären oder ambulanten Behandlung 
Ihres Kindes, ohne dass Verzögerungen der Behandlung oder des Entlasszeitpunktes 
resultieren. Die geplanten Untersuchungen werden in einem Zeitraum von 2-3 Wochen 
durchgeführt, so dass die Untersuchungen nicht zu einer Belastung führen. Sie werden 
vor den entsprechenden Untersuchungen jeweils mit den entsprechenden 
Einverständniserklärungen  in persönlichen Gesprächen noch einmal aufgeklärt. 
 
Welche Vor- und Nachteile gibt es für Sie und Ihr Kind? 
Durch Ihre Bereitschaft an der Untersuchung teilzunehmen, leisten Sie einen wichtigen 
Beitrag zur Erforschung der möglichen Ursachen des Aufmerksamkeitsdefizit-
  
112 
 
/Hyperaktivitätssyndroms (ADHS). Die gewonnenen Erkenntnisse könnten 
möglicherweise zur Entwicklung neuer und besserer Medikamente beitragen. Ein 
unmittelbarer Nutzen besteht gegenwärtig jedoch weder für Sie noch Ihre 
Familienangehörigen. Wie bei jeder herkömmlichen Blutentnahme können an der 
Einstichstelle vorübergehende Reizungen auftreten. 
 
Freiwilligkeit. Können Sie oder Ihr Kind aus der Untersuchung wieder ausscheiden? 
Selbstverständlich ist Ihre Teilnahme an dieser Untersuchung und den unterschiedlichen 
Teiluntersuchungen freiwillig. Sie können die Untersuchung oder Teiluntersuchungen 
jederzeit und ohne Angabe von Gründen abbrechen, ohne dass sich dadurch Nachteile 
für Ihre weitere ärztliche Versorgung ergeben. Wenn Sie es wünschen, vernichten wir 
Ihre Blutprobe bzw. die aus den weißen Blutkörperchen gewonnene Erbsubstanz (DNA). 
 
Wie vertraulich werden die ermittelten Daten behandelt? 
Die im Rahmen dieses Forschungsprojektes erhobenen Daten aus den Interviews, der 
verschiedenen Untersuchung, einschließlich auch der Untersuchungen der Erbsubstanz 
werden in Computersystemen der beteiligten Kliniken und Forschungseinrichtungen in 
anonymisierter Form auf unbestimmte Zeit gespeichert. 
Die Schlüsselliste, die allein eine Zuordnung der Daten zu den untersuchten Personen 
gestattet, verbleibt unter Verschluss in unserer Klinik. Sobald der Forschungszweck 
erreicht ist – ein Zeitpunkt lässt sich derzeit nicht angeben – wird die jeweilige 
Schlüsselliste gelöscht. Bis zu diesem Zeitpunkt wird die Schlüsselliste in einem 
verschlossenen Raum der jeweiligen Klinik aufbewahrt und die Datenspeicherung- und  
Bearbeitung erfolgt in anonymisierter Form. 
Im Rahmen von Projekten mit anderen Forschungseinrichtungen werden häufig 
wissenschaftliche Daten ausgetauscht. Hierbei können Daten zu Ihrem Kind oder Ihrer 
Person in anonymisierter Form an derartige Forschungseinrichtungen möglicherweise in 
Zukunft weitergegeben werden. In keinem Fall werden die Namen von Personen bzw. 
Familien weitergegeben, die an der Untersuchung teilgenommen haben. 
 
Name der Kontaktpersonen 
Bei Rückfragen wenden Sie sich bitte zunächst an die verantwortlichen Studienleiter der 
jeweiligen Klinik oder an: 
 
Dr. med. M. Romanos, Fr. Dr. med. Wirth, Stichwort „Katamnese“ 
Klinik und Poliklinik für Kinder- und Jugendpsychiatrie und Psychotherapie der 
Universität Würzburg; 
Füchsleinsstraße; 97080 Würzburg 
Tel.: 0931/ 201-78600 od. 77590 
Fax: 0931/ 201-78620 
 
Wir möchten uns bei Ihnen für Ihre Mitarbeit ausdrücklich bedanken! 
 
Würzburg, den 1.9.2003, geändert am 01.05.2005, 06.11.2006, 29.11.2006 und 
08.07.2008. 
 
Prof. Dr. A. Warnke und PD Dr. C. Mehler-Wex 
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DFG - Klinische Forschergruppe 
Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom - Molekulare Pathogenese und 
Endophänotypen im Therapieverlauf  
 
Teilprojekt 1 
Charakterisierung  von Patient/innen mit Aufmerksamkeitsdefizit-
/Hyperaktivitätssyndrom (ADHS) unter Einschluss familiengenetischer 
Untersuchungsstrategien und Längsschnittbeobachtung 
 
 
Einwilligungserklärung 
 
Die Teilnahme an der Studie ist freiwillig, das Einverständnis kann jederzeit (auch für einzelne 
Teile der Studie widerrufen werden) ohne Angabe von Gründen und ohne Nachteile für Sie 
widerrufen werden.   
Ihre Angaben und die Ihres Kindes werden selbstverständlich streng vertraulich behandelt. Sie 
werden niemandem außerhalb der an der Untersuchung beteiligten Ärzte zugänglich gemacht. 
Schriftliche Aufzeichnungen werden in der Klinik sicher verwahrt. Die Auswertung der Daten, 
einschließlich deren wissenschaftlichen Veröffentlichung erfolgt ohne Namensnennung, so dass 
keinerlei Rückschlüsse auf Ihre Person möglich sind. Die Datenschutzbestimmungen werden 
eingehalten. 
 
Ich erkläre, dass ich dieses Informationsblatt gelesen und verstanden habe und meine Fragen 
durch Dr. med.  …………………………….. zufrieden stellend beantwortet wurden. Ich bin mit der 
Teilnahme an der obigen Untersuchung und der Speicherung meiner Dateien unter Beachtung 
aller relevanten datenschutzrechtlichen Aspekte einverstanden und habe keine weiteren 
Fragen. Ich kann jederzeit das Einverständnis zur Teilnahme an dem gesamten oder einzelnen 
Vorhaben widerrufen, ohne dass mir dadurch Nachteile entstehen. 
 
 
........................., den ................... 
 
 
 
____________________________  ________________________________ 
 
 
       ________________________________ 
 
Unterschrift des aufklärenden Arztes Unterschriften der 
Erziehungsberechtigten 
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A2:   DSM-IV Criteria 
 
 
Diagnostische Kriterien für Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung 
aktuell 
 
A. Entweder Punkt (1) oder Punkt (2) müssen zutreffen: 
(1) sechs (oder mehr) der folgenden Symptome von Unaufmerksamkeit sind  
während der letzten 6 Monate beständig in einem mit dem Entwicklungsstand des 
Kindes nicht zu vereinbarenden und unangemessenen Ausmaß vorhanden gewesen: 
 
Unaufmerksamkeit 
(a) beachtet häufig Einzelheiten nicht oder macht Flüchtigkeitsfehler bei den 
Schularbeiten, bei der Arbeit oder bei anderen Tätigkeiten 
(b) hat oft Schwierigkeiten, längere Zeit die Aufmerksamkeit bei Aufgaben 
oder beim Spielen aufrechtzuerhalten 
(c) scheint häufig nicht zuzuhören, wenn andere ihn/sie ansprechen 
(d) führt häufig Anweisungen anderer nicht vollständig durch und kann 
Schularbeiten, andere Arbeiten oder Pflichten am Arbeitsplatz nicht zu Ende 
bringen (nicht aufgrund oppositionellen Verhaltens oder 
Verständnisschwierigkeiten) 
(e) hat häufig Schwierigkeiten, Aufgaben und Aktivitäten zu organisieren 
(f) vermeidet häufig, hat eine Abneigung gegen oder beschäftigt sich häufig nur 
widerwillig mit Aufgaben, die länger andauernde geistige Anstrengungen 
erfordern (wie Mitarbeit im Unterricht oder Hausaufgaben) 
(g) verliert häufig Gegenstände, die er/sie für Aufgaben oder Aktivitäten benötigt 
(z.B. Spielsachen, Hausaufgabenhefte, Stifte, Bücher oder Werkzeug) 
(h) lässt sich öfter durch äußere Reize leicht ablenken 
(i) ist bei Alltagstätigkeiten häufig vergesslich 
 
(2) sechs (oder mehr) der folgenden Symptome der Hyperaktivität und Impulsivität sind 
während der letzten 6 Monate beständig in einem mit dem Entwicklungsstand des 
Kindes nicht zu vereinbarenden und unangemessenen Ausmaß vorhanden gewesen: 
 
Hyperaktivität 
(a) zappelt häufig mit Händen oder Füßen oder rutscht auf dem Stuhl herum 
(b) steht in der Klasse oder in anderen Situationen, in denen Sitzenbleiben erwartet 
wird, häufig auf 
(c) läuft häufig herum oder klettert exzessiv in Situationen, in denen dies unpassend 
ist ( bei Jugendlichen oder Erwachsenen kann dies auf ein subjektives 
Unruhegefühl beschränkt bleiben) 
(d) hat häufig Schwierigkeiten, ruhig zu spielen oder sich mit Freizeitaktivitäten ruhig 
zu beschäftigen 
(e) ist häufig „auf Achse“ oder handelt oftmals, als wäre er/sie „getrieben“ 
(f) redet häufig übermäßig viel 
 
Impulsivität 
(g) platzt häufig mit den Antworten heraus, bevor die Frage zu Ende gestellt ist 
(h) kann nur schwer warten, bis er/sie an der Reihe ist 
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(i) unterbricht und stört andere häufig (platzt z.B. in Gespräche oder in Spiele 
anderer hinein) 
 
 
 
B. Einige Symptome der Hyperaktivität-Impulsivität oder Unaufmerksamkeit, die 
Beeinträchtigungen verursachen, treten bereits vor dem Alter von sieben Jahren auf. 
C. Beeinträchtigungen durch diese Symptome zeigen sich in zwei oder mehr Bereichen 
(z.B. in der Schule bzw. am Arbeitsplatz und zu Hause). 
D. Es müssen deutliche Hinweise auf klinisch bedeutsame Beeinträchtigungen der 
sozialen, schulischen oder beruflichen Funktionsfähigkeit vorhanden sein. 
E. Die Symptome treten nicht ausschließlich im Verlauf einer tiefgreifenden 
Entwicklungsstörung, Schizophrenie oder einer anderen Psychotischen Störung auf 
und können auch nicht durch eine andere psychische Störung besser erklärt werden 
(z.B. Affektive Störung, Angststörung, Dissoziative Störung oder eine 
Persönlichkeitsstörung) 
 
Codiere je nach Subtypus: 
314.01 (F90.0) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung, Mischtypus: liegt vor, 
wenn die Kriterien A1 und A2 während der letzten 6 Monate erfüllt waren 
314.00 (F98.8) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung, Vorwiegend 
Unaufmerksamer Typus: liegt vor, wenn Kriterium A1, nicht aber Kriterium A2 während 
der letzten 6 Monate erfüllt war 
314.01 (F90.1) Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung, Vorwiegend Hyperaktiv-
Impulsiver Typus: liegt vor, wenn Kriterium A2, nicht aber Kriterium A1 während der letzten 6 
Monate erfüllt war 
 
Codierhinweise: Bei Personen (besonders Jugendlichen und Erwachsenen), die zum 
gegenwärtigen Zeitpunkt Symptome zeigen, aber nicht mehr alle Kriterien erfüllen, wird 
Teilremittiert spezifiziert. 
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 A3:   Child Behaviour Check List (CBCL) 
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A4:   Task instructions presented on a computer screen before 
 
a) Continuous Performance Task 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 1-back task 
 
 
 
 
 
 
 
 
 
 
 
 
 
c) 2-back task 
 
 
 
 
 
 
 
 
 
Sie werden gleich eine Reihe von Buchstaben sehen, 
die nacheinander auf dem Bildschirm erscheinen. 
 
Sie sollen dabei immer dann auf die Leertaste drücken, 
wenn zuerst ein O und direkt danach ein X erscheint. 
 
Erscheint nach einem O ein anderer Buchstabe als X, 
drücken Sie bitte nicht. 
 
Zum starten: Leertaste drücken 
 
 
Sie werden gleich einige Minuten lang Buchstaben auf dem 
Bildschirm präsentiert bekommen. 
 
Drücken Sie bitte immer dann auf die Leertaste, 
wenn ein Buchstabe mit dem vorherigen Buchstaben übereinstimmt. 
                              
zum Starten: Leertaste drücken 
 
 
 
Sie werden gleich einige Minuten lang Buchstaben auf dem 
Bildschirm präsentiert bekommen. 
 
Drücken Sie bitte immer dann auf die Leertaste, 
wenn ein Buchstabe mit dem vorletzten Buchstaben übereinstimmt. 
                              
zum Starten: Leertaste drücken 
 
 
 
 
 
k 
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B 1   Genotype and Allele frequencies   (T1) 
 
 
ADHDunmed ADHDmed Controls 
 
Chi² p 
COMT 
No Met 12 11 16 39 
112 .796 .672 
Met 24 24 24 72 
 
DAT 
10/10 18 16 21 55 
113 .492 .782 
other 19 20 19 58 
 
LPHN3 
Risk 18 19 20 57 
108 .794 .672 
No risk 18 13 20 51 
 Table S1  Comparison of binary genotype frequencies between diagnostic groups 
    
  Group Differences 
(Genotypes) 
Hardy-Weinberg 
 
ADHDunmed ADHDmed Controls 
 Total 
N 
Chi² p Chi² p 
COMT 
CC 12 11 16 39 
112 1.151 .886 0.036 0.85 CG 19 18 18 55 
GG 5 7 6 18 
  
DAT1 
9/9 4 3 4 11 
113 2.752 .839 
0.249 0.618 9/10 15 15 14 44 
10/10 18 16 21 55 
10/11 0 2 1 3  
  
 
LPHN3 
rs6551665 AA 13 13 14 40 
108 1.560 .816 1.349 0.245 AG 18 15 23 56 
GG 4 5 3 12 
     
rs2345039 CC 4 5 7  
108 6.724 .151 1.999 0.157 CG 20 23 17  
GG 11 5 16  
     
rs1947274 AA 14 13 14 41 
110 2.368 .668 0.866 0.352 AC 18 15 23 56 
CC 4 6 3 13 
Table S2  Comparison of genotype frequencies between diagnostic groups and calculation of Hardy-Weinberg-Equilibrium 
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B 2   Behavioural Parameters   (T1) 
 
 
COMT 
(T1) 
CPT  1-back  2-back 
no Met Met 
p 
 no Met Met 
p 
 no Met Met 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 2,92 ,52 4,46 ,79 ,709  6,69 1,27 7,39 1,10 ,624  21,64 1,74 21,59 1,09 ,680 
False Alarm 1,31 ,365 2,35 ,350 ,025  2,28 ,375 3,33 ,60 ,391  5,64 ,99 5,95 ,68 ,452 
Reaction times 490,67 20,92 510,78 15,53 ,446  475,63 24,78 489,32 19,18 ,539  518,49 29,23 578,76 22,04 ,090 
SD (RT) 135,61 8,01 165,8 8,63 ,031  246,42 10,26 245,41 12,04 ,781  343,17 13,86 366,99 11,65 ,331 
all ps 2-tailed 
Table S3  Influence of COMT-Genotype on Error Rates, Response Times and RTV (T1) 
 
 
 
DAT1 
(T1) 
CPT  1-back  2-back 
10/10 other 
p 
 10/10 other 
p 
 10/10 other 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 3,47 ,69 4,29 ,81 ,175  7,06 1,34 7,40 1,03 ,248  21,02 1,24 22,46 1,42 ,231 
False Alarm 1,94 ,323 2,03 ,403 ,765  2,15 ,30 3,75 ,72 ,133  5,74 ,72 5,93 ,87 ,660 
Reaction times 500,42 15,68 507,21 18,88 ,873  469,47 20,75 497,97 21,51 ,404  565,77 24,62 543,71 25,32 ,930 
SD (RT) 155,87 8,62 154,25 9,26 ,852  231,06 12,34 260,59 11,58 ,057  371,9 12,28 343,29 12,63 ,172 
all ps 2-tailed 
Table S4  Influence of DAT1-Genotype on Error Rates, Response Times and RTV (T1) 
 
 
 
LPHN3 
(T1) 
CPT  1-back  2-back 
Risk No Risk 
p 
 Risk No Risk 
p 
 Risk No Risk 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 5,21 ,98 2,66 ,40 ,337  7,95 1,401 6,50 ,91 ,439  22,23 1,38 21,52 1,38 ,657 
False Alarm 2,50 ,397 1,48 ,35 ,044  3,23 ,69 2,77 ,44 ,799  6,32 ,94 5,50 ,68 ,803 
Reaction times 513,28 15,39 489,66 18,95 ,166  500,53 18,80 460,72 24,86 ,168  560,94 26,34 547,32 25,42 ,914 
SD (RT) 162,71 8,28 147,08 10,35 ,121  263,54 12,57 228,11 11,91 ,158  351,98 13,74 364,76 12,49 ,337 
all ps 2-tailed 
Table S5  Influence of LPHN3-Genotype on Error Rates, Response Times and RTV (T1) 
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Group 
(T1) 
CPT 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 5,71 1,09 3,36 ,89 5,32 1,89 ADHDunmed vs. ADHDmed : p = .036, ADHDunmed vs. ADHDmed : p = .017 
False Alarm 2,48 ,55 2,14 ,50 1,71 ,41 - 
Reaction times 517,30 21,83 493,43 21,05 497,00 25,75 - 
SD (RT) 172,58 11,51 140,96 7,33 142,07 11,97 ADHDunmed vs. ADHDmed : p = .080 
    
 1-back 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 10,74 1,57 4,53 ,88 5,74 ,90 ADHDunmed vs. ADHDmed : p < .001, ADHDunmed vs. ADHDmed : p = .011 
 False Alarm 3,54 ,58 3,17 1,01 2,26 ,35 - 
Reaction times 524,21 25,14 472,25 24,40 463,74 27,37 ADHDunmed vs. ADHDmed : p = .098, 
SD (RT) 263,81 15,51 250,52 13,33 226,61 13,33 ADHDunmed vs. ADHDmed : p = .064 
 
 2-back 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 27,54 1,98 19,94 1,24 20,11 1,35 ADHDunmed vs. ADHDmed : p = .015, ADHDunmed vs. ADHDmed : p = .014 
False Alarm 8,30 1,47 5,06 ,72 4,97 ,63 - 
Reaction times 596,88 33,38 532,65 30,72 549,25 28,18 - 
SD (RT) 385,52 13,79 353,99 13,60 352,77 16,17 - 
all ps 2-tailed 
Table S6  Influence of Diagnostic Group on Error Rates, Response Times and RTV (T1) 
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B 3   Response Inhibition: Amplitudes and Latencies   (T1) 
 
 
 
 
COMT 
(T1) 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -2,46 1,08 -3,55 1,11 -2,08 1,11  -5,22 1,00 -3,41 0,61 -4,19 0,83 
NoGo N200 (V) -5,24 1,53 -5,13 1,50 -5,05 1,11  -6,55 0,99 -6,00 0,72 -6,30 0,93 
Go N200 (L) 294,9
2 
6,13 
300,7
0 
10,57 
295,6
1 
8,21 
 313,8
0 
4,01 
286,2
6 
5,56 
306,9
3 
4,42 
NoGo N200 (L) 298,8
2 
10,79 
289,7
5 
8,83 
280,8
2 
10,08 
 309,3
5 
4,55 
293,9
0 
5,65 
294,9
3 
7,39 
     
Go P300 (V) GFP 5,35 1,14 6,48 1,25 6,49 0,71  6,21 0,90 5,82 0,65 6,24 0,62 
NoGo P300 (V) GFP 5,08 1,06 4,85 0,70 6,85 0,81  4,80 0,56 5,30 0,51 5,68 0,57 
Go P300 (L) GFP 324,0
0 
13,24 
350,9
0 
15,94 
319,1
4 
8,48 
 338,4
0 
9,18 
320,7
1 
7,57 
317,5
0 
6,51 
NoGo P300 (L) GFP 363,8
3 
17,66 
389,9
0 
15,93 
374,5
7 
13,22 
 377,3
0 
12,53 
377,2
9 
10,82 
353,7
7 
8,46 
     
Go P300 (V) Pz 12,11 1,66 16,85 2,21 16,71 0,95  16,13 1,46 14,77 1,24 14,56 1,50 
NoGo P300 (V) Cz 9,67 1,96 9,91 1,60 15,49 1,41  9,31 1,53 11,70 1,05 10,88 1,35 
Go P300 (L) Pz 334,7
5 
16,41 
344,5
0 
15,59 
324,0
0 
11,83 
 336,9
5 
11,48 
308,1
9 
6,23 
333,9
1 
6,92 
NoGo P300 (L) Cz 416,0
0 
9,34 
413,4
0 
14,04 
387,5
0 
12,88 
 415,8
5 
7,91 
392,8
1 
8,17 
403,5
9 
7,99 
     
NGA 0,32 0,16 0,01 0,18 0,37 0,12  0,16 0,10 0,34 0,11 0,19 0,10 
Centroid (Go) 3,84 0,21 3,86 0,21 4,09 0,08  4,22 0,06 4,10 0,08 4,12 0,10 
Centroid (NoGo) 3,52 0,24 3,86 0,17 3,72 0,19  4,06 0,14 3,76 0,13 3,92 0,13 
 
 Table S7   Influence of COMT-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T1) 
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DAT1 
(T1) 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -3,56 1,14 -4,69 0,83 -3,57 1,11  -5,11 1,03 -1,95 0,34 -3,17 0,81 
NoGo N200 (V) -5,44 1,28 -6,26 1,08 -6,14 1,17  -6,78 1,02 -5,08 0,74 -5,48 0,84 
Go N200 (L) 309,4
7 
4,86 
289,9
1 
6,88 
299,7
8 
5,30 
 305,1
5 
5,49 
292,1
4 
7,96 
305,2
8 
6,65 
NoGo N200 (L) 303,4
3 
7,78 
287,6
8 
7,38 
286,8
1 
8,71 
 308,3
8 
5,68 
298,5
0 
5,17 
292,0
8 
8,47 
     
Go P300 (V) GFP 5,34 1,05 6,57 0,73 6,62 0,61  6,57 0,90 5,38 0,95 6,05 0,70 
NoGo P300 (V) GFP 4,50 0,85 5,55 0,59 6,89 0,70  5,44 0,58 4,68 0,55 5,38 0,61 
Go P300 (L) GFP 326,6
9 
11,34 
317,2
9 
7,64 
313,5
6 
8,76 
 337,6
5 
9,65 
346,4
3 
12,99 
322,7
2 
5,27 
NoGo P300 (L) GFP 376,5
0 
17,76 
377,7
1 
12,69 
382,7
8 
10,71 
 365,7
1 
10,03 
385,7
9 
12,59 
340,9
4 
7,62 
     
Go P300 (V) Pz 13,46 1,61 15,28 1,47 14,77 1,32  15,69 1,52 15,64 1,70 16,02 1,51 
NoGo P300 (V) Cz 7,13 1,76 10,97 1,27 12,71 1,16  11,48 1,35 11,31 1,24 12,64 1,79 
Go P300 (L) Pz 334,5
6 
11,54 
316,2
9 
7,32 
337,1
7 
10,25 
 339,1
8 
14,12 
324,2
9 
13,26 
322,9
4 
6,88 
NoGo P300 (L) Cz 417,9
4 
7,82 
403,7
6 
10,56 
396,7
2 
8,79 
 412,7
6 
8,75 
394,2
1 
9,85 
397,9
4 
11,18 
     
NGA 0,30 0,15 0,38 0,14 0,34 0,10  0,13 0,08 0,05 0,12 0,18 0,12 
Centroid (Go) 4,00 0,17 4,31 0,06 4,09 0,12  4,18 0,09 3,67 0,13 4,12 0,08 
Centroid (NoGo) 3,70 0,21 3,93 0,14 3,75 0,13  4,05 0,14 3,62 0,14 3,94 0,17 
 
 Table S8   Influence of DAT-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T1) 
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LPHN3 
(T1) 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -5,74 1,17 -4,02 0,68 -4,08 0,94  -2,63 0,88 -1,82 0,48 -2,73 0,97 
NoGo N200 (V) -7,19 1,17 -5,44 0,90 -6,97 1,08  -4,90 1,13 -5,09 0,88 -4,78 0,90 
Go N200 (L) 307,0
0 
4,39 
292,3
2 
6,37 
304,0
0 
5,44 
 306,4
4 
6,16 
291,7
7 
10,07 
301,2
1 
6,46 
NoGo N200 (L) 313,7
8 
5,32 
296,1
8 
5,84 
297,2
1 
7,85 
 296,9
0 
7,71 
285,2
7 
9,24 
282,5
0 
8,84 
    
Go P300 (V) GFP 6,70 1,00 5,08 0,79 6,62 0,54  5,08 0,97 6,83 0,90 6,08 0,74 
NoGo P300 (V) GFP 5,09 0,76 4,71 0,51 6,51 0,68  4,71 0,72 5,50 0,75 5,80 0,66 
Go P300 (L) GFP 324,8
7 
5,78 
330,4
1 
10,51 
320,1
2 
8,75 
 341,1
2 
13,93 
337,4
5 
13,60 
316,3
7 
5,87 
NoGo P300 (L) GFP 353,8
1 
9,77 
386,9
4 
12,04 
358,5
9 
11,02 
 390,6
9 
16,89 
386,6
4 
15,04 
364,7
9 
10,15 
    
Go P300 (V) Pz 14,02 1,85 12,78 1,37 17,27 1,43  15,23 1,39 17,58 1,48 13,72 1,30 
NoGo P300 (V) Cz 8,30 1,53 11,05 1,18 13,13 0,93  10,59 1,81 11,42 1,62 12,27 1,84 
Go P300 (L) Pz 325,2
5 
12,15 
323,6
5 
8,51 
323,2
4 
10,37 
 347,0
0 
13,91 
317,6
4 
15,27 
336,1
6 
7,18 
NoGo P300 (L) Cz 412,1
9 
8,94 
407,6
5 
9,26 
393,9
4 
7,58 
 419,6
3 
8,09 
388,0
0 
11,80 
400,3
7 
11,59 
    
NGA 0,08 0,09 0,38 0,11 0,27 0,11  0,36 0,14 0,04 0,20 0,26 0,11 
Centroid (Go) 4,31 0,06 4,05 0,13 4,13 0,10  3,85 0,16 3,94 0,14 4,08 0,10 
Centroid (NoGo) 4,23 0,13 3,66 0,14 3,86 0,17  3,50 0,20 3,90 0,16 3,83 0,14 
 
 Table S9   Influence of LPHN3-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T1) 
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B 4   Working Memory: Amplitudes and Latencies   (T1) 
 
COMT    (T1) 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
et
 
N100 -4,20 0,74 -4,55 0,79 -5,34 0,77  -5,69 0,60 -5,05 0,59 -4,30 0,50 
P150 8,04 1,64 5,66 1,12 7,86 1,33  5,12 0,85 6,80 1,08 4,92 0,78 
N300 -4,00 1,37 -4,22 1,13 -3,20 1,76  -5,21 0,82 -4,00 0,94 -4,28 0,92 
P450 4,07 0,76 6,11 0,66 5,90 0,82  4,61 0,55 4,60 0,48 3,56 0,48 
   
ta
r P100 7,42 1,70 15,16 2,39 12,81 2,24  13,78 1,65 14,31 1,49 13,47 1,74 
P300 8,93 2,27 16,41 1,73 12,89 1,60  15,05 2,05 15,22 1,45 11,17 1,13 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
et
 
N100 -3,45 0,71 -5,86 0,51 -5,70 0,70  -5,35 0,60 -5,56 0,73 -4,39 0,55 
P150 7,33 1,48 5,78 1,14 6,93 1,46  5,99 1,20 6,34 1,12 4,17 0,72 
N300 -3,63 1,44 -4,60 0,74 -3,51 1,82  -4,39 0,91 -3,75 0,96 -3,73 0,64 
P450 3,05 0,49 4,15 0,50 4,67 0,57  4,16 0,64 3,69 0,49 3,09 0,46 
   
ta
r P100 6,91 1,85 15,39 1,81 13,21 2,21  14,07 2,18 14,70 1,82 13,53 1,88 
P300 11,49 2,81 17,15 1,28 17,18 2,21  15,99 2,67 15,56 1,78 12,13 1,31 
  
 
 
Latencies 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 125,67 5,12 115,33 7,07 123,67 3,96  125,10 2,36 121,83 2,97 127,19 3,79 
P150 205,86 5,92 197,03 6,81 197,00 6,20  206,40 5,34 192,56 4,07 205,28 3,67 
N300 346,72 8,42 325,52 11,10 324,45 12,10  333,23 6,98 330,18 7,27 330,33 4,93 
   
ta
r P100 134,08 3,13 123,88 3,01 126,47 3,41  125,90 4,36 126,49 3,91 122,67 3,77 
P300 292,92 6,38 322,18 14,40 311,72 10,20  322,19 10,42 333,28 11,89 317,88 7,04 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 123,39 3,45 113,45 7,28 117,43 4,24  130,43 3,07 124,19 2,85 124,89 3,36 
P150 207,19 5,28 193,79 5,74 188,93 5,10  201,93 4,38 190,15 5,01 194,56 4,00 
N300 354,39 7,40 340,67 5,62 357,93 9,30  345,70 5,51 345,51 3,73 346,65 4,90 
 
  
ta
r P100 128,67 5,41 118,48 4,08 121,28 6,04  128,67 2,30 125,28 3,58 122,00 3,11 
P300 304,08 10,47 324,42 11,55 323,17 7,18  326,43 11,93 306,58 6,74 321,00 5,82 
  
  Table S10  Influence of COMT-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T1) 
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DAT 1   (T1) 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-t
ar
ge
t N100 -5,14 0,80 -5,24 0,62 -5,07 0,67  -5,52 0,60 -4,47 0,72 -4,37 0,55 
P150 5,45 1,26 6,18 1,03 5,77 1,14  6,66 1,09 6,76 1,34 6,20 0,95 
N300 -4,71 1,16 -4,88 1,04 -4,11 1,30  -5,30 0,92 -3,10 0,98 -3,70 1,18 
P450 3,75 0,55 4,92 0,67 4,29 0,63  5,04 0,65 5,25 0,40 4,52 0,67 
   
ta
r P100 8,26 1,58 15,85 1,89 13,22 2,15  14,81 1,67 13,16 1,59 13,25 1,80 
P300 7,87 1,51 16,25 1,79 11,93 1,37  17,43 1,89 14,88 1,29 11,67 1,27 
   
2
-b
a
ck
 
N
o
n
-t
ar
ge
t N100 -4,53 0,79 -5,00 0,63 -5,13 0,58  -5,02 0,56 -6,44 0,84 -4,67 0,66 
P150 6,10 1,44 6,21 1,24 5,59 1,35  6,62 1,12 6,10 1,13 4,86 0,76 
N300 -4,00 1,12 -3,84 0,75 -4,01 1,03  -4,44 1,04 -4,23 1,26 -3,36 1,13 
P450 3,39 0,58 4,02 0,59 3,24 0,39  4,19 0,65 3,61 0,43 4,03 0,60 
   
ta
r P100 6,69 1,40 16,12 2,00 14,16 2,02  2,20 13,58 1,78 12,89 2,00 2,20 
P300 9,71 2,10 16,07 1,95 14,20 2,04  2,69 16,09 1,64 13,71 1,52 2,69 
  
 
 
Latencies 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 125,73 3,33 122,18 4,21 119,61 2,84  126,29 3,57 116,96 4,27 130,98 4,22 
P150 208,27 5,14 197,75 4,48 193,53 5,45  206,35 6,33 189,46 5,38 209,27 3,33 
N300 339,53 8,11 328,70 7,42 315,25 8,92  337,40 6,88 328,73 10,01 338,62 5,69 
   
ta
r P100 131,21 6,30 128,22 2,63 126,95 4,12  128,33 1,46 122,75 5,18 121,95 3,60 
P300 296,79 6,32 341,41 12,59 314,48 9,84  321,44 12,41 316,50 13,14 316,57 7,12 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 130,55 3,49 121,54 4,14 123,14 2,89  125,75 3,04 119,96 4,69 121,33 4,28 
P150 209,06 4,49 189,82 6,13 188,78 5,04  198,71 4,49 193,04 4,40 195,48 3,94 
N300 347,12 5,23 340,37 3,96 344,39 7,23  351,52 7,02 348,29 4,76 356,00 5,90 
   
ta
r P100 130,85 4,32 127,74 2,96 124,05 3,05  127,78 2,24 117,83 4,63 120,13 4,43 
P300 316,30 14,90 315,37 8,91 321,24 7,91  317,11 9,30 308,96 8,00 322,13 5,40 
  
  Table S11  Influence of DAT1-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T1)     
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LPHN3    (T1) 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
et
 
N100 -4,91 0,72 -4,96 0,75 -5,64 0,72  -5,30 0,65 -4,39 0,53 -3,82 0,42 
P150 6,47 1,17 6,47 1,20 6,64 1,15  6,02 1,20 7,10 1,28 5,43 0,91 
N300 -5,69 1,14 -4,34 1,16 -5,90 1,50  -4,03 0,91 -3,49 0,90 -2,07 0,76 
P450 3,92 0,62 4,73 0,57 4,40 0,49  4,79 0,63 5,46 0,65 4,44 0,77 
   
ta
r P100 12,83 2,93 15,83 2,05 13,38 1,66  10,52 1,18 14,00 1,53 13,09 2,20 
P300 14,29 3,40 12,57 1,57 13,54 1,17  11,81 1,56 18,35 1,21 10,01 1,32 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
et
 
N100 -4,51 0,70 -5,31 0,83 -5,66 0,69  -4,74 0,67 -6,05 0,73 -4,17 0,53 
P150 6,91 1,19 6,28 1,19 6,09 1,09  6,17 1,38 7,04 1,31 4,37 0,96 
N300 -4,93 1,38 -4,05 1,20 -5,47 1,22  -3,47 0,87 -4,10 0,79 -2,01 0,82 
P450 3,42 0,77 3,55 0,51 3,85 0,49  3,99 0,53 4,36 0,64 3,52 0,57 
   
ta
g P100 12,55 3,08 15,99 2,24 12,70 1,72  10,72 1,98 14,10 1,63 14,13 2,31 
P300 15,78 3,94 14,68 2,02 14,92 1,36  13,37 2,11 17,08 1,81 12,91 2,01 
  
 
 
Latencies 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 127,10 4,13 120,52 3,30 125,11 3,97  123,93 2,80 117,81 5,90 126,60 3,99 
P150 211,02 5,76 191,54 5,03 204,63 4,86  202,44 5,37 194,90 5,20 200,07 4,48 
N300 336,19 7,52 331,85 8,99 330,13 6,89  339,93 7,85 322,88 9,59 326,40 8,23 
   
ta
r P100 122,74 6,52 127,65 2,75 125,75 4,68  133,13 2,14 127,43 4,12 122,27 2,82 
P300 321,04 16,37 336,71 13,77 314,00 6,16  304,97 6,06 324,86 15,09 317,41 9,87 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
et
 N100 125,05 3,32 123,22 3,38 122,04 3,64  129,93 3,30 117,95 6,07 122,23 3,96 
P150 205,00 4,45 191,35 5,80 197,35 3,78  203,06 4,97 191,29 5,86 188,10 4,77 
N300 349,88 6,79 348,00 3,91 353,44 7,28  348,24 5,98 338,17 5,25 348,43 5,99 
   
ta
r P100 130,00 3,18 127,96 3,69 120,04 5,03  127,74 3,44 119,19 3,61 123,45 2,91 
P300 314,07 9,35 309,88 7,97 315,57 4,27  321,23 13,40 315,14 11,06 327,96 7,72 
  
  Table S12  Influence of LPHN3-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T1) 
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B 5   Sensory Gating 
 
COMT 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Conditioning P50 (V) 6,70 1,87 5,58 0,88 7,45 1,31  3,37 0,64 3,27 1,39 6,03 0,91 
Testing P50 (V) 0,39 0,99 1,84 0,75 1,48 0,74  1,54 0,36 0,79 0,54 1,05 0,37 
Conditioning P50 (L) 60,86 2,27 57,80 1,53 60,77 2,65  59,80 1,79 61,00 6,73 60,15 2,01 
Testing P50 (L) 56,57 1,69 58,20 4,59 57,62 3,00  56,20 4,07 59,00 1,73 56,40 2,19 
   
P50 Suppression (%) 78,21 13,14 60,82 13,86 81,73 12,31  53,83 6,57 82,24 6,91 83,02 9,17 
Table S13   Modulation of P50 Sensory Gating Amplitudes and Latencies and Suppression Ratio by COMT-Genotype 
 
 
DAT1 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Conditioning P50 (V) 4,80 1,22 4,82 1,56 6,89 1,18  4,66 1,51 4,34 1,02 6,34 0,99 
Testing P50 (V) 0,83 0,73 0,56 0,66 1,25 0,52  1,40 0,46 2,02 0,60 1,20 0,52 
Conditioning P50 (L) 60,00 1,83 58,50 6,19 57,67 2,91  60,57 2,21 59,80 2,75 62,67 1,45 
Testing P50 (L) 59,00 3,35 61,25 3,09 56,47 2,25  52,57 3,21 56,40 3,82 57,22 2,66 
   
P50 Suppression (%) 63,41 11,50 88,30 9,76 80,89 10,99  64,53 6,31 55,98 9,92 83,86 9,93 
Table S14   Modulation of P50 Sensory Gating Amplitudes and Latencies and Suppression Ratio by DAT1-Genotype 
 
 
LPHN3 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Conditioning P50 (V) 2,73 0,47 5,27 1,29 6,52 1,15  6,54 1,47 3,66 0,98 6,65 1,02 
Testing P50 (V) 1,49 0,36 0,82 0,57 0,66 0,50  0,69 0,82 2,06 0,77 1,75 0,50 
Conditioning P50 (L) 62,13 1,70 59,00 4,82 60,38 2,75  58,56 2,02 59,50 3,52 60,41 1,73 
Testing P50 (L) 56,13 3,90 60,00 2,70 57,94 2,67  56,56 3,25 56,75 4,91 55,88 2,34 
   
P50 Suppression (%) 46,43 7,08 85,39 8,10 99,18 10,52  79,38 9,26 51,54 11,45 66,82 8,66 
Table S15   Modulation of P50 Sensory Gating Amplitudes and Latencies and Suppression Ratio by LPHN3-Genotype 
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B 6   Catamnestic Re-Examination of Sub-Sample 
 
 
ADHDunmed ADHDmed Controls 
 
Chi² p 
COMT 
No Met 4 8 8 20 
50 1.150 .563 
Met 10 9 11 30 
 
DAT 
10/10 7 9 12 28 
50 .664 .717 
other 7 8 7 22 
 
LPHN3 
Risk 6 8 11 25 
47 .857 .651 
No risk 8 6 8 22 
Table S16   Comparison of binary genotype frequencies between diagnostic groups (T2) 
    
  Group Differences 
(Genotypes) 
Hardy-Weinberg 
 
ADHDunmed ADHDmed Controls 
 Total 
N 
Chi² p Chi² p 
COMT 
CC 4 8 9 20 
50 1.583 .812 .688 .407 CG 7 7 7 21 
GG 3 2 4 9 
 
DAT1 
9/9 2 2 0 4 
50 2.811 .590 
.000 .986 9/10 5 6 7 18 
10/10 7 9 12 20 
10/11 0 0 0 0  
 
 
LPHN3 
rs6551665 AA 6 6 5 17 
46 2.047 .727 .659 .417 AG 6 6 12 24 
GG 1 2 2 5 
     
rs2345039 CC 2 3 4 9 
46 3.481 .481 .007 .935 CG 7 9 7 23 
GG 4 2 8 14 
     
rs1947274 AA 7 6 5 18 
48 4.816 .307 .739 .390 AC 6 6 13 25 
CC 1 3 1 5 
Table S17   Comparison of genotype frequencies between diagnostic groups and calculation of Hardy-Weinberg-Equilibrium (T2) 
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B 6.1   Behavioural Parameters (T2) 
 
 
COMT 
(T2) 
CPT  1-back  2-back 
no Met Met 
p 
 no Met Met 
p 
 no Met Met 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 1,33 0,34 1,93 0,47 0,649  4,29 0,85 5,60 0,84 0,293  16,95 1,50 18,90 1,86 0,701 
False Alarm 0,88 0,31 0,32 0,14 0,107  4,48 2,32 1,97 0,55 0,162  11,71 5,06 7,90 1,69 0,651 
Reaction times 450,87 24,36 484,52 22,07 0,344  403,88 29,74 421,99 25,79 0,497  543,48 26,70 536,65 29,06 0,985 
SD (RT) 342,16 68,07 316,38 48,44 0,787  240,96 23,13 226,32 13,88 0,886  383,19 23,16 326,54 16,89 0,075 
all ps 2-tailed 
Table S18   Influence of COMT-Genotype on Error Rates, Response Times and RTV (T2) 
 
DAT1 
(T2) 
CPT  1-back  2-back 
10/10 other 
p 
 10/10 other 
p 
 10/10 other 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 1,71 0,45 1,67 0,40 0,584  4,68 0,82 5,52 0,92 0,462  17,50 1,51 18,83 2,11 0,864 
False Alarm 0,63 0,19 0,39 0,24 0,187  2,00 0,58 4,22 2,12 0,287  7,25 1,64 12,17 4,68 0,403 
Reaction times 446,26 20,28 510,39 25,96 0,053  382,11 24,42 454,01 29,42 0,042  515,54 27,13 568,59 29,58 0,212 
SD (RT) 335,32 50,97 312,70 63,39 0,787  230,32 18,49 234,82 16,41 0,902  345,03 16,11 355,76 24,97 0,985 
all ps 2-tailed 
Table S19   Influence of DAT1-Genotype on Error Rates, Response Times and RTV (T2) 
 
LPHN3 
(T2) 
CPT  1-back  2-back 
Risk No Risk 
p 
 Risk No Risk 
p 
 Risk No Risk 
p 
m SE m SE  m SE m SE  m SE m SE 
Miss 1,22 0,30 1,70 0,44 0,470  3,76 0,78 6,04 0,90 0,025  17,72 1,90 19,13 1,84 0,569 
False Alarm 0,39 0,18 0,74 0,27 0,280  1,44 0,21 4,87 2,18 0,225  6,92 1,29 11,65 4,89 0,633 
Reaction times 456,10 23,67 489,88 26,28 0,233  393,64 26,19 431,25 31,41 0,183  523,48 28,22 558,03 32,65 0,219 
SD (RT) 447,12 66,85 216,34 25,63 0,034  205,29 9,63 255,62 23,63 0,078  317,71 15,34 383,65 23,47 0,014 
all ps 2-tailed 
Table S20   Influence of LPHN3-Genotype on Error Rates, Response Times and RTV (T2) 
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Group 
(T2) 
CPT 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 1,79 0,60 2,12 0,62 1,13 0,35 - 
False Alarm 1,07 0,34 0,24 0,14 0,36 0,25 ADHDunmed vs. ADHDmed : p = .020, ADHDunmed vs. KG : p = .039 
Reaction times 459,81 34,80 497,42 25,77 452,59 26,04  
SD (RT) 283,23 59,72 303,28 61,42 393,10 82,27  
    
 1-back 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 6,07 1,24 4,82 1,24 4,47 0,72  
 False Alarm 6,27 3,30 1,71 0,46 1,58 0,28  
Reaction times 403,93 45,32 450,71 23,96 390,54 31,14  
SD (RT) 243,14 22,54 269,28 25,34 190,79 12,78 ADHDunmed vs. KG : p = .071, ADHDmed vs. KG : p = .014 
 
 2-back 
ADHDunmed ADHDmed Controls 
p 
m SE m SE m SE 
Miss 20,60 2,03 17,41 2,90 16,74 1,43  
False Alarm 14,00 7,27 8,12 1,71 7,11 1,80  
Reaction times 591,69 44,45 551,14 25,48 487,77 31,95 ADHDunmed vs. KG : p = .064 
SD (RT) 364,55 33,26 354,34 23,29 334,28 19,13  
all ps 2-tailed 
Table S21   Influence of Diagnostic Group on Error Rates, Response Times and RTV (T2) 
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B 6.2   Response Inhibition at T2 
 
 
 
 
 
COMT 
(T2) 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -5,50 1,29 -0,41 1,21 -0,99 1,18  -3,90 1,21 -0,69 1,07 -5,78 2,12 
NoGo N200 (V) -4,94 0,27 -3,50 0,94 -2,85 1,12  -6,22 1,11 -2,71 0,84 -5,65 2,13 
Go N200 (L) 317,3
3 
14,73 
284,9
3 
12,12 
287,8
8 
4,35 
 286,2
5 
6,45 
273,0
6 
15,42 
311,5
0 
6,26 
NoGo N200 (L) 288,1
7 
14,68 
265,2
5 
9,64 
257,1
3 
10,52 
 278,1
5 
7,21 
272,5
0 
11,41 
287,1
7 
18,02 
   
Go P300 (V) GFP 6,02 1,25 4,96 0,70 6,97 1,11  4,06 0,82 3,69 1,02 5,47 2,20 
NoGo P300 (V) GFP 6,53 0,21 5,10 1,26 7,17 0,54  3,48 0,80 3,03 0,80 5,10 1,81 
Go P300 (L) GFP 355,6
7 
32,54 
324,7
1 
11,11 
316,5
0 
18,35 
 334,1
0 
8,98 
332,0
0 
14,52 
315,6
7 
12,45 
NoGo P300 (L) GFP 363,0
0 
35,37 
361,3
8 
14,74 
378,0
0 
30,38 
 358,3
0 
14,19 
392,1
3 
20,67 
333,3
3 
4,37 
   
Go P300 (V) Pz 15,05 0,75 12,47 1,70 15,07 1,91  12,77 2,39 12,39 2,97 13,47 5,80 
NoGo P300 (V) Cz 9,27 3,92 11,25 2,45 11,49 2,42  7,49 2,48 5,50 1,07 5,29 4,23 
Go P300 (L) Pz 337,0
0 
5,29 
298,7
1 
4,68 
291,5
0 
7,97 
 303,4
0 
9,39 
319,2
5 
6,17 
321,3
3 
24,21 
NoGo P300 (L) Cz 392,0
0 
5,51 
383,8
8 
13,65 
389,7
5 
27,76 
 387,8
0 
14,05 
388,3
8 
12,46 
388,6
7 
6,06 
   
NGA -0,03 0,26 0,37 0,32 0,12 0,31  0,22 0,19 0,48 0,32 -0,10 0,08 
Centroid (Go) 3,86 0,39 3,70 0,21 4,04 0,24  4,00 0,12 3,96 0,08 4,35 0,12 
Centroid (NoGo) 3,89 0,32 3,45 0,24 3,91 0,20  3,77 0,21 3,47 0,36 4,45 0,07 
 
Table S22   Influence of COMT-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T2) 
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DAT1 
(T2) 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -6,26 1,21 -2,16 0,99 -5,90 2,36  -1,94 0,92 0,84 0,96 -1,90 1,56 
NoGo N200 (V) -7,18 1,08 -4,01 0,96 -3,69 0,89  -4,46 1,20 -2,20 0,69 -4,19 1,64 
Go N200 (L) 311,0
0 
6,61 
290,7
1 
12,62 
299,2
5 
19,25 
 272,9
2 
5,01 
268,0
0 
14,26 
297,5
0 
5,81 
NoGo N200 (L) 284,2
1 
8,28 
281,9
4 
11,30 
289,2
5 
20,25 
 276,0
8 
10,18 
255,8
1 
7,11 
262,3
0 
12,18 
     
Go P300 (V) GFP 5,02 1,04 4,82 0,87 6,72 0,74  3,92 0,98 3,81 0,94 6,17 1,52 
NoGo P300 (V) GFP 4,62 1,17 3,18 0,74 7,77 0,03  3,67 0,79 4,95 1,33 5,68 1,10 
Go P300 (L) GFP 335,7
1 
14,37 
326,8
6 
17,22 
301,5
0 
23,50 
 343,0
0 
13,96 
330,1
3 
9,16 
322,0
0 
12,78 
NoGo P300 (L) GFP 362,4
3 
20,98 
389,8
8 
22,71 
338,5
0 
10,50 
 355,8
3 
15,32 
363,6
3 
12,13 
367,0
0 
25,72 
     
Go P300 (V) Pz 14,63 1,34 15,00 2,41 14,95 1,89  11,73 3,78 10,18 2,26 14,16 3,48 
NoGo P300 (V) Cz 6,96 1,91 6,04 1,00 15,63 1,91  9,00 4,03 10,70 2,64 6,11 2,31 
Go P300 (L) Pz 318,2
9 
10,09 
322,1
4 
6,13 
310,0
0 
33,00 
 302,8
3 
13,73 
298,7
5 
4,24 
302,0
0 
13,30 
NoGo P300 (L) Cz 397,7
1 
13,61 
399,7
5 
15,98 
365,0
0 
13,00 
 378,3
3 
17,31 
372,5
0 
5,88 
399,0
0 
19,34 
     
NGA 0,28 0,28 0,37 0,31 0,46 0,44  0,04 0,09 0,49 0,33 -0,14 0,14 
Centroid (Go) 3,98 0,18 4,05 0,12 4,37 0,02  3,95 0,18 3,65 0,15 4,09 0,21 
Centroid (NoGo) 3,70 0,27 3,75 0,25 3,91 0,46  3,92 0,21 3,17 0,31 4,23 0,14 
 
Table S23   Influence of DAT1-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T2) 
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LPHN3 
(T2) 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
Go N200 (V) -4,33 1,49 1,82 0,77 -5,78 2,12  -4,19 1,34 -1,74 1,05 -0,99 1,18 
NoGo N200 (V) -5,81 1,13 -2,38 0,69 -5,65 2,13  -6,06 1,43 -3,24 1,08 -2,85 1,12 
Go N200 (L) 300,8
6 
10,80 
270,6
7 
20,08 
311,5
0 
6,26 
 284,7
5 
7,17 
280,6
4 
12,84 
287,8
8 
4,35 
NoGo N200 (L) 280,3
6 
6,93 
272,5
0 
9,69 
287,1
7 
18,02 
 280,5
8 
11,82 
264,9
4 
12,78 
257,1
3 
10,52 
     
Go P300 (V) GFP 4,54 0,99 4,15 1,18 5,47 2,20  4,48 1,11 3,75 0,83 6,97 1,11 
NoGo P300 (V) GFP 4,25 1,20 5,06 1,64 5,10 1,81  4,11 0,80 3,52 0,96 7,17 0,54 
Go P300 (L) GFP 338,4
3 
13,71 
325,0
0 
14,08 
315,6
7 
12,45 
 339,8
3 
15,04 
337,2
9 
15,33 
316,5
0 
18,35 
NoGo P300 (L) GFP 362,4
3 
22,21 
383,6
7 
20,17 
333,3
3 
4,37 
 355,8
3 
12,68 
387,0
0 
17,81 
378,0
0 
30,38 
     
Go P300 (V) Pz 12,36 2,14 12,46 2,72 13,47 5,80  14,39 3,29 11,92 3,01 15,07 1,91 
NoGo P300 (V) Cz 6,45 1,99 10,43 2,66 5,29 4,23  9,59 3,90 7,53 2,20 11,49 2,42 
Go P300 (L) Pz 323,2
9 
10,52 
300,1
7 
5,89 
321,3
3 
24,21 
 297,0
0 
11,28 
318,0
0 
7,80 
291,5
0 
7,97 
NoGo P300 (L) Cz 379,7
1 
5,90 
383,1
7 
8,72 
388,6
7 
6,06 
 399,3
3 
22,57 
389,2
5 
17,26 
389,7
5 
27,76 
     
NGA 0,10 0,29 0,67 0,41 -0,10 0,08  0,25 0,07 0,40 0,30 0,12 0,31 
Centroid (Go) 3,94 0,18 3,65 0,16 4,35 0,12  4,00 0,17 3,90 0,16 4,04 0,24 
Centroid (NoGo) 3,84 0,29 2,98 0,36 4,45 0,07  3,76 0,18 3,59 0,24 3,91 0,20 
 
Table S24   Influence of LPHN3-Genotype on Go- and NoGo-Components in Diagnostic Groups during Continuous Performance Task (T2) 
 
 
 
  
137 
 
 
B 6.3   Working Memory at T2 
 
COMT    (T2) 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,44 0,96 -3,63 0,77 -3,47 0,37  -3,43 0,65 -3,19 1,03 -3,65 1,07 
P150 6,00 1,20 5,00 1,14 6,71 1,74  3,44 0,78 5,53 1,39 4,06 1,68 
N300 -2,34 1,52 -0,79 0,71 -2,10 1,37  -2,98 0,88 -1,43 0,93 -2,41 0,92 
P450 4,45 1,40 3,67 0,86 3,40 0,56  2,79 0,47 3,05 0,99 3,43 0,65 
   
ta
r
ge t
 P100 8,16 3,09 9,47 1,91 14,37 2,09  6,76 1,43 4,59 1,37 10,22 2,03 
P300 12,06 2,99 12,86 2,08 14,54 1,98  11,46 2,07 5,60 1,55 11,57 1,41 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,03 0,95 -3,65 0,66 -3,50 0,30  -3,70 0,63 -3,40 0,85 -2,95 1,00 
P150 6,63 2,04 4,53 0,84 7,20 1,40  3,67 0,92 5,29 1,80 2,80 0,80 
N300 -3,71 1,63 -1,97 0,50 -2,25 1,20  -2,85 0,71 -1,61 1,09 -2,67 1,01 
P450 3,04 0,65 2,71 0,52 3,27 0,46  2,26 0,37 2,93 0,79 2,54 0,62 
   
ta
r
ge t
 P100 6,44 2,68 10,32 1,26 15,50 2,23  7,57 1,54 6,46 1,69 12,19 2,00 
P300 8,45 2,45 9,80 2,28 15,28 2,10  9,94 2,01 8,60 1,91 14,54 1,66 
  
 
 
Latencies 
no Met allele  at least one Met allele 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 116,83 7,09 115,17 4,51 114,95 5,85  121,33 4,09 112,92 4,64 111,33 6,18 
P150 185,92 9,26 193,08 11,55 186,24 10,00  189,87 8,25 182,08 7,71 195,83 5,90 
N300 316,58 25,22 310,79 14,32 299,10 21,44  317,90 13,37 322,63 13,25 321,33 14,37 
   
ta
r
ge t
 P100 103,50 15,10 111,42 7,74 124,10 4,09  115,93 6,28 114,00 8,99 122,27 5,99 
P300 339,17 16,94 328,25 23,40 314,67 11,63  320,13 6,54 312,08 4,86 332,13 15,47 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 114,83 10,37 115,17 3,55 119,81 4,12  122,53 4,34 110,42 6,10 117,67 5,07 
P150 190,58 7,08 180,63 6,06 190,33 6,28  187,44 6,77 182,46 6,69 183,19 5,46 
N300 312,25 22,13 339,29 11,83 358,81 8,30  315,89 11,65 340,71 8,97 355,86 7,90 
   
ta
r
ge t
 P100 126,00 5,26 120,75 3,59 114,95 3,97  124,00 4,70 120,19 7,74 119,87 4,90 
P300 313,83 15,73 326,08 6,55 305,52 5,07  331,78 10,77 324,29 17,93 331,07 13,93 
  
  Table S25   Influence of COMT-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T2) 
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DAT1    (T2) 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,54 0,77 -4,41 0,93 -2,62 0,30  -3,33 0,75 -2,41 0,72 -4,14 0,75 
P150 5,81 0,95 5,06 1,38 6,28 2,49  2,54 0,62 5,47 1,16 4,99 1,37 
N300 -2,85 0,93 -1,88 0,95 -1,17 0,69  -2,75 1,21 -0,33 0,57 -2,91 1,24 
P450 4,45 0,73 3,22 0,97 3,86 0,72  2,08 0,46 3,49 0,89 3,14 0,50 
   
ta
r
ge t
 P100 7,17 2,19 8,57 1,52 8,77 1,17  7,14 1,57 5,82 1,97 15,40 1,95 
P300 11,67 2,01 10,20 2,14 15,65 1,94  11,59 2,78 8,48 2,31 11,62 1,60 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,56 0,79 -4,44 0,71 -2,48 0,50  -3,46 0,72 -2,60 0,64 -3,64 0,73 
P150 6,44 1,18 4,78 1,68 5,61 1,23  2,41 0,89 5,04 1,07 4,65 1,41 
N300 -3,99 0,91 -2,96 0,84 -2,03 1,06  -2,08 0,90 -0,61 0,59 -2,70 1,05 
P450 3,21 0,36 3,29 0,64 2,62 0,17  1,66 0,31 2,35 0,65 3,07 0,60 
   
ta
r
ge t
 P100 1,90 9,54 1,48 11,08 1,26 1,90  5,23 1,46 7,62 1,68 16,43 2,23 
P300 1,99 10,46 2,00 14,33 1,33 1,99  7,15 2,19 8,16 2,16 15,46 2,24 
  
 
  
Latencies 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 120,86 4,63 119,83 2,99 103,73 5,19  119,24 5,46 108,25 4,86 119,25 4,90 
P150 191,05 8,24 186,46 9,12 173,53 9,72  186,43 10,08 188,71 10,86 201,38 4,76 
N300 335,00 8,84 324,96 7,54 282,93 17,45  300,05 19,62 308,46 17,73 325,88 16,55 
   
ta
r
ge t
 P100 105,43 11,31 124,86 5,86 126,40 6,53  119,33 4,04 103,26 8,01 121,14 3,44 
P300 322,19 11,39 332,48 25,16 326,67 9,42  328,95 8,04 310,59 7,97 318,57 14,96 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 118,48 6,67 117,75 3,85 115,07 3,38  122,19 5,42 107,83 5,44 120,78 4,53 
P150 197,19 5,46 181,38 7,45 179,33 8,80  178,17 7,08 181,71 5,11 190,89 3,92 
N300 316,00 13,65 338,00 10,87 345,33 13,18  313,33 16,17 342,00 10,07 364,00 3,64 
   
ta
r
ge t
 P100 128,38 4,48 119,05 4,40 114,00 5,51  120,22 5,41 121,75 6,55 119,14 3,55 
P300 318,38 11,44 336,48 17,14 311,47 10,43  335,44 13,87 315,42 5,86 319,52 10,36 
  
  Table S26   Influence of DAT1-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T2) 
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LPHN3    (T2) 
Risk haplotype  No risk haplotype 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
Amplitudes m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,28 0,79 -2,92 0,73 -3,88 0,76  -3,55 0,73 -3,70 1,22 -3,03 0,54 
P150 3,84 0,70 5,13 1,00 5,48 1,68  4,42 1,16 6,56 1,47 5,49 1,95 
N300 -3,26 1,36 -1,30 0,87 -3,08 0,94  -2,45 0,85 -0,06 0,70 -0,90 1,42 
P450 3,44 0,71 3,12 1,04 2,85 0,44  3,14 0,79 4,20 0,95 4,33 0,64 
   
ta
r
ge t
 P100 7,19 1,99 7,09 2,39 10,83 1,09  7,12 1,67 7,51 1,75 13,93 2,50 
P300 10,29 1,69 10,28 2,65 12,72 1,49  13,41 3,17 7,66 2,46 13,72 2,09 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t N100 -3,34 0,70 -3,43 0,55 -3,93 0,74  -3,64 0,77 -3,38 0,99 -2,29 0,49 
P150 4,36 1,22 4,27 1,15 5,41 1,40  4,72 1,37 6,44 1,73 4,44 1,46 
N300 -3,83 1,28 -3,25 0,78 -3,66 0,85  -2,66 0,78 -0,07 0,66 -0,86 1,10 
P450 2,56 0,58 3,11 0,79 2,67 0,44  2,46 0,41 2,75 0,68 3,23 0,70 
   
ta
r
ge t
 P100 7,08 1,86 8,07 1,99 11,63 1,57  7,45 1,81 9,63 1,37 15,35 2,15 
P300 7,26 1,41 10,55 2,38 15,36 1,96  13,03 2,79 5,88 1,13 14,71 1,84 
  
 
 
Latencies 
other  10/10 
ADHDunmed ADHDmed Controls  ADHDunmed ADHDmed Controls 
m SE m SE m SE  m SE m SE m SE 
1
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 117,22 4,78 113,52 3,87 113,00 5,78  122,17 4,99 111,90 5,77 113,73 6,15 
P150 186,50 11,59 176,33 6,56 195,71 7,64  190,42 7,45 195,43 11,80 182,60 9,34 
N300 305,89 19,92 315,43 11,95 320,13 18,85  326,25 13,63 315,29 18,43 292,13 15,49 
   
ta
r
ge t
 P100 108,83 10,34 109,43 8,52 128,80 5,55  117,11 4,12 108,57 8,48 119,43 3,64 
P300 328,00 8,01 306,76 9,72 348,53 10,73  322,33 12,41 336,76 24,59 302,95 8,45 
   
2
-b
a
ck
 
N
o
n
-
ta
rg
e
t 
N100 117,22 4,76 112,86 3,92 119,25 4,28  122,67 6,51 110,48 6,77 118,06 5,10 
P150 179,67 9,51 176,48 7,79 192,67 4,51  193,88 5,17 185,14 6,06 178,89 6,57 
N300 317,53 11,67 331,05 13,95 359,92 5,22  313,04 15,18 349,86 7,84 353,89 11,40 
   
ta
r
ge t
 P100 129,42 3,34 121,62 7,58 117,07 5,71  116,93 6,44 117,78 4,96 116,95 3,66 
P300 320,00 11,29 312,29 8,31 334,27 10,43  336,27 14,59 339,22 18,81 303,24 6,69 
  
  Table S27   Influence of DAT1-Genotype on Amplitudes and Latencies of Target and non-Target Components in Diagnostic Groups during n-Back Task (T2) 
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 Time Condition Time*Condition Additional effects 
      
 
N200 Amplitudes 
 
T1 > T2 
 
Go < NoGo 
 
 
 
 
Group F1, 27 = 15.03, p = .001 F1, 27 = 23.86, p < .001 F1, 27 = 4.39, p = .046 - 
COMT F1, 28 = 16.36, p < .001 F1, 28 = 25.25, p < .001 F1, 28 = 4.10, p = .013 - 
DAT F1, 28 = 16.47, p < .001 F1, 28 =28.15 , p < .001 F1, 28 =5.79 , p = .053 DAT1, condition*DAT1 
LPHN3 F1, 26 = 13.00, p = .001 F1, 26 = , p < .001 F1, 26 = 4.02, p = .056 - 
 
N200 Latencies 
 
T1 > T2 
 
Go > NoGo 
  
Group F1, 27 = 73.01, p < .001 F1, 27 = 3.63, p = .067 F1, 27 = 7.08 , p = .023 - 
COMT F1, 28 =75.03 , p < .001 F1, 28 = 4.59, p = .041 F1, 28 = 7.83, p = .020 - 
DAT F1, 28 = 87.64, p < .001 F1, 28 = 3.32, p = .079 F1, 28 = 6.06, p = .056 time*DAT1 
LPHN3 F1, 26 = 73.18, p < .001 F1, 26 = 2.91, p = .100 F1, 26 =4.69 , p = .040 - 
 
Repeated Measures ANOVA with factors ‘time and ‘condition’ 
N200 amplitude F1, 29 = 17.61, p < .001 F1, 29 = 28.31, p < .001 F1, 29 = 4.720, p = .038  
 T1          p < .001 
T2          p = .002 
Go < NoGo 
Go          p = .001 
NoGo     p < .001 
T1 > T2 
N200 latency F1, 29 = 82.03, p < .001 F1, 29 = 3.30, p = .080 F1, 29 = 6.51, p = .016  
 T1          p = .833 
T2          p = .013 
 
Go > NoGo 
Go          p = .001 
NoGo     p < .001 
T1 > T2 
 
Table S28   Developmental Effects on Response Inhibition Related Components (N200)
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